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Abstract: Cholesterol oxidation products, also named “oxysterols”, were first mentioned and studied in
1913 by I. Lifschütz while developing the worldwide famous products Eucerin® and Nivea® cream. He
described oxysterols of non-enzymatic origin, being principally oxygenated at the sterol ring. In con-
trary enzymatically derived oxysterols were discovered 50 years later and appeared to be mainly side
chain oxygenated sterols. However, a few oxysterols of both origins exist. Nowadays, it is known that
oxysterols tightly regulate cholesterol homeostasis that plays a major role in human health. This regu-
lation takes place by the mean of four different pathways. The first is the inhibition of the commonly
activated sterol regulatory element binding protein (SREBP) pathway and the second is the activation
of liver X receptors ￿ and ￿ (LXR￿ and LXR￿). The third action of oxysterols is the accelerated degra-
dation of the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), a key enzyme of choles-
terol synthesis. The final pathway triggered by oxysterols is the enhanced cholesterol esterification for
cell storage. These regulatory pathways as well as other oxysterol mediated mechanisms that do not
regulate cholesterol levels, appeared in the last years to be important for several human physiological
processes. For example it was found that 25-hydroxycholesterol (25-OHC) possesses anti-viral functions.
This illustrates that the physiological importance of oxysterols was underestimated and that their im-
plications are still not completely unravelled. Oxysterol analysis, however, is tricky and hampered by
several difficulties, such as the large excess of cholesterol, the low endogenous concentrations of oxys-
terols, the possible autoxidation of cholesterol and oxysterols, the cellular localisation of oxysterols in
membranes, the possible modifications of oxysterols like esterifications, reductions, or sulphations and
finally their chemical structures and properties making mass spectrometry (MS) analysis difficult and
not very specific. In this work, two liquid chromatography coupled to tandem mass spectrometry (LC-
MS/MS) methods were established for the analysis of oxysterols in human diseases. The first method
was developed and implemented for the analysis of oxysterols of non-enzymatic origin in a clinical set-
ting of Niemann-Pick type C (NP-C) diagnosis. In addition, a second method was optimised for the
analysis of enzymatically-derived oxysterols in the plasma of patients with Inflammatory Bowel Disease
(IBD), opening a new research domain. In the first part dealing with the analysis of NP-C-specific oxys-
terols, we were able to precisely, accurately, and robustly measure Cholestane-3￿,5￿,6￿-triol (C-triol) and
7-Ketocholesterol (7-KC) following a Steglich esterification. We established reference ranges for NP-C di-
agnostics, which turned out to be neither age nor gender-dependent and we established the pre-analytical
stability of the compounds. We found an important intra-individual variation for both analytes, but
could show increased C-triol levels in all Niemann-Pick patients including Niemann Pick type A and
B patients. Our results suggest that especially the C-triol is a biomarker for all three Niemann-Pick
diseases. In the second part dealing with the oxysterol fingerprint in IBD, we were able to separate in
one chromatographic run 24(S)-hydroxycholesterol (24(S)-OHC), 25-hydroxycholesterol (25-OHC), 27-
hydroxycholesterol (27-OHC), 7￿,24(S)-dihydroxycholesterol (7￿,24(S)-OHC), 7￿,25-dihydroxycholesterol
(7￿,25-OHC), 7￿,27-dihydroxycholesterol (7￿,27-OHC), 7￿,25-dihydroxycholesterol (7￿,25-OHC), and 7￿,27-
dihydroxycholesterol (7￿,27-OHC). The most important finding of our investigation in IBD is that 27-
OHC and eventually 25-OHC are reduced in plasma of IBD patients compared to healthy volunteers.
Both oxysterols are agonists for the LXR receptors, which are implicated in inflammation and thus may
possibly participate in inflammatory mechanisms in IBD. The analysis of mono-and dihydroxycholesterols
as biomarkers for IBD is a novel approach which shows promise but more IBD samples are required to
corroborate the observed differences in oxysterol levels between the different groups, meaning the control
group, patients with active Crohn’s disease or in remission, and patients with active Ulcerative colitis or
in remission.
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I 
SUMMARY 
Cholesterol oxidation products, also named “oxysterols”, were first mentioned and studied in 1913 by I. 
Lifschütz while developing the worldwide famous products Eucerin® and Nivea® cream. He described 
oxysterols of non-enzymatic origin, being principally oxygenated at the sterol ring. In contrary enzymatically 
derived oxysterols were discovered 50 years later and appeared to be mainly side chain oxygenated sterols. 
However, a few oxysterols of both origins exist. Nowadays, it is known that oxysterols tightly regulate 
cholesterol homeostasis that plays a major role in human health. This regulation takes place by the mean of 
four different pathways. The first is the inhibition of the commonly activated sterol regulatory element binding 
protein (SREBP) pathway and the second is the activation of liver X receptors α and β (LXRα and LXRβ). The 
third action of oxysterols is the accelerated degradation of the 3-hydroxy-3-methyl-glutaryl-coenzyme A 
reductase (HMGCR), a key enzyme of cholesterol synthesis. The final pathway triggered by oxysterols is the 
enhanced cholesterol esterification for cell storage. These regulatory pathways as well as other oxysterol 
mediated mechanisms that do not regulate cholesterol levels, appeared in the last years to be important for 
several human physiological processes. For example it was found that 25-hydroxycholesterol (25-OHC) 
possesses anti-viral functions. This illustrates that the physiological importance of oxysterols was 
underestimated and that their implications are still not completely unravelled. Oxysterol analysis, however, is 
tricky and hampered by several difficulties, such as the large excess of cholesterol, the low endogenous 
concentrations of oxysterols, the possible autoxidation of cholesterol and oxysterols, the cellular localisation of 
oxysterols in membranes, the possible modifications of oxysterols like esterifications, reductions, or 
sulphations and finally their chemical structures and properties making mass spectrometry (MS) analysis 
difficult and not very specific.  
In this work, two liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods were 
established for the analysis of oxysterols in human diseases. The first method was developed and implemented 
for the analysis of oxysterols of non-enzymatic origin in a clinical setting of Niemann-Pick type C (NP-C) 
diagnosis. In addition, a second method was optimised for the analysis of enzymatically-derived oxysterols in 
the plasma of patients with Inflammatory Bowel Disease (IBD), opening a new research domain.  
In the first part dealing with the analysis of NP-C-specific oxysterols, we were able to precisely, accurately, and 
robustly measure Cholestane-3β,5α,6β-triol (C-triol) and 7-Ketocholesterol (7-KC) following a Steglich 
esterification. We established reference ranges for NP-C diagnostics, which turned out to be neither age nor 
gender-dependent and we established the pre-analytical stability of the compounds. We found an important 
intra-individual variation for both analytes, but could show increased C-triol levels in all Niemann-Pick patients 
including Niemann Pick type A and B patients. Our results suggest that especially the C-triol is a biomarker for 
all three Niemann-Pick diseases.  
In the second part dealing with the oxysterol fingerprint in IBD, we were able to separate in one 
chromatographic run 24(S)-hydroxycholesterol (24(S)-OHC), 25-hydroxycholesterol (25-OHC), 27-
hydroxycholesterol (27-OHC), 7α,24(S)-dihydroxycholesterol (7α,24(S)-OHC), 7α,25-dihydroxycholesterol 
(7α,25-OHC), 7α,27-dihydroxycholesterol (7α,27-OHC), 7β,25-dihydroxycholesterol (7β,25-OHC), and 7β,27-
dihydroxycholesterol (7β,27-OHC). The most important finding of our investigation in IBD is that 27-OHC and 
eventually 25-OHC are reduced in plasma of IBD patients compared to healthy volunteers. Both oxysterols are 
agonists for the LXR receptors, which are implicated in inflammation and thus may possibly participate in 
inflammatory mechanisms in IBD. The analysis of mono-and dihydroxycholesterols as biomarkers for IBD is a 
novel approach which shows promise but more IBD samples are required to corroborate the observed 
differences in oxysterol levels between the different groups, meaning the control group, patients with active 
Crohn’s disease or in remission, and patients with active Ulcerative colitis or in remission.  
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II 
ZUSAMMENFASSUNG 
Cholesterinoxidationsprodukte, auch "Oxysterole" genannt, wurden erstmals 1913 von I. Lifschütz erwähnt und 
untersucht, während er die weltweit bekannten Produkte Eucerin® und Nivea® Creme entwickelte. Er 
beschrieb Oxysterole, die nicht-enzymatisch gebildet werden und vor allem am Sterol-Ring oxidiert sind. 
Enzymatisch gebildete Oxysterole, die im wesentlich an den Seitenketten oxygeniert sind, wurden dagegen erst 
50 Jahre später entdeckt. In wenigen Fällen werden Oxysterole durch eine Kombination dieser beiden 
Stoffwechselwege generiert. Heutzutage ist bekannt, dass Oxysterole die Cholesterinhomöostase kontrollieren, 
die ein wichtiger biochemischer Prozess darstellt und wesentlich auf die menschliche Gesundheit einwirkt. Die 
Regulierung der Cholesterinhomöostase wird durch vier verschiedene Mechanismen bedingt. Der erste 
Regulationsmechanismus ist die Hemmung der Cholesterinbiosynthese durch die Hemmung des Sterol 
Regulatory Element-Binding Proteins (SREBPs), während als zweiter Regulationsmechanismus, die Aktivierung 
der Leber-X-Rezeptoren α und β (LXRα and LXRβ) zu vermehrtem Cholesterinexport führt. Der beschleunigte 
Abbau der 3-hydroxy-3-methyl-glutaryl- coenzyme A reductase (HMGCR), die als Schlüsselenzym der 
Cholesterinbiosynthese fungiert, ist der dritte Regulationsmechanismus der Cholesterin Homöostase. Der letzte 
Mechanismus, der durch die Oxysterole reguliert wird, besteht in der erhöhten Cholesterinveresterung zur 
Cholesterinzellspeicherung. Diese, sowie andere Oxysterol vermittelte Mechanismen, die nicht zur 
Cholesterinreguliergung beitragen, haben sich in den letzten Jahren als wichtige humanphysiologische 
Regulationsmechanismen etabliert. So wurde zum Beispiel die antivirale Eigenschaft von 25-hydroxycholesterol 
(25-OHC) entdeckt. Dies veranschaulicht, dass die physiologische Bedeutung der Oxysterole unterschätzt wurde 
und dass ihre Auswirkungen noch nicht vollständig verstanden werden. Dies hat auch damit zu tun, dass die 
Analytik der Oxysterole kompliziert ist und durch mehrere problematische Eigenschaften der Oxysterole 
behindert wird. Die Schwierigkeiten bei der Analytik sind unter anderem der große Cholesterinüberschuß, die 
geringen endogenen Oxysterolkonzentrationen, die mögliche Autoxidation von Cholesterin oder der Oxysterole 
selbst, die möglichen sonstigen chemischen Modifikationen, wie Veresterung, Reduktion oder Sulfatierung, die 
Lokalisierung in den Membranen, und schließlich ihre inerte chemische Struktur. Alle diese Faktoren, 
erschweren die Massenspektrometrische (MS) -Analyse und machen sie realtiv unspezifisch.  
In dieser Arbeit wurden zwei Methoden für die Analyse von Oxysterolen in humanem Plasma mittels 
Flüssigchromatographie gekoppelt mit Tandem-Massenspektrometrie (LC-MS/MS) etabliert. Die erste Methode 
wurde für die Analyse von nicht-enzymatischen Oxysterolen im klinischen Kontext der Niemann-Pick Typ C (NP- 
C) Krankheitsdiagnose entwickelt. Die zweite Methode wurde für die Erforschung der Rolle von enzymatisch 
generierten Oxysterolen bei chronisch entzündlichen Darmerkrankungen (IBD) generiert. 
In dem ersten Teil, der sich mit der Oxysterolanalyse für die NP-C Diagnose befasst, waren wir in der Lage, 
Cholestan-3β,5α,6β-triol (C-Triol) und 7-Ketocholesterol (7-KC) nach einer Steglich-Veresterung präzise, richtig 
und robust zu messen. Wir haben Referenzintervalle für die NP-C Diagnose erstellt, welche unabhängig von 
Alter oder Geschlecht sind und haben die prä-analytische Stabilität definiert. Wir fanden eine hohe 
intraindividiuelle Variation für beide Analyten, konnten jedoch erhöhte C-Triol Werte in allen Niemann-Pick - 
Patienten einschließlich Niemann-Pick Typ A und B - Patienten zeigen. Unsere Ergebnisse deuten darauf hin, 
dass vor allem C-triol ein Biomarker für alle drei Niemann-Pick Krankheiten ist.  
Im zweiten Teil, der sich mit dem Oxysterol-Fingerabdruck in IBD befasst, waren wir in der Lage in einem 
chromatographischen Lauf 24(S)-hydroxycholesterol (24(S)-OHC), 25-hydroxycholesterol (25-OHC), 27-
hydroxycholesterol (27-OHC), 7α,24(S)-dihydroxycholesterol (7α,24(S)-OHC), 7α,25-dihydroxycholesterin (7α, 
25-OHC), 7α,27-Dihydroxycholesterin (7α,27-OHC), 7β,25-dihydroxycholesterin (7β,25-OHC) und 7β,27-
dihydroxycholesterin (7β,27-OHC) aufzutrennen und zu quantifizieren. Unser bedeutenstes Ergebnis ist die 
Verminderung von 27-OHC und möglicherweise auch von 25-OHC im Plasma von IBD-Patienten im Vergleich zu 
gesunden Freiwilligen. Beide Monohydroxycholesterine sind Liganden der LXR Rezeptoren deren positiver 
Einfluss bei Entzündungen bereits in der Literatur beschrieben wurde. Die gemessene Verminderung der 
Liganden könnte somit die Entzündungsmechanismen bei IBD beeinflussen. Die Analyse der Mono- und 
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III 
Dihydroxycholesterine als Biomarker für IBD ist ein neuer viel versprechender Ansatz, der allerdings mehr IBD 
Proben benötigt, um weitere Unterschiede zwischen den verschiedenen Studiengruppen d.h. der 
Kontrollgruppe, der aktiven und inaktiven Morbus Crohn und der aktiven und inaktiven Colitis Ulcerosa Gruppe 
aufzuzeigen.  
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ABBREVIATIONS 
24(S),25-EC:  24(S),25-epoxycholesterol 
24(S)-OHC:  24(S)-hydroxycholesterol 
25-OHC:   25-hydroxycholesterol  
27-OHC:   27-hydroxycholesterol (also known as (25R)-26-hydroxycholesterol) 
4β-OHC:   4β-hydroxycholesterol 
7-KC:   7-ketocholesterol 
7α,24(S)-OHC:  7α,24(S)-dihydroxycholesterol 
7α,25-OHC:  7α,25-dihydroxycholesterol 
7α,27-OHC:  7α,27-dihydroxycholesterol 
7α-OHC:  7α-hydroxycholesterol 
7β,25-OHC:  7β,25-dihydroxycholesterol 
7β,27-OHC:  7β,27-dihydroxycholesterol 
7β-OHC:   7β-hydroxycholesterol 
ABCA1:   ATP-binding cassette proteins, subfamily A, member 1 
ABCG1:   ATP-binding cassette protein, sub-family G, member 1 
ABCG5:   ATP-binding cassette protein, sub-family G, member 5 
ABCG8:   ATP-binding cassette protein, sub-family G, member 8 
ACN:   Acetonitrile 
APCI:   Atmospheric pressure chemical ionisation 
Apo (A1 or E):  Apoliporotein A1 or E 
BHT:   Butylated hydroxytoluene 
CD:   Crohn disease 
CE:   Collision energy 
CH25H:   Cholesterol 25 hydroxylase 
CI:   Confidence interval 
COPII:   Coat protein complex II 
Cps:   Counts per second 
C-triol:   Cholestane-3β,5α,6β-triol 
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CTX:   Cerebrotendinous xanthomatosis 
CV:   Coefficient of variation  
CVw    Coefficient of variation for intra-individual variation  
CXP:   Cell exit potential 
CYP:   Cytochrome P450 
CYP27A1:  Serol 27-hydroxylase 
CYP46A1:  Cholesterol 24-hydroxylase 
CYP7A1:   Cholesterol 7α-hydroxylase 
CYP7B1:   Oxysterol 7α-hydroxylase 
DP:   Declustering potential  
EBI2 or GPR183:  Epstein-Barr virus-induced G-protein coupled receptor 2  
EP:   Entrance potential 
ER:   Endoplasmic reticulum 
ESI:   Electrospray 
EtOH:   Ethanol 
FA:   Formic acid 
GC:   Gas chromatography 
GC-MS:   Gas chromatography coupled to mass spectrometry 
HDL:   High density lipoprotein 
HMGCR:   3-hydroxy-3-methyl-glutaryl- coenzyme A reductase (HMG-CoA reductase) 
HPLC:   High performance liquid chromatography 
HPLC–MS/MS:  High-performance liquid chromatography coupled to tandem mass spectrometry 
HQC:   High quality control (endogenous level with 100 ng/mL standard) 
IBD:   Inflammatory Bowel Diseases 
IFN:   Interferons 
INSIG:   Insulin-induced gene protein 
IS:   Internal standards 
IUPAC:   International union of pure and applied chemistry 
LC-MS/MS:  Liquid chromatography coupled to tandem mass spectrometry 
LDL:   Low density lipoprotein 
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LOD:   Limit of detection 
LOQ:   Limit of quantification  
LQC:   Low quality control (endogenous level) 
LXR:   Liver X receptor 
MeOH:   Methanol 
MQC:   Medium quality control (endogenous level with 30 ng/mL standard) 
MRM:   Multiple reaction monitoring 
MS:   Mass spectrometry 
NP-A:   Niemann-Pick type A 
NP-B:   Niemann-Pick type B  
NP-C:   Niemann-Pick type C 
ORP:   OSBP-related proteins 
POIS:   Performance optimising injection sequence  
PUFA:   Polyunsaturated fatty acids 
QC:   Quality controls  
RORγt:   RAR (Retinoic acid receptor)-related orphan receptor gamma t 
ROS:   Reactive oxygen species 
S/N:   Signal to noise ratio 
SCAP:   SREBP cleavage-activating protein 
sER:   Smooth endoplasmic reticulum 
SPE:   Solid-phase extraction 
SREBP:   Sterol regulatory element binding protein 
TOF-MS:  Time of flight mass spectrometry 
UC:   Ulcerative colitis 
UHPLC:   Ultra high performance liquid chromatography 
UPC2:   Ultra performance convergence chromatography 
VLDL:   Very low density lipoprotein 
XIC:   Extracted ion chromatogram 
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1.1 BACKGROUND ON OXYSTEROLS  
1.1.1 DEFINITION 
Oxysterols are cholesterol oxidation derivatives with 27 carbon atoms, carrying an alcohol (ex: 7β-
hydroxycholesterol (7β-OHC) Figure 1A), a carbonyl (ex: 7-ketocholesterol (7-KC) Figure 1B) or an epoxide group 
(ex: 5,6-epoxycholesterol Figure 1C) 
1,2
. The oxysterol common name indicates at which carbon number the 
cholesterol backbone is oxidised. Oxysterols are either categorised according to their origin or, although 
overlapping with this first categorisation, according to the oxidation side either on the ring or on the side-chain.  
 
FIGURE 1| Three examples of different oxysterols A. 7β-hydroxycholesterol B. 7-ketocholesterol (7-KC), Figure C. 5,6-epoxycholesterol. 
1.1.2 CLASSIFICATION AND CHEMICAL STRUCTURE 
According to the LIPID MAPS classification, oxysterols are members of the sterol lipid family with the LIPID 
MAPS number ST0101 
3, 4
. The International union of pure and applied (IUPAC’s) broad sterol definition is 
“Sterols are steroids carrying a hydroxyl group at C-3 and most of the skeleton of cholestane. Additional carbon 
atoms may be present in the side chain “
5
. The best known sterol example is cholesterol ((3β)-cholest-5-en-3-
ol), from which the oxysterols directly derive ( 
Figure 2).  
 
Figure 2| Illustration of the chemical structure of cholesterol 
Sterols, together with bile acids and steroid hormones, belong on their turn to the steroid compound class. 
Steroids are defined by IUPAC as “compounds possessing the skeleton of cyclopenta*α+phenanthrene or a 
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skeleton derived therefrom by one or more bond scissions or ring expansions or contractions. Methyl groups 
are normally present at C-10 and C-13. An alkyl side chain may also be present at C-17” 
5
. 
1.1.3 NOMENCLATURE 
Oxysterols nomenclature follows the IUPAC convention for steroids 
5
 (Figure 3). 
 
Figure 3| Sterol backbone with ring labelling and carbons numbering according to the IUPAC nomenclature. Ring denomination is 
labelled in black, carbon numbers are labelled in blue and the cyclopenta[α]phenanthrene is highlighted in dark purple. 
It is to mention that the orientation of the hydrogen at position C-5 depends on the position of ring A towards 
ring B. If the A/B ring configuration is in trans then the C-5 hydroxyl is in alpha. In contrary, A/B cis 
configuration results in C-5 in beta position 
6
. Generally, the C-5 hydrogen atom of sterols is in alpha position, 
while the C-5 hydrogen atom of bile acids is in beta position 
6,7
. Steroid hormones do not have a hydroxyl group 
at C-5, but a double bond between C-4 and C-5. In the IUPAC guideline for nomenclature of steroids, the 
authors emphasis that “If one of the two methyl groups attached to C-25 is substituted it is assigned the lower 
number; if both are substituted, that carrying the substituent cited first in the alphabetical order is assigned the 
lower number“ 
5
. However, this last simple rule was violated by many scientists and manufacturers of 
chemicals, so that (25R)-26-hydroxycholesterol is now known and referred to as 27-hydroxycholesterol. R. 
Fakheri and N. Javitt counteracted by publishing in 2012 a review on the nomenclature and stereochemistry of 
26-hydroxylated sterols explaining the misnaming of 27-hydroxycholesterol, nevertheless without noticeable 
acceptance from the readers 
8
. In this manuscript we will use the name of 27-hydroxycholesterol since it is now 
the most commonly used denomination, especially in the medical literature and PubMed. 
1.1.4 HISTORICAL PERSPECTIVE 
At the beginning of the 20
th
 century the chemist I. Lifschütz extracted from sheep wool wax a cholesterol- rich 
substance mixture which he called Eucerit. It was the first water-in-oil emulsifier and when added with paraffin 
it becomes a perfect basis for salve products called Eucerin. J. Lifschütz patented his discovery in 1902 and 
continued his research on Eucerin leading to the development of the worldwide famous Nivea Cream. During 
his experimentation he observed a novel substance class, which he named “Oxycholesterin”, later known as 
oxysterols 
9
. The oxysterol research era was born. Since then many discoveries were made and the main 
milestone discoveries are summarised in Table 1. 
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Table 1| Selected discoveries of oxysterols research milestones. The abbreviations and acronyms are explained in the chapter. Table 
adapted from Gill et al. (2008) 10. 
Year Discovery Reference  
1769 Cholesterol isolation by Poulletier de la Salle 
11
 
1816 Cholesterol characterisation and naming by Chevreul 
12
 
1906 Oxysterol discovery by Lifschütz 
9,11
 
1927-28 Windaus and Wieland Nobel Prize awarding for elucidation of cholesterol and bile acids structures 
13
 
1933 Cholesterol negative feedback regulation 
14
 
1953 24(S)-OHC (cerebrosterol) discovered in human brain 
15
 
1956 Oxysterols of enzymatic origin 
16
 
1964 Bloch and Lynen Nobel Prize awarding for elucidating the cholesterol and fatty acid biosynthetic 
pathways.  
13
 
1978 Oxysterol hypothesis on negative feedback regulation 
17
 
1985 Brown and Goldstein Nobel Prize awarded for elucidating the regulation of cholesterol metabolism, 
including the LDL receptor discovery 
13
 
1992 Discovery of the oxysterol binding proteins (OSBP) 
18
 
1993 SREBP (master regulators of cholesterol homeostasis) activation inhibition by certain oxysterols 
19
 
1994 27-OHC provides a cholesterol elimination mechanism for macrophages 
20
 
1996 24(S)-OHC provides a cholesterol elimination mechanism for brain 
21
 
2003 Accelerated HMGCR degradation by oxysterols and sterol intermediates of cholesterol synthesis 
22
 
2007 Oxysterols are LXRs ligands 
& Insig identification as oxysterol sensor in the ER 
23,24
 
2008 24(S),25-epoxycholesterol as acute regulator for smoothing cholesterol homeostasis response  
25
 
2010 C-triol and 7-KC as biomarker for NP-C 
26
 
2011 7α,25-OHC as EBI2 ligand for B cell homing within a lymph node 
27,28
 
2013 Indications that oxysterols are implicated in IBDs 
29
 
In 2010 to follow the rapid expansion of oxysterol research, several groups associated to form the European 
Network on Oxysterols Research (ENOR). It is a self-promoting and self-sustaining oxysterols organisation with 
about 80 members open to any research group worldwide and to any oxysterol research subdomain 
2,30
  
1.1.5 FUNCTION 
Oxysterols are molecules present in the cell in very small amounts but exert multiple functions which are 
discussed in detail in the next subchapters. Long-time considered as cholesterol autoxidation side product they 
were of no concern but since more and more functions were discovered, they gained interest in the scientific 
community (Figure 4). First, the main function of oxysterols in cholesterol homeostasis will be discussed 
1,31–33
. 
Second, the recent oxysterol research is explained, which focuses on their implication in immunology with still 
many unanswered questions 
28,34–36
. Finally, the focus will be on the implication of oxysterols in other 
physiological pathways, which indicates that oxysterols play a more important role in human physiology than 
initially expected.  
 
 
Figure 4| Overview of current functions attributed to oxysterols. Oxysterols regulate cholesterol homeostasis but they are also 
implicated in immunology, they have cytotoxic properties, are involved in signalling, development and cell differentiation, in sterol 
transport and finally they are metabolic intermediates. The abbreviations and acronyms are explained in the chapter. Adapted from 
Olkkonen et al. (2012) 37. 
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1.1.5.1 OXYSTEROLS REGULATING CHOLESTEROL HOMEOSTASIS 
Cholesterol is a key component in living organisms and has an essential role in membrane structure, is a 
precursors for steroid hormones and bile acids, influences signalling processes and can be covalently attached 
to proteins 
38,39
. Despite its crucial functions too much of it is deleterious and therefore its levels need to be 
tightly controlled. In this subchapter, cholesterol’s own feedback regulation with the oxysterol contribution to 
it will be explained in detail. Cholesterol’s own feedback regulation was discovered in the beginning of the 19
th
 
century by Schoenheimer and Breusch 
14
. However, the oxysterol contribution to this process was only 
identified nearly half a decade later by Kandutsch et al. 
17
. Nowadays oxysterols, in particular 25- 
hydroxycholesterol (25-OHC), 24(S)-hydroxycholesterol (24(S)-OHC) and 27-hydroxycholesterol (27-OHC), are 
known to be implicated in cholesterol homeostasis by the mean of different regulatory pathways acting on 
cellular cholesterol uptake, synthesis and efflux 
1
 (Figure 5).  
 
Figure 5| General overview on cholesterol homeostasis regulated by oxysterols. Oxysterols inhibit SREBP activity which reduces cellular 
cholesterol uptake (1.), they increase HMGCR degradation (2.) and cholesterol cell efflux (4.) and also increase the storage of cholesterol 
in form of cholesteryl esters (3.). The abbreviations and acronyms are explained in the chapter. Figure adapted from Brown et al. (2009) 
1. 
1.1.5.1.1 CHOLESTEROL HOMEOSTASIS REGULATION ON A TRANSCRIPTIONAL LEVEL BY 
OXYSTEROLS  
The transcription factor sterol regulatory element binding protein (SREBP) acts on many genes directly involved 
in cholesterol, fatty acid biosynthesis, and low density lipoprotein (LDL) cell endocytosis 
40
. These regulated 
genes exhibit the sterol responsive element (SRE) motif necessary for SREBP recognition and binding, leading to 
the activation of gene transcription 
19,41
.  
The activity of SREBP is tightly regulated. At high sterol levels, cholesterol binds to SREBP cleavage-activating 
protein (SCAP) which retains SREBP in the membrane of the endoplasmic reticulum (ER) thereby suppressing 
SREBP gene activation 
42
 (Figure 6A). This is the classical cholesterol feedback regulation mechanism. However, it 
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is also possible that in the same condition oxysterols, like 25-OHC, bind to Insulin-induced gene 1 protein (Insig) 
which is a third ER membrane protein coupled to the SCAP - SREBP complex thereby also holding back SREBP 
23,43–45
. Whether cholesterol binding directly to SCAP or oxysterols binding to Insig, the outcome is exactly the 
same: SREBP is retained in the ER membrane and cannot act as transcription factor 
46
.  
In the opposite situation, when cholesterol levels fall under a critical threshold, the SCAP-SREBP complex 
dissociates from Insig and moves via a coat protein complex II (COPII) vesicle transport to the Golgi 
44,45,47,48
 
(Figure 6B 1-2). Once located in the Golgi membrane SREBP will be sequentially cleaved by two proteases, site-1 
protease (S1P) and site-2 protease (S2P), releasing the basic helix-loop-helix Zip type (bHLH-Zip) domain of 
SREBP, which translocate to the nucleus and activates target gene transcription 
42,49
 (Figure 6B 3-4). 
This description is a simplified version of a very complex process. In order to make the cholesterol homeostasis 
regulation more comprehensive, the different actors will be discussed in more details here below.  
In the cell, cholesterol is to 95 % present in the plasma membrane or resides in lipid droplets. ER is the 
organelle with very little cholesterol, thus being the perfect cholesterol sensor in the cell 
39
. Cholesterol 
concentration detection is mediated in the ER membrane by SCAP at its sterol-sensing domain in the N-
terminus consisting of 5 of SCAP’s 8 transmembrane regions 
51–53
. An important hexapeptide sequence called 
MELDAL standing for methionine- glutamic acid- leucine- alanine- aspartic acid- leucine is located at SCAP’s 
cytoplasmic loop 6 
54
. At the C-terminus a regulatory region with 4 motifs called WD40 physically interacts with 
SREBP 
42
. During cholesterol deprivation, the MELDAL sequence is accessible for Sec24 binding, a component of 
the Sar1/Sec23/Sec24 complex of COPII coat proteins 
54,55
. Through this specific binding the SCAP-SREBP 
complex is sequestered in COPII- coated vesicles that leave the ER for the Golgi. When the sterol level is rising 
and cholesterol is binding to SCAP or oxysterols to Insig, loop 6 of SCAP changes its conformation. The 
consequence is that the MELDAL sequence binds to Insig and can no longer be recognised by the COPII proteins 
thus abrogating the transport pathway 
55
.  
Insig is considered to be a small ER retention protein, consisting of 6 transmembrane domains. Insig-oxysterol 
interaction takes place at the third and fourth transmembrane span, while SCAP binding occurs at the cytosolic 
loop between transmembrane domains 4 and 5. Insig has two isoforms: Insig-1 and Insig-2 
44,45
. Insig-1 is a 277 
amino acid long protein highly expressed in human liver, while Insig-2 contains 255 amino acids and is 
ubiquitously expressed. Insig-1 expression is transcriptionally controlled by SREBP meaning that cholesterol 
biosynthesis is accompanied by the synthesis of one of its own regulatory elements 
40,56
. In contrast, the Insig-2 
promoter is activated by insulin receptor signalling 
43–45
. Oxysterol binding to the Insig proteins has a second 
effect besides ER retention of the SCAP-SREBP complex 
23
. Upon oxysterol binding, Insigs are able to interact 
with 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA reductase or HMGCR), the rate-limiting 
enzyme in cholesterol biosynthesis also located in the ER membrane. Insig’s binding to HMGCR causes its 
degradation by the ubiquitin-proteasomal system 
22,57–59
.  
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Figure 6| Cholesterol feedback mechanism. At high sterol level, the Insig-SCAP-SREBP complex is retained in the ER (A.). At low sterol levels, Insig dissociates from the SCAP-SREBP complex and the MELDAL sequence 
(highlighted in red on SCAP) is accessible for Sec24 binding, thus being a starting point for vesicle formation (B.1). SCAP-SREBP are via COPII vesicle transported from the ER to the Golgi (B.2). In the Golgi the SCAP-
SREBP complex is sequentially spliced by S1P and S2P to deliver the SREBP transcription factor (B.3). The SREBP transcription factor moves into the nucleus activating genes at the SRE recognition site (B.4). The 
abbreviations and acronyms are explained in the chapter. Figure adapted from Ikonen et al. (2008) 50 
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SREBP is a 2 transmembrane protein with its C-Terminus interacting with SCAP. The N-Terminus consists of a 
transcription factor motif of the basic helix-loop-helix Zip type 
60
. Both terminuses are exposed to the cytosolic 
side. SREBP is encoded by two distinct genes generating SREBP-1 and SREBP-2 proteins 
61,62
. SREBP-1 
expression can be activated by high cellular sterol content binding to liver X receptors (LXRs), while SREBP-2 is 
not 
62,63
. In addition SREBP-1 exists under two isoforms: SREBP-1a and 1c, both controlling genes of fatty acids 
synthesis and each a specific set of genes 
63,64
. SREBP-1a regulates also genes of the cholesterol biosynthetic 
pathways whereas SREBP-1c regulates genes involved in glucose utilisation 
40,65
. SREBP-2, is the predominant 
transcription factor in liver, regulating genes involved in cholesterol homeostasis including genes encoding 
cholesterol biosynthetic enzymes and genes responsible for LDL receptor expression 
40
. SREBPs are finally 
activated after translocation to the Golgi by the action of two Golgi-associated membrane bound proteases 
49,66
. SCAP stimulates the first cleavage mediated by site-1 protease, a serine protease, at the luminal loop 
between the two transmembrane domains 
67
. The second cleavage is mediated by the site-2 protease, a Zn
2+
 
metalloprotease 
68
 and results in the cytosolic release of the N-terminal the basic helix-loop-helix Zip type 
motif. This mature transcription factor migrates into the nucleus and activates its target genes 
49,68
. 
1.1.5.1.2 CHOLESTEROL HOMEOSTASIS REGULATION ON A POSTTRANSLATIONAL LEVEL BY 
OXYSTEROLS  
1.1.5.1.2.1 ACCELERATED DEGRADATION OF THE HMG-COA REDUCTASE 
As already highlighted during the description of Insig functions, oxysterol-activated Insig interaction leads to 
HMGCR destruction by the ubiquitin-proteasomal system (Figure 7). Insig associates with ubiquitin ligases gp78 
(= autocrine motility factor receptor (AMFR)) and translocation in renal cancer from chromosome 8 (Trc8), both 
responsible for HMGCR ubiquitination. This ubiquitination is then recognised by ATPases associated with 
various cellular activities - Valosin-containing protein (AAA-ATPase VCP/p97) extracting the HMGCR across the 
ER membrane. Ubiquinated HMGCR released into the cytosol will then be degraded in the proteolytic chamber 
of the 20S proteasome 
69
. This captivation, extraction and destruction process is called ER-associated 
degradation (ERAD) 
70,71
. It was shown that the ubiquitin-proteasomal degradation pathway is also activated on 
a posttranslational level. Mevalonate-derived metabolites like geranylgeraniol are known to destabilise HMGCR 
58,72,73
 and it was recently shown that they increase the sterol-accelerated ERAD of HMGCR by a still badly 
understood mechanism but do not affect sterol-induced ubiquitination 
74
. The transcriptional and 
posttranslational regulations of HMGCR demonstrate the need for a tight control of this rate-controlling 
enzyme in cholesterol biosynthesis. 
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Figure 7| Posttranslational HMGCR degradation mechanism. Oxysterols induce HMGCR ubiquitination being a molecular signalling for 
HMGCR membrane extraction and subsequent degradation by the proteasome. The abbreviations and acronyms are explained in the 
chapter. Figure adapted from Schumacher et al. (2015) 74. 
1.1.5.1.2.2 INCREASED CHOLESTEROL EFFLUX BY LIVER X RECEPTORS ACTIVATION 
LXRs were declassified as orphan nuclear receptors when it was shown that oxysterols are their natural ligands 
24,75
. LXRα and LXRβ dimerise with the obligate partner 9-cis retinoic acid receptor α (RXRα) followed by LXR 
response element binding in the promoter region of LXR target genes 
76,77
. The heterodimer senses cellular 
oxysterols and their binding provokes conformational changes of LXR, releasing in that way co-repressors and 
recruiting co-activators for gene activation 
78–81
.  
Up-regulated genes are those that control sterol and fatty acid metabolism including genes involved in reverse 
cholesterol transport 
82
. The main actors of reverse cholesterol transport activated by LXRs are: ATP-binding 
cassette protein, sub-family A, member 1 (ABCA1), ATP-binding cassette protein, sub-family G, member 1 
(ABCG1), ATP-binding cassette protein, sub-family G, member 5 (ABCG5) and ATP-binding cassette protein, 
sub-family G, member 8 (ABCG8), as well as apolipoprotein E (apoE), cholesteryl ester transfer protein (CETP), 
phospholipid transfer protein (PLTP), and scavenger receptor B1 (SR-B1) 
82
. 
In reverse cholesterol transport, the ATP-binding cassette transporters such as ABCA1 and G1 of macrophages 
facilitate the charging of cell phospholipids and cholesterol onto exchangeable apolipoproteins, especially on 
apoA-I, to initiate and propagate high density lipoprotein (HDL) formation 
83,84
. The cholesterol of the growing 
HDL is subsequently converted into cholesteryl esters by the lecithin-cholesterol acyltransferase (LCAT) and 
further transported by the mean of three possible mechanisms. The first and most important mechanism in 
humans is the selective uptake of HDL-derived cholesteryl esters by the liver through the scavenger receptor B1 
85
. The second mechanism is the exchange of cholesteryl esters from HDL to VLDL and LDL by the cholesteryl 
ester transfer protein. Consequently, the second mechanism allows the third mechanism of liver uptake of 
(V)LDL- derived cholesteryl esters through the LDL receptors 
63
. The liver and the intestine expresses ABCG5 
and ABCG8, which are half-transporters that form obligate heterodimers allowing the cholesterol export into 
the bile, respectively in the intestinal lumen, thus leading to the cholesterol excretion from the body 
86–88
. 
Cholesterol conversion into bile acids is in rodents additionally enhanced through the LXRs, since LXRs control 
and activate the rodent cholesterol 7α-hydroxylase (CYP7A1), being the rate-limiting enzyme of the ‘‘classical’’ 
bile acid synthesis pathway 
89
. 
An alternative to cholesterol body export is to store cholesterol as cholesteryl esters within lipid droplets, 
which is the cell’s dominant strategy in situation of excess cellular cholesterol 
90
. The esterification occurs in the 
ER by the action of acetyl-coenzymeA -acetyltransferase (ACAT) 
90
. Acetyl-coenzymeA -acetyltransferase 
possesses a catalytic and an allosteric activator binding site, with only cholesterol being able to strongly bind to 
the allosteric site. The molecular mechanism of oxysterol - activated cholesterol esterification is therefore still 
unclear 
91
. 
1.1.5.1.2.3 24(S),25-EPOXYCHOLESTEROL AS MONITOR AND MODULATOR OF CHOLESTEROL 
SYNTHESIS 
24(S),25-epoxycholesterol (24(S),25-EC) was identified to be an oxysterol with a particular role in the regulation 
of cholesterol homeostasis. Its origin is atypical since it is synthesised in a shunt of the mevalonate pathway, 
parallel to cholesterol synthesis. In the shunt pathway squalene epoxidase adds not one but two epoxide 
groups to squalene forming diepoxysqualene (DOS) 
92,93
. 2,3-oxidosqualene cyclase (OSC) cyclises further both 
diepoxysqualene and monooxidosqualene (MOS) but with a preference for diepoxysqualene to give rise to the 
endproducts of 24(S),25-EC and cholesterol by the mean of multiple steps 
94
. 24(S),25-EC is able to inhibit 
cholesterol synthesis similar to 25-OHC, 24(S)-OHC and 27-OHC by stimulating HMGCCR degradation, 
suppressing SREBP activation and stimulating cholesterol efflux. 24(S),25-EC in addition is able to inhibit the 
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desmosterol reductase (DHCR24), inhibiting so the desmosterol-cholesterol conversion 
95
. Taking together all 
actions of endogenous 24(S), 25-EC indicates that this molecule is fine-tuning the acute control of cellular 
cholesterol 
25
 (Figure 8). 
 
Figure 8| 24(S),25-EC's Shunt pathway (A). 24(S),25-EC is synthesised in parallel to cholesterol by squalene epoxidase by a second 
epoxide addition to squalene and further metabolisation by oxidosqualene cyclase (A). The hypothetical cholesterol response over time 
in absence (black line) and presence of 24(S),25-EC demonstrating the smoothing effect of the latest (B). The abbreviations and 
acronyms are explained in the chapter. Figure adapted from Gill et al. (2008) 10. 
1.1.5.1.2.4 OXYSTEROL-MEMBRANE INTERACTIONS IN THE REGULATION OF CELLULAR 
CHOLESTEROL HOMEOSTASIS 
Oxysterols are among others imbedded in plasma membrane but whether they exert any impact on the 
membrane structure was till recently unknown. Gale et al. were one of the first to show in 2009 that the “side 
chain oxysterols, but not steroid ring modified oxysterols, exhibit membrane expansion behaviour in 
phospholipid monolayers and bilayers in vitro” 
96
. The presence of oxysterols in membrane reduces membrane-
cholesterol affinity, although the mechanism behind it is not known 
97–100
. Recently, Ory’s group further 
elucidate the so called membrane expansion behaviour in showing that increased cholesterol liberation was 
due to 25-OHC presence in membrane resulting in membrane thinning 
101
.  
1.1.5.1.3 BRAIN CHOLESTEROL HOMEOSTASIS 
Cholesterol homeostasis regulation by oxysterols such as described in the previous sections cannot be applied 
to brain cholesterol homeostasis. The reason, is that cholesterol is unable to cross the blood-brain barrier thus 
limiting the exchange of cholesterol between the cerebrum and the periphery. However, central nervous cells, 
such as neurons and glial cells are extremely high cholesterol requestors meaning that the brain essentially 
depends on de novo synthesis and recycling 
102
. In addition, the regulation of brain cholesterol homeostasis 
requires oxysterols since they are able to cross the blood-brain barrier in contrary to cholesterol. In brain, 
cholesterol can be metabolised into 24(S)-OHC, which is then able to leave the brain, accounting as the main 
brain efflux mechanism 
21,103,104
. In the opposite direction, 27-OHC being the major plasma oxysterol, is able to 
enter the brain 
105
. These two oxysterols are as already mentioned, LXRs agonists activating thereby the 
expression of cholesterol efflux transmembrane transporters 
106
. LXRβ is highly expressed in the brain and 
through its activation; oxysterols regulate the cerebral cholesterol pool according the brain’s needs 
107–109
. 
Further regulatory roles of oxysterols in brain metabolism other than cholesterol homeostasis have been 
observed. A first example is the discovery of LXRα and β activation by oxysterols promoting myelination and 
remyelination in the cerebellum, while in the central nervous system (CNS) and peripheral nervous system 
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(PNS) the opposite effect was observed 
110,111
. A second example, is the negative influence of 27-OHC on 
learning, for which the mechanism has not been solved 
112
. 
1.1.5.2 OXYSTEROL PARTICIPATION IN IMMUNITY 
“25-hydroxycholesterol may be more important as a regulator of immunity than as a regulator of cholesterol 
metabolism “, was Diczfalusy’s provoking statement in his review on 25-OHC 
113
. It is too early to judge whether 
this affirmation is true or not, but it highlights the different functions discovered in innate and adaptive 
immunity for 25-OHC and its metabolite 7α,25-dihydroxycholesterol (7α,25-OHC).  
1.1.5.2.1 OXYSTEROL’S IMPLICATION IN THE ADAPTIVE IMMUNE SYSTEM 
1.1.5.2.1.1 ANTI-INFLAMMATORY AND ANTIVIRAL PROPERTIES 
25-OHC function in adaptive immunity is still controversial, however, it mainly appears to be anti-inflammatory 
and anti-viral (Figure 9). The anti-inflammatory property of 25-OHC is currently thought to play a role during 
Type 1 Interferon’s (IFNs) (IFN α and β) suppressive effects of the immune system 
114
. This cytokine class is 
known to be a major host defence mechanism after Toll-like receptor (TLRs) activation by bacterial or viral 
ligands. Type 1 IFNs help to prevent uncontrolled inflammation by down regulating inflammasome’s action and 
by reducing the production of pro-inflammatory IL-1 cytokines (IL-1α, IL-1β and IL-18) 
115–117
. It was discovered 
that type 1 IFNs increase cholesterol 25 hydroxylase (CH25H) expression in the ER, consequently producing 25-
OHC that suppresses SREBP activation 
114,117,118
. In turn, reduced SREBP activity decreases the expression of IL-
1β and the inflammasome activity, mediating the negative feedback pathway to prevent new IL-1 cytokine 
production and release 
114
. How SREBP promotes IL-1β expression is yet not defined, and may be both 
independent and downstream of sterol biosynthesis. Currently, the effect is mainly believed to be of indirect 
nature, since no direct interaction between SREBPs and the IL-1β promoter could be found 
34
.  
IFN dependent 25-OHC action of blocking of SREBP activation appears also to be the underlying mechanisms 
for the antiviral properties of 25-OHC. During infections, viruses alter host cellular lipid metabolism to support 
their own replication 
119,120
. However, most viral infections are combated with a strong induction of IFNs 
increasing 25-OHC levels, which down regulate sterol biosynthesis and thus decrease virus entry into the cell 
and replication 
121
. The exact pathway of 25-OHC antiviral effect is still under investigation and several 
hypotheses have been raised. Among them are altered cholesterol content of the plasma membrane, which 
could neutralise viral fusion and entry, or altered cholesterol content of internal membranes to avoid the 
reprogramming of organelles for viral assembly and packaging, or suppression of endogenous and viral protein 
prenylation which is involved in viral replication and assembly, and finally a possible direct inhibition of viral 
replication 
121–124
. Even if more studies are required to understand 25-OHC antiviral mechanism, 25-OHC was 
proposed as a therapeutic option against viruses 
122,125,126
. 
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Figure 9| Oxysterols implication in immunity. Oxysterols were shown to have anti-viral properties (A) and anti- but also pro-
inflammatory properties (B). The anti-inflammatory pathway is highlighted in black, while the pro-inflammatory pathway is highlighted 
in red (B). The abbreviations and acronyms are explained in the chapter. Figure adapted from Cyster et al. (2014) 34. 
25-OHC implication in immunology is known since the 1970s but 7α,25-hydroxycholesterol (7α,25-OHC) 
participation was first published in two parallel studies in Nature in 2011 
28,35
. They described 7α,25-OHC as a 
ligand for the Epstein–Barr virus-induced gene 2 receptor (EBI2, also known as GPR183). EBI2 is a G-protein-
coupled receptor connected with Gαi subunits, which triggers several signal transduction cascades upon ligand 
activation. Among the mobilised pathways are the activation of RHO family GTPases and mitogen-activated 
protein kinase (MAPK), including extracellular signal-regulated kinase (Erk) and p38- mitogen-activated protein 
kinase, and intracellular calcium flux 
35,127–129
. EBI2 is expressed on B cells in the secondary lymph organs and in 
vitro and in vivo studies shed light on the involvement of the EBI2 receptor-7α,25-OHC system in the humoral 
immune response. 
To summarise, B cells express the EBI2 receptor on their surface in the follicles of the secondary lymph organs. 
After antigen contact at the follicle T cell zone interface, B cells undergo a series of migratory steps that are 
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mediated by the concentration gradient of 7α,25-OHC. B cell motion towards distinct microenvironments in the 
follicle is crucial for induction, maturation and survival of plasmablasts and thereby for the activation of the 
immune response 
34,35,130–133
. 
Given all these information of oxysterols role in adaptive immunity Cyster et al. hypothesised that 25-OHC and 
7α,25-OHC operate in a hand-in-hand manner: Exposure to TLR ligands during viral infection increases 25-OHC 
making it more available for oxysterol 7α hydroxylase (CYP7B1) to convert it into 7α,25-OHC. 7α,25-OHC, as 
EBI2 ligand, will induce B cell motion in secondary lymph organs and in this way activate an immune response. 
Probably, the remaining 25-OHC quenches inflammasome activity and exerts its antiviral effects to limit cell 
damage 
34
.  
1.1.5.2.1.2 OXYSTEROLS PRO-INFLAMMATORY ACTIONS  
In contrary to the anti-inflammatory and antiviral properties of the oxysterols studied so far, also pro-
inflammatory properties have been reported in the last years. At first, 25-OHC was shown to amplify the 
secretion of IL-6, IL-8 and macrophage colony-stimulating factor (M-CSF) in macrophages and in airway 
epithelial cells after infection by a double-stranded (ds) RNA virus 
36,134
. At second, a very recent revelation was 
that retinoic acid receptor (RAR)-related orphan receptor gamma t (RORγt) binds to 7α,27-OHC and 7β,27-OHC 
135
. The ligand-receptor binding showed to drive the differentiation of TH17 cells producing IL-17 and thus 
initiating an immune response 
135
. 
1.1.5.2.2 25-OHC IMPLICATION IN THE INNATE IMMUNE SYSTEM 
Oxysterols are besides their role in adaptive immunity, also implicated in the innate immune system. Ecker et 
al. showed that 25-OHC suppressed the differentiation of monocyte into macrophages. Since macrophages 
produce and secrete 25-OHC in response to TLR activation, it may be a negative-feedback mechanism that 
reduces the number of phagocytes capable of synthesising 25-OHC 
136,137
. 
1.1.5.3 OXYSTEROLS IMPLICATION IN DIFFERENT PHYSIOLOGICAL MECHANISMS 
1.1.5.3.1 OXYSTEROL BINDING PROTEINS - RELATED PROTEINS (OSBP) 
A conserved family of lipid transfer proteins, the OSBP-related proteins (ORP) discovered by the finding of 
oxysterol binding proteins require the binding of oxysterols for their functioning. However, ORPs do not only 
bind to oxysterols but to a variety of lipids such as phosphosinositides and phosphatidic acid. Their function 
consists in the transfer of sterols in exchange of phosphatidylinositol 4- phosphate at ER membrane contact 
sites (MCS) with other organelles. This intracellular sterol transport mechanism is thought to regulate lipid 
fluxes, organelle lipid compositions and cell signalling 
138
.  
1.1.5.3.2 HEDGEHOG PATHWAY 
The hedgehog pathway is important for embryonic pattern formation and adult tissue homeostasis 
139
. Several 
studies found a link between oxysterols and the hedgehog pathway but they differ with respect to whether 
oxysterols are a hedgehog pathway activator or inhibitor 
140–144
. Research on oxysterol’s implication in the 
hedgehog pathway was based on three different theoretical links between the hedgehog pathway and sterols 
in general. The first argument is the covalent modification of the hedgehog protein by cholesterol to facilitate 
the protein anchoring to the plasma membrane. Here, the cholesterol availability for covalent protein 
modifications is probably regulated by the cholesterol homeostasis function of oxysterols 
10,145
. Secondly, a 
sterol sensing domain (SSD), also found in the structure of proteins implicated in cholesterol homeostasis such 
as HMGCR, SREBP and SCAP, was detected in a hedgehog receptor named Patched 
146,147
. Finally, disorders of 
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cholesterol biosynthesis like Smith-Lemli-Opitz Syndrome lacking the enzyme of the final cholesterol 
conversion step and resulting in the accumulation of 7-dehydrocholesterol, are associated with gross 
developmental abnormalities 
141,142
.  
1.1.6 OXYSTEROL ANABOLISM AND CATABOLISM IN THE ORGANISM 
1.1.6.1 OXYSTEROL ORIGINS 
Oxysterols have three different possible origins: one exogenous through dietary intake and two others of 
endogenous origin, either due to cholesterol autoxidation or due to enzymatic transformations (Figure 10). 
Although this holds for being generally true, exceptionally some oxysterols like 7α-hydroxycholesterol (7α-
OHC), 4β-hydroxycholesterol (4β-OHC) and 25-OHC stem from both origins, meaning that they can be 
synthesised either enzymatically or non-enzymatically 
148–150
. The cholesterol autoxidation products, which 
were discovered first, are mainly oxidised on their B-ring. Oxysterols metabolised by the enzymatic pathways 
are hydroxylated either at the side-chain or on their A or B-ring, depending on the enzyme and the tissue 
151,152
.  
1.1.6.1.1 OXYSTEROLS FROM EXOGENOUS DIETARY SOURCE 
Modern human’s exogenous source of oxysterols derives especially from dairy, egg and meat products in the 
western cholesterol-rich diet. The oxysterols are thought to be generated by auto oxidation during food 
manufacturing like cooking, processing and storage 
153
. The estimated oxysterol content in western diet varies 
from ppm ranges 
154,155
 to 1% 
156
. The most representative food oxysterols are 7-KC, 7α-OHC, 7β-OHC, 5α,6α-
epoxycholesterol, and 5β,6β-epoxycholesterol (5β,6β-EC) 
153,157
. They are absorbed by the gut and carried on 
chylomicrons in the blood circulation 
158–162
. Several absorption studies were made but the results varied from 
very low oxysterol absorption of 6 % 
163
 to extremely high oxysterol absorption of 93 % 
161
. The discrepancy of 
the oxysterol absorption results might be explained by the use of different doses, models and vehicles used to 
administer the oxysterols 
153
. Other hypotheses for the large difference are the preferential absorption of some 
oxysterols or eventually, the oxysterol hydrolysation directly in the gut 
153
. The impact of dietary oxysterols on 
human health is unresolved. However, there is a tendency to consider them harmful, like Biasi et al., who 
suggested oxysterols to be a potential trigger and/or worsening factor for Inflammatory Bowel Diseases (IBD) 
29,164–166
.  
 
Chapter: Background on oxysterols 
 
15 
 
Figure 10| Oxysterols from enzymatic and non-enzymatic origins. Cholesterol is transformed to monohydroxycholesterols as for example 24(S)-hydroxycholesterol (24(S)-OHC), 27-hydroxycholesterol (27-OHC) and 
25-hydroxycholesterol (25-OHC) through the enzymatic action of cholesterol 24-hydroxylase (CYP46A1), sterol 27-hydroxylase (CYP27A1) or cholesterol 25-hydroxylase (CH25H), respectively. 24-OHC is then 
converted to 7α,24(S)-dihydroxycholesterol (7α,24-OHC) by the action of the oxysterol 7α-hydroxylase 2 (CYP39A1), while 27-OHC and 25-OHC are both converted to their respective dihydroxycholesterols by the 
oxysterol 7α-hydroxylase (CYP7B1). Additionnaly to the enzymatic conversion, 25-OHC derives also from non-enzymatic origin through radical oxygen species (ROS). Other examples of non-enzymatic generated 
oxysterols are 7-ketocholesterol (7-KC) and cholestane-3β,5α,6β-triol (C-triol). The abbreviations and acronyms are explained in the chapter. Figure adapted from Cyster et al.(2014) 34. 
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1.1.6.1.2 NON-ENZYMATIC CHOLESTEROL OXIDATION 
The non-enzymatic cholesterol oxidation mechanism is divided into two main pathways, although in vivo some 
exchanges between both pathways occur 
167
.  
1.1.6.1.2.1 THE FREE RADICAL-MEDIATED CHOLESTEROL OXIDATION PATHWAY  
The major non-enzymatic cholesterol oxidation pathway is mediated by radical oxygen species involving an 
initiation, propagation and an ending phase 
1,166,167 
(Figure 11). 
The initiation phase consists of hydrogen abstraction by a free radical on the carbon with a labile hydrogen 
followed by oxygen capture 
1,167
. In the case of cholesterol, the abstraction takes place at the allylic hydrogen 
atom at C-7. The generated C-7 centered radical is relatively long-lived and further reacts with molecular 
oxygen to form a cholesterol peroxyl radical 
1
. Free radical-mediated cholesterol oxidation is triggered by 
radical oxygen species such as hydroxyl radical (HO●), peroxynitrite (ONOO-) or transition metals in a redox-
active state 
166
.  
The resulting cholesterol peroxyl radical is highly reactive and recruits further non-oxidised lipids, resulting in 
the formation of cholesterol hydroperoxides or other lipid peroxides restarting thus the chain reaction, also 
called propagation 
167,168
. 
In plasma, in contrary to in vitro conditions, polyunsaturated fatty acids (PUFA) are more readily attacked by 
reactive oxygen species (ROS) than cholesterol 
167
. This is the reason why polyunsaturated fatty acid 
autoxidation has been intensively studied in comparison to cholesterol oxidation but both are triggered by a 
similar mechanism. Oxidation on polyunsaturated fatty acids results in isoprostanes, regio-and stereoisomers 
of prostaglandins, while cholesterol oxidation gives rise to oxysterols 
167
. Oxidation of both substances is 
usually described as separate events but occurs cooperatively at the cellular levels. The oxidation site for both 
entities is either in cell membranes or on the lipoproteins. It causes alterations in fluidity, permeability and 
structure. The propagation of the radical oxidation is facilitated by the more hydrophilic nature of the oxidation 
products than its parent molecules, which partition thereby more easily in more aqueous cell compartments on 
the intra-and intercellular level 
167
. In addition, the dispersion step of the radical reaction was found to be 
facilitated by the sterol carrier protein-2 (SCP-2) which is responsible for intracellular lipid trafficking including 
lipid hydroperoxides, thus participating in the peroxidative damage 
169
.  
The ending phase is engaged by either endogenous chain-breaking antioxidants such as α-tocopherol or by the 
enzyme phospholipid glutathione peroxidase (PHGPx), which converts cholesterol hydroperoxides into more 
stable hydroxyl-products 
167,170
. A typical example of an end product of the free radical mediated cholesterol 
oxidation pathway is 7-KC 
167,168
 . 
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Figure 11| The free- radical mediated cholesterol oxidation pathway. Cholesterol (1.) is transformed by a free radical to a cholesterol 
(C7) carbon centred radical (2.). This highly reactive compound then reacts with molecular oxygen to result in a cholesterol peroxyl 
radical (3.), which further reacts to form a cholesterol hydroperoxide (4.). Finally, through the intervention of phospholipid glutathione 
peroxidase (PHGPx) and α-tocopherol the reactions is stopped and stable oxysterols as for example 7-KC are formed (5.). The 
abbreviations and acronyms are explained in the chapter. Figure adapted from Iuliano et al. (2011) 167. 
1.1.6.1.2.2 NON-RADICAL MEDIATED CHOLESTEROL OXIDATION PATHWAYS 
To date three non-radical mediated cholesterol oxidation mechanisms were described (Figure 12). Singlet 
oxygen (
1
O2) is an important non-radical molecule involved in cholesterol oxidation and is formed when 
molecular oxygen receives an input of energy, for example by photoactivation 
167
. Singlet oxygen’s half-life is 
extremely short and when reacting with cholesterol gives rise to four primary oxysterols: the preferentially 
formed 5α-cholesterol-hydroperoxide, 6α-cholesterol-hydroperoxide, 6β-cholesterol-hydroperoxide and chol-
dioxetane 
166,167,171
. Allylic rearrangement may further occur on these primary oxysterols as for example the 
rearrangement of 5α-cholesterol-hydroperoxide to 7α-cholesterol-hydroperoxide or 7β-cholesterol-
hydroperoxide 
172,173
.  
Ozone (O3) in lungs reacts with cholesterol to yield cholesterol-trioxolane. Cholesterol ozonolysis is very fast 
and complex, involving the decomposition of cholesterol-trioxolane into a series of unstable intermediates and 
end products 
11,166,167
. Cholesterol-trioxolane rearrangement mainly results in reactive electrophiles (5,6-
secosterol) which are in equilibrium with their carboxaldehyde, able to form adducts with proteins 
174–176
.  
Molecular chlorine (Cl2) can also oxidise cholesterol to generate a family of chlorinated oxysterols as for 
example α-chlorohydrin, β-chlorohydrin or 5,6-dichloro-cholesterol 
167
. Molecular chlorine is generated by the 
phagosome myeloperoxidases in neutrophils during innate host defence. The bulky chlorohydrins affects host 
membrane stability and function and react with a variety of substances weakening thereby the invader cells.
177
. 
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Figure 12| The non- radical mediated cholesterol oxidation pathway. Cholesterol (1.) is oxidised by singlet oxygen to result in four 
different oxysterol species: 5α-cholesterol-hydroperoxide (2.), 6α-cholesterol-hydroperoxide (3.), 6β-cholesterol-hydroperoxide (4.) and 
chol-dioxetane (5.). 5α-cholesterol-hydroperoxide (2.) can further react to result in 7α-cholesterol-hydroperoxide (6.). Ozone reacting 
with cholesterol (1.) leads to the unstable cholesterol-trioxolane (7.). Cholesterol reacting with molecular chlorine generates a family of 
chlorinated oxysterols like α- chlorohydrin (8.), β-chlorohydrin (9.) or 5,6-dichloro-cholesterol (10.) The abbreviations and acronyms are 
explained in the chapter. Figure adapted from Iuliano et al. (2011) 167. 
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1.1.6.1.2.3 OXYSTEROLS AS BIOMARKER FOR NON-ENZYMATIC MEDIATED CHOLESTEROL 
OXIDATION 
H. Sies was the first to define oxidative stress as the imbalance between oxidants and antioxidants in favour of 
the oxidants, potentially leading to damage 
178,179
. Basal to low level of oxidative stress is physiologically normal 
and controlled by antioxidant enzymes 
180
. When the flux of ROS increases or the antioxidant is reduced, the 
organism is in intermediate to high oxidative stress condition and this raises modifications of different cellular 
components, considerably disturbing cellular homeostasis 
180
. Because of the short life span of free radicals and 
their high reactivity, their measurement is limited to the detection of their end products 
167
. The analysis of 
these resulting end products being the non-enzymatic mediated cholesterol oxidation products was considered 
to be specific and sensitive enough to be used as biomarker for oxidative stress 
181,182
. L. Iuliano suggests the 
monitoring of free radical-mediated cholesterol oxidation by the mean of 7β-OHC, 7-KC, 5β,6β-
epoxycholesterol, and cholestane-3β,5α,6β-triol (C-triol) levels 
167
 . For ozone/singlet oxygen-driven oxidation, 
as found for example in inflammation, 5,6-secosterol, 5α-hydroxycholesterol, and 6α-hydroxycholesterol could 
serve as biomarkers. In addition, Hazen et al. proposed the analysis of α- and β-chlorohydrins to assess for 
neutrophil-mediated tissue damage 
183
. However, for the evaluation of oxysterols as new biomarker for a 
particular oxidative stress condition, it should be ensured that the potential biomarker is of real in vivo 
oxidation origin and not of in vitro origin occurring for example during sample preparation. In addition, as 
mentioned already, some oxysterols, as for example 7α-OHC, 4β-OHC and 25-OHC can be of both, enzymatic 
and of non-enzymatic origin 
11,149,150
. The possible in vitro oxidation of cholesterol or oxysterols is an important 
pre-analytical issue influencing the measured oxysterols concentration.  
1.1.6.1.3 ENZYMATIC CHOLESTEROL OXIDATION 
Most in vivo oxysterols are of enzymatic origin and each oxysterol is synthetised by a different enzyme 
1,152
. 
Enzymatic oxysterol biosynthesis was first discovered in 1956 by Frederickson and Ono using radiolabeled 
cholesterol incubation in subcellular fractions enriched in mitochondria, leading to the formation of 25-OHC 
and 27-OHC 
16
. Almost all oxysterol synthetising enzymes belong to the class of monooxygenase of the 
cytochrome P450 (CYP) family which are named after the characteristic absorption wavelength at 450 nm 
168
. 
This enzyme class consists of a disparate group of proteins with a similar structural fold containing in their 
active center a single heme-bound iron atom 
184
. They are located in the membrane compartment of cells, 
either in the ER or in the mitochondria and utilise NADPH as a cofactor to catalyse oxysterol biosynthesis 
149
. 
Cytochrome P450 monooxygenases differ in substrate specificity, sequence, tissue distribution and subcellular 
localisation 
149,185
. 
In the following paragraphs the main enzymes of oxysterol synthesis are described in more detail and 
summarised in Table 2. 
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Table 2| Human enzymes implicated in oxysterol synthesis. The abbreviations and acronyms are explained in the chapter. Table adapted from Russell et al. (2000) 149. 
Enyzme Class Subcellular 
localisation 
Tissue mRNA levels Substrate Product Enzyme commission 
number (EC), and 
References 
Cholesterol 24-
hydroxylase 
(CYP46A1) 
Cytochrome 
P450 
sER Brain > liver cholesterol 24(S)-OHC 1.14.13.98 
186
 
Cholesterol 25-
hydroxylase 
(CH25H) 
Di-iron 
containing 
protein 
ER, Golgi Heart, lung, kidney, plus 
other tissues at low levels 
(interfollicular and outer 
follicular regions of 
lymphoid tissues) 
cholesterol 25-OHC 1.14.99.38 
187
 
Sterol 27-
hydroxylase 
(CYP27A1) 
Cytochrome 
P450 
Inner 
mitochondrial 
membrane 
Liver, small intestine, 
adrenal, lung, macrophages 
> kidney, spleen 
cholesterol, 
cholesterol, 
lanosterol,  
zymosterol, 
desmosterol,  
7-dehydrocholesterol, 
trihydroxycoprostan, 
5β-cholestane-3α,7α,12α,27-tetrol, 
27-OHC, 
25-OHC,  
C27-diol and C27-acids of lanosterol, 
zymosterol, and desmosterol 
 
27-hydroxy-7-dehydrocholsterol, 
5β-Cholestane-3α,7α,12α,27-tetrol, 
3α,7α,12α-Trihydroxy-5β-cholestanoic acid 
1.14.13.15 
188,189
 
Cholesterol 7α-
hydroxylase 
(CYP7A1) 
Cytochrome 
P450 
sER Liver cholesterol 7α-OHC 1.14.13.17 
 
190
 
Cytochrom P450 
3A4(CYP3A4) 
Cytochrome 
P450 
sER  Liver cholesterol 4β-OHC 1.14.13. [157, 32, 
67,97]  
191,192
 
2,3-Oxidosqualene 
cyclase 
(OSC) 
Intra-
molecular 
transferase 
sER Liver, 
macrophages 
squalene 
monooxidosqualene 
monooxidosqualene 
diepoxysqualene 
5.4.99.7 
92,93,193
 
Oxysterol 7α-
hydroxylase 
(CYP7B1) 
Cytochrome 
P450 
ER  Brain, kidney, liver, 
reproductive tract,  
interfollicular and outer 
follicular 
regions of lymphoid tissues 
25-OHC 
27-OHC 
Dehydroepiandrosterone,  
Pregnenolone 
7α,25-OHC 
7α,27-OHC 
7α-hydroxy Dehydroepiandrosterone 
7α-hydroxy pregnenolone 
 
1.14.13.100 
194–197
 
Oxysterol 7α-
hydroxylase 2 
(CYP39A1) 
Cytochrome 
P450 
ER Liver, 24(S)-OHC 7α,24(S)-OHC 1.14.13.99 
198
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1.1.6.1.3.1 STEROL 27-HYDROXYLASE  
Sterol 27-hydroxylase (CYP27A1) is a mitochondrial cytochrome P450 oxidase distributed in a wide range of 
tissues and organs but is particularly highly expressed in liver, lung and in macrophages 
1,168,199
. It is one of the 
rare cytochrome P450 enzymes of sterol side chain oxidation accepting different substrates and undertaking 
several reactions 
200
. CYP27A1 depends on NADPH for its enzymatic activity and the availability of two electron 
transporters, adrenodoxin and adrenodoxin reductase 
201
. Additionally, it is hypothesised that a specific 
mitochondrial membrane transporter is required to bring cholesterol to the enzyme 
202
. The best-studied 
reaction is the first step of the “alternative” pathway of bile acid synthesis where cholesterol is converted to 
27-OHC. 27-OHC is the major oxysterol found in human circulation and co-localises with macrophages in 
human atherosclerotic plaques 
203,204
. Besides cholesterol also lanosterol, zymosterol, desmosterol, and 7-
dehydrocholesterol can be used as substrate for the synthesis of oxysterols 
189
. In addition to different 
substrates, the enzyme is also capable of sequential hydroxylation leading to the unexpected formation of 3β-
hydroxy-5-cholestenoic acid 
1
. CYP27A1 contributes, through the generation of 27-OHC, in two ways to 
cholesterol homeostasis: 27-OHC activates SREBPs, decreasing thus cholesterol synthesis. Furthermore, 27-
OHC through binding to the LXRα receptor up-regulates the expressions of ABC transporters responsible for 
cholesterol cell efflux. Loss of function mutations in the CYP27A1 gene is known as Cerebrotendinous 
xanthomatosis (CTX) leading to cholesterol accumulation in the brain of CTX patients 
205
.  
1.1.6.1.3.2 CHOLESTEROL 24-HYDROXYLASE  
Cholesterol 24-hydroxylase (CYP46A1), is a brain-specific cytochrome P450 oxidase expressed in the smooth 
endoplasmic reticulum (sER) of neuronal cells which synthesise 24(S)-OHC 
186,206
. 24(S)-OHC as blood-brain 
barrier passing molecule is found in the circulation before it is further metabolised to bile acids in the liver 
21
. 
Since 24(S)-OHC represents the cholesterol efflux of the brain, it was proposed to be used as cerebral 
cholesterol turnover marker for neurodegenerative diseases such as Alzheimer disease 
207–209
. In this particular 
disease, 24(S)-OHC increase in plasma is associated with decreased brain influx of blood-born Amyloid-β 
peptides characteristic of Alzheimer disease, hence, 24(S)-OHC was suggested to act as a brain protector 
109,210,211
.  
1.1.6.1.3.3 CHOLESTEROL 25-HYDROXYLASE  
25-hydroxycholesterol can be synthesised by autoxidation or by two different enzymes, either by CH25H or as a 
side product by CYP27A1 
11,187,212
. In comparison to all other oxysterol-synthetising enzymes, cholesterol 25-
hydroxylase is not a member of the cytochrome P450 family but belongs to the non-heme iron-containing 
proteins 
149,187
. This enzyme family appears also in bacteria and plants and they hydroxylate, desaturate, 
epoxidate or acetylinate various lipid substrates 
149
. CH25H is located in the membrane of the ER and Golgi 
where its product, 25-OHC, exerts its function 
186
. As mentioned before, 25-OHC is a regulator of the SREBP 
pathway for the transcriptional regulation of cholesterol homeostasis 
149,187
. Although 25-OHC is a biologically 
important cholesterol metabolite it is only a minor oxysterol in human plasma 
149
.  
1.1.6.1.3.4 OTHER OXYSTEROL SYNTHETISING ENZYMES 
Although CYP27A1, CYP46A1, and CH25H have been extensively studied, there are many other oxysterol-
synthetising enzymes. For example cholesterol 7α-hydroxylase is an important hepatic enzyme producing 7α-
OHC in the first step of the “classical” bile acid pathway 
213
. CYP3A4 is a drug-metabolizing enzyme converting 
cholesterol into 4β-OHC
 150,214
. 24(S),25-EC is produced by 2,3-oxidosqualene cyclase in a shunt of the same 
mevalonate pathway that produces cholesterol 
94
. The enzymatic synthesis of dihydroxycholesterols like 7α,25-
OHC or 7α,27-OHC occurs in a 2 step manner: first the corresponding side-chain mono-hydroxycholesterols are 
synthesised followed by a C-7 hydroxylation by CYP7B1 
197,215,216
. An exception occurs for 7α,24(S)-
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dihydroxycholesterol (7α,24(S)-OHC), for which the second hydroxylation is mediated by CYP39A1 instead of 
CYP7B1 
217
. In the case of 7α,25-OHC it is known that both required enzymes, CH25H and CYP7B1 are expressed 
in the ER of for instance lymphoid stromal cells, indicating a straightforward synthesis pathway of 
dihydroxycholesterols at the location of their function 
35,130
. 
The number of enzymes implicated in oxysterol synthesis indicates that oxysterol formation is a tightly 
regulated process in many vertebrates in order to trigger specific signalling pathways of for example the 
immune system and to precisely control the cell and body cholesterol concentration 
34,149,218
. 
1.1.6.2 CELLULAR LEVELS AND LOCATION 
Oxysterols are like cholesterol, confined either in non-polar cell locations meaning in cell membranes, lipid 
droplets or in the circulation in low density lipoproteins (LDL) 
1,168
. Under normal physiological conditions, their 
concentrations are about 10
3
 to 10
6
 times lower than the concentration of cholesterol 
1,31
. In vivo studies on 
subcellular localisation are rare and most quantification attempts were carried out in human plasma (Table 3). 
The concentration of each oxysterol in plasma varies but generally the order of magnitude for free oxysterols is 
around 5-50 ng/mL. Most plasma quantification studies are made on free oxysterols being biologically active 
but on a cellular level most enzymatic derived oxysterols are inactivated through esterification to 
approximately 74-98 % 
219–221
. The situation in plasma clearly shows that oxysterols do not occur alone but 
always in a mix of different species, making their individual study difficult 
1
.  
Table 3| oxysterol plasma concentrations reported in the literature. All values have been converted into nM allowing a simpler 
comparison. The abbreviations and acronyms are explained in the chapter. 
Compound Concentration of free OSt in 
ng/mL (nM) 
Concentration of total OSt in 
ng/mL (nM) 
Co-elution of  
24(S)-OHC and 25-OHC 
24S-OHC 5,46 ± 0,05 (13,56 ± 0,12) 
222
  
5,46 ± 0,19 (13,56 ± 0,47) 
223
 
6.86 ± 0,31 (17,04± 0,77 ) 
224
  
22,1 ± 0,8 (54,9 ± 10,2) 
223
 
51 ± 12 (127 ± 30) 
225
 
56,1 ± 1,18 (139.3 ± 2,93) 
226
 
64 ± 14 (159 ± 44) 
227
 
146 ± 6 (363 ± 15) 
156
 
1,77 ± 0,6 (4,4± 1,5) 
220
 
25-OHC 0,7 ± 0,02 (1,74 ± 0,05) 
222
 
4,06 ± 0,22 (10,08 ± 0,55) 
224
  
9 ± 1 (22± 2) 
156
 
11,8 ± 0,28 (28,3 ± 0,70) 
226
 
31 ± 11 (77 ± 27) 
225
  
27-OHC 10,33 ± 0,60 (25,65 ± 1,49) 
222
 
15,52 ± 0,96 (38,54 ± 2,38) 
220
  
19,12 ± 70,70 (47,49 ± 175,59) 
224
 
117 ± 35 (291 ± 87) 
225
 
120 ± 30 (298 ± 75) 
227
 
151,4 ± 3,03 (376 ± 7,5) 
226
 
235 ± 3 (628 ± 7) 
156
 
 
7-KC 0,59 ± 0,33 (1,47 ± 0,82) 
222
 
5,51 ± 3,16 (13,68 ± 7,85) 
223
 
22,8 ± 3, 0 (56,6 ± 7,5) 
228
 
77,4 (192,2) 
26
 
49,1 ± 33,4 (121,9 ± 82,9) 
223
 
84 ± 3,78 (209 ± 9,39) 
226
 
 
 
7α25-OHC <0,2 (<0,48) 
224
 
0,09 ± 0,02 (0,21 ± 0,05) 
220
  
0,12 ± 0,04 (0,29 ± ) 
222
 
  
7α27-OHC 0,26 ± 0,09 (0,62 ± 0,22) 
222
 
1,42 ± 0,04 (3,4±0,1) 
220
  
1,65 ± 0,39 (3,94 ± 0,97) 
224
 
10 ± 0,24 (23,89 ± 0,60) 
226
  
C-triol 9,7 ± 1,2 (24,1 ±3,0) 
228
 
20,1 (49,9) 
26
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1.1.6.3 OXYSTEROL METABOLISM 
Oxysterols can be further metabolised in the cell by four mechanisms often requiring the same enzyme set as 
cholesterol does (Figure 13):  
1. Esterification of oxysterols is mediated (like for cholesterol) by acetyl-coenzyme A-acetyltransferase in cells 
and lecithin-cholesterol acyltransferase in plasma. Acetyl-coenzymeA -acetyltransferase possesses two sterol-
binding sites: one being catalytic the other being an allosteric activator. Interestingly only cholesterol is able to 
bind strongly to the allosteric site, meaning that oxysterols need cholesterol for their own esterification, which 
reflects a possible in vivo scenario. Like for cholesterol the esterification biologically inactivates the oxysterols 
152,219,221,229
. 
2. Some enzymes like CYP27A1 are able to act on cholesterol and on few ring-oxygenated sterols leading to 
further oxidation products. Since this secondary oxysterols are more hydrophilic they can be easily excreted 
from cells and are therefore associated with less cellular toxicity than the parent oxysterol 
230–232
.  
3. Sulphation may occur by sulphotransferases (SULTs) like SULT2 specifically sulfating the 3β-hydroxyl group of 
steroids and sterols or SULT2B1b sulphating ring-oxygenated side-chain oxysterols. The oxysterol- sulphate 
conjugation resulting into more hydrophilic compounds, is an important cell detoxification mechanism for non-
enzymatic derived oxysterols 
233
. In addition, oxysterol sulphation inactivates the oxysterol activity on LXRs 
234
. 
Cholesterol sulphation products are present in all mammalian cells but are particularly abundant in keratinised 
tissue, such as skin and hooves. Cholesterol sulphate, the main circulating sterol sulphate in plasma is supposed 
to have a role in skin layer integrity and adhesion 
24,168,233,235
.  
4. A reduction reaction was discovered for 7-KC to obtain 7β-OHC by 11β-hydroxysteroid dehydrogenase type 1 
(11β-HSD 1). This metabolisation step is suggested to be a detoxifying mechanism of dietary 7-KC in the liver 
and in adipose tissue 
236
. 11β-HSD 1 main enzymatic function is, however, the conversion of cortisone to the 
active receptor-binding derivative cortisol in glucocorticoid metabolism, thus indication a possible 
interconnection between oxysterol and glucocorticoid metabolic pathways 
236,237
.  
 
Figure 13| Possible reactions occurring on oxysterols. Oxysterols can be esterified, oxidised, sulphurised and reduced. The abbreviations 
and acronyms are explained in the chapter. Figure adapted from Brown et al. (2009) 1. 
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1.1.6.4 OXYSTEROL ELIMINATION 
As previously discussed, oxysterol are confined in non-polar locations due to their hydrophobic nature. This is 
the reason why they cannot be directly eliminated from cells apart from a few exceptions like 24(S)-OHC or 27-
OHC having a more hydrophilic side-chain 
238
. The elimination process requires therefore specific membrane 
lipid transporters and plasma carriers. Examples of such transporters are scavenger receptor B1, ABCA1 or 
ABCG1 
239
. ABCA1 is a phospholipid flippase that transports phospholipids and cholesterol to lipid-free ApoA1. 
Through its flippase activity, ABCA1 changes the lipid packing of the plasma membrane. ApoA1 is the major 
protein component of high-density lipoproteins and contains multiple amphipathic α-helical domains. It is 
suggested that ApoA1 interacts via its hydrophobic faces with the plasma membrane directly after ABCA1 
flippase activity. Once ApoA1 is bound to the plasma membrane it desorbs some membrane phospholipids, 
cholesterol and oxysterols 
1
. A second possible oxysterol elimination pathway is through passive diffusion that 
can occur spontaneously for cholesterol or oxysterols from cell membranes to HDL 
240,241
. The diffusion rate of 
7-KC and 7β-OHC to the HDL particle was found to be similar as for cholesterol 
240
. Passive diffusion can be 
accelerated by proteins like scavenger receptor B1 able to make a bi-directional exchange or by ABCG1 capable 
of a uni-directional export to the HDL particle 
239
. It is hypothesised that ABCG1 promotes the efflux of toxic 
oxysterols like 7-KC and 7β-OHC, which are considered to induce apoptosis in cells, thereby protecting the cell.  
1.1.7 TOXICITY AND PATHOLOGICAL EFFECTS OF OXYSTEROLS 
Oxysterol toxicity was characterised early and was mainly interpreted in 1981 and 1989 by Smith as a 
“biological effect” 
11,32
. At that time, he already exhaustively summarised the aspects of cytotoxicity, 
atherogenicity, mutagenicity, carcinogenicity and their effect on cell membranes. Nevertheless, he was not 
aware of how exactly oxysterols lead to these effects and even nowadays not all oxysterol toxicological 
properties are completely understood. Oxysterol toxicity and side effects can trigger pathophysiological 
conditions, such as cancer, atherosclerosis and neurological disorders, and probably many more. However, 
conclusions on in vivo oxysterol toxicity have to be taken cautiously since healthy cells have mechanisms to 
eliminate or store excess oxysterols. Figure 14 is a summary of the described toxic and pathological effects of 
oxysterol in vivo.  
 
Figure 14| Summary of the toxicity attributed to oxysterols. They are considered to have cytotoxic effects, mutagenic and carcinogenic 
properties, are pro-inflammatory and a disturbance in their own turnover can have negative health effects. The abbreviations and 
acronyms are explained in the chapter. 
1.1.7.1 CYTOTOXIC PROPERTIES OF OXYSTEROLS 
Oxysterol cytotoxicity was studied in vitro in different cell types as well as in vivo in different animal models 
31,32,242,243
. The observed cellular effects after in vitro oxysterol administration were diminished cellular 
functions, with reduced cellular growth, and reduced cellular proliferation. Similar observations were made in 
vivo with cessation of growth, loss of weight, and diminished appetite, in addition to damages to arteries and 
increased aortal lesion formation in models of atherosclerosis 
32
. Cytotoxicity of the most cytotoxic oxysterols 
(7-hydroxy-, 7-keto- and triol cholesterol derivatives) is thought to be due to perturbation of the intracellular 
calcium levels, as well as the overproduction of intracellular ROS affecting membrane fluidity and integrity 
243,244
. The cellular consequence of oxysterol cytotoxicity is apoptosis, which is the desired effect in cancer 
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therapy making oxysterols an interesting drug candidate for treatment 
245
. In contrary, Mathieu et al. were 
interested to increase cellular resistance towards the cytotoxic activity of oxysterols by lysosomal-targeted 
clearance of 7-KC. The reasoning behind it is that cellular sterol uptake occurs via receptor-mediated 
endocytosis of LDL leading to sterol accumulation in lysosomes. Consequently lysosomes are a major site of 
non-enzymatic oxysterol concentration and Brown et al. could show that the 7-KC level is particularly high in 
endosomal and lysosomal compartments 
232
. However, 7-KC-metabolising enzymes are localised in other 
organelles as for example in the ER, in the mitochondria and in the cytoplasma. With the lysosomal-targeted 
Chromobacterium sp. DS1 cholesterol oxidase, Mathieu et al. were able to enhance fibroblast cell resistance 
towards 7-KC thus being an interesting therapeutic approach for disorders accumulating non-enzymatic 
oxysterols 
246
. 
1.1.7.2 MUTAGENIC AND CARCINOGENIC PROPERTIES OF OXYSTEROLS 
In contradiction to the reported cytotoxic effects, oxysterols were also described to be mutagenic and 
carcinogenic. Oxysterol mediated mutagenicity was only found for C-triol, and 7-KC on Chinese hamster ovary 
epithelial cells, and on mitochondrial DNA of retinal pigmented epithelium cells, respectively. This led Gramajo 
et al. to propose oxysterol mutagenicity to be implicated in the pathogenesis of retinal diseases 
247,248
.  
In addition to oxysterol mutagenicity, different cancers where shown to be either initiated or further 
progressed by oxysterols as it is for example the case in cholangiocarcinogenesis by 22R-hydroxycholesterol. In 
this particular situation, 22R-hydroxycholesterol stabilises cyclooxygenase-2 (COX-2) mRNA via the p38- 
Mitogen-activated protein kinase pathway enhancing thus COX-2 protein expression. Cyclooxygenase-2 
promotes cellular replication and inhibits apoptosis contributing so to cholangiocarcinogenesis progression 
249–
251
. 
1.1.7.3 ATHEROSCLEROSIS AND OXYSTEROLS 
Atherosclerosis is a chronic inflammatory disease closely related with the deregulation of lipid metabolism 
252
. 
It is a pathological process consisting in an inflammatory signal cascade leading to lipid and cell accumulation in 
the intimal arterial wall resulting in plaque formation 
253
. Atherosclerosis can be considered as a three-step 
process consisting in lesion initiation, lesion progression and plaque rupture. The lesion initiation is due to 
hyperlipidaemia in arterial walls, which activates endothelial cells for rapid monocyte influx into the arterial 
intima. In the arterial intimia, the monocytes-derived macrophages take up oxidised LDL through their 
scavenger receptors giving thereby rise to foam cells, visible as fatty streaks. If the influx is persistent, we come 
to atherosclerosis second step of lesion progression in which cytokines and growth factors secreted from 
leukocytes promote lymphocyte and smooth muscle cell migration. The migrated smooth muscle cells as well 
as their released matrix proteins form a fibrotic cap blocking off the foam cells 
252,254
. Finally, plaque disruption 
is accelerated by the apoptosis of foam cells releasing metalloproteinases (MMP) which degrade the fibrotic 
cap and thus destabilise it 
254
. Disrupted plaques lead to thrombus formation which blocks the arterial blood 
cirulation leading to heart attacks and ischemic strokes 
255
. It was discovered that oxysterols, mainly 27-OHC is 
produced in atherosclerotic lesions via CYP27A1 in macrophage-derived foam cells 
152,199,204,256
. The oxysterol 
production in atherosclerosis was considered to be a defence response towards the high cholesterol load 
204
. 
However recently, Umetani et al. identified 27-OHC as ligand of the estrogen receptor α (ERα) which 
surprisingly triggers an upregulation of pro-inflammatory genes in contrary to estrogen 
257,258
. The pro-
inflammatory action is mediated through Nuclear factor-κβ (NF-κβ) activation via the extracellular-signal-
regulated kinases 1 and 2 (Erk1,2) and c-Jun N-terminal kinase (JNK)-dependent degradation of the nuclear 
factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IκBα). From these results, the 
authors conclude that 27-OHC promotes atherosclerosis via activation of pro-inflammatory pathways as well as 
via the attenuation of estrogen-related atheroprotection 
257
. In addition other oxysterols, like 25-OHC stimulate 
IL-8 production, which is an important cytokine of atherosclerosis since it recruits neutrophils and vascular 
smooth muscle cells into the subendothelium. IL-8 also inhibits the expression of the local inhibitors of 
Chapter: Background on oxysterols 
 
26 
metalloproteinases-1 (TIMP-1), thus enhancing fibrous cap destabilisation 
259–261
. This finding demonstrates 
that oxysterol mediated IL-8 production establishes and preserves the inflammatory micro-environment in 
arterial cell walls and contributes to plaque disruption. 
1.1.7.4 NEUROTOXICITY OF OXYSTEROLS 
Mutations in oxysterol-forming enzymes, oxysterol excess, as well as depletion can have neurological 
consequences, as it is the case for Alzheimer disease, CTX and for Hereditary Spastic Paresis (HSP) type SPG5 
202
. Oxysterol’s implication in Alzheimer disease was already mentioned and will not be further discussed here, 
while CTX was only shortly mentioned. CTX is a rare inherited autosomal recessive disorder caused by 
mutations in the CYP27A1 gene with the translated enzyme located at the inner mitochondrial membrane in 
most cells of the organism 
202
. Due to CYP27A1 mutations, CTX patients have a reduced rate of bile acid 
synthesis, and therefore the normal homeostatic feedback regulation of cholesterol is disrupted, which further 
enhances the production of bile alcohols and cholestanol from bile acid precursors. The consequence is the 
formation of xanthomas potentially anywhere in the body but particularly in the nervous system, in 
atherosclerotic plaques and tendons of CTX patients. The most serious disease effect arises due to the 
xanthomas in the neurological system, which preferentially occurs in the brain white matter. CTX patients are 
characterised by dementia, ataxia and cataracts. Typical disease onset is in infancy with cholestatic jaundice, 
cataracts and diarrhea followed by mental retardation. Untreated CTX patients usually die between the ages of 
30 years and 60 years from progressive neurological dysfunction or myocardial infarction 
262
.  
The Hereditary Spastic Paresis are a genetically and clinically heterogeneous group of upper-motor-neuron 
degenerative diseases characterised by selective axonal loss in the corticospinal tracts and dorsal columns 
263
. 
Symptoms include progressive spasticity of the lower limbs and muscle weakness, frequently associated with 
deep sensory loss and urinary urgency. In addition more “complex” Hereditary Spastic Paresis are accompanied 
by other neurological signs such as ataxia, mental retardation, dementia, visual dysfunction, and epilepsy 
202
. 
Recently, about 40 different loci for Hereditary Spastic Paresis were identified with various types of inheritance 
264–266
. The first locus defined was named SPG5 and was later identified to be the CYP7B1 encoding gene 
263
. 
CYP7B1 has broad substrate specificity including 25-OHC, 27-OHC, and a number of C19 and C21-steroids 
194–
197
. CYP7B1 is of importance both for bile acid synthesis, which is a well-understood role, and for the 
metabolism of neurosteroids, much less studied. When CYP7B1 is mutated, monohydroxycholesterols can’t be 
further metabolised and therefore Hereditary Spastic Paresis patients with the SPG5 mutation, have increased 
plasma levels of 27-OHC (6- to 9-fold) and 25-OHC (100-fold) 
267
.  
1.1.8 STRATEGIES FOR OXYSTEROL ANALYSIS 
Despite oxysterol’s early discovery over one century ago, their research was hampered by the challenges of 
accurate separation-, detection- and identification methods. Most discoveries were made possible in the last 
20 years due to the improved analytical instrumentation. The challenge of oxysterol analysis is to overcome 
several parallel difficulties, namely:  
1. Cholesterol presence in large excess  
2. Low cellular concentrations  
3. Autoxidation of cholesterol and oxysterols  
4. Cellular localisation in membranes  
5. Possible chemical modifications like esterification, reduction, or sulphation 
6. Chemical structures and properties 
1,24,31,148,152,233,268,269
. 
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The last issue is an important since oxysterols do not possess a strong chromophore making them difficult or 
impossible to detect by ultraviolet absorption (UV)-spectroscopy. Furthermore, oxysterols are neutral 
hydrophobic molecules, poorly ionisable in electrospray (ESI) and atmospheric pressure chemical ionisation 
(APCI) and are mainly isomeric compounds with very similar mass spectrometry (MS) spectra. The different 
existing methods for analysis will be discussed in the next section (Figure 15). 
 
Figure 15| Summary of the instrumental methods used in the past, currently and probably in the future to identify and quantify 
oxysterols in biological matrices. The abbreviations and acronyms are explained in the chapter. 
Lifschütz, the discoverer of cholesterol oxidation products detected oxysterols using UV-vis spectrophotometry 
after a colour-inducing reaction was carried-out with highly concentrated sulphuric acid 
9
. Since it neither 
allows separation nor identification of oxysterols with similar structure, this detection method fell into oblivion. 
Thin layer chromatography (TLC) has the advantage of being cheap, simple and rapid and was used as a method 
for oxysterol analysis in the 70
th
 and 80
th
. The strategy was the detection of oxysterols trimethylsilyl (TMS) 
ether derivatives or ∆
4
-3-keto derivatives (∆= position of the double bond) obtained by enzymatic 
transformation with cholesterol oxidase. The thin layer chromatography stationary phase consisted in silica, 
silica gel, silica-G60 or silica gel G-AgNO3 plates with or without fluorescent indicator, mainly separating mono-
hydroxycholesterols from each other 
31
. Aringer and Nordström did an impressive task in separating by thin 
layer chromatography, GC-MS and in the combination of both the standards of 165 oxygenated sterols 
including oxygenated derivatives of plant sterols 
270
. As highlighted by Schroepfer, also this large collection of C-
27 oxysterols did not include all physiologically relevant oxysterols with oxygen functions at carbon atoms 4, 
20, and 22 and 24,25-epoxysterols 
31
. This study proved that thin layer chromatography has a limited capability 
to provide useful oxysterol separation in complex mixtures such as blood and tissues.  
Separation of complex mixtures is best archived on LC, but usually LC was coupled to a ultraviolet–visible 
detector (LC-UV/VIS). As mentioned before, oxysterols UV-absorption is very limited, making their analysis not 
suitable for LC-UV/VIS. Nevertheless, Teng and Smith were able to separate and detect 6 different oxysterols 
(7β-OHC, 7-KC, 19-OHC, 20-OHC, 25-OHC, 26-OHC) with LC-UV-vis, after enzymatic transformation by 
cholesterol oxidase converting 3β-hydroxy-5-ene groups to UV-absorbing (231–233 nm) 3-oxo-4-enes 
271
. 
Zhang exploited this method for 24(S)-OHC, 25-OHC and 27-OHC analysis in rodent liver 
272
. 
1.1.8.1 CURRENT STRATEGIES FOR OXYSTEROL ANALYSIS 
1.1.8.1.1 GC-MS 
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In 1995, Dzeletovic et al. published an oxysterol GC-MS (EI) method for the analysis of human plasma that 
became the reference method 
156
. Several groups applied it to determine oxysterol levels in tissues, cells and 
cerebrospinal fluid, to extend the analyte panel or to further optimise it 
273–279
. Griffith et al. summarised the 
key steps of Dzeletovic‘s method as follow: 
“1. Blood was collected in Ethylenediaminetetraacetic acid (EDTA) K3 containing vacutainers, and 
following centrifugation (1400 g, 10 min) to prepare plasma, butylated hydroxytoluene (BHT, 50 
mg/mL) was added. BHT is an antioxidant while EDTA traps metal ions there-by avoiding the Fenton 
reaction and metal catalysed oxidations. Deuterium-labelled internal standards (IS) were added at this 
point.  
2. Alkaline hydrolysis was performed under Ar using 0.35 M ethanolic potassium hydroxide (KOH) for 2 
h at room temperature (22 °C). The solution was neutralised with phosphoric acid and sterols were 
extracted into chloroform. The solvent was evaporated and the residue was dissolved in toluene. 
3. Oxysterols were separated from cholesterol on a silica cartridge, cholesterol eluting in 0.5% propan-
2-ol in hexane followed by oxysterols in 30% propan-2-ol in hexane.  
4. After removal of solvent, samples were converted to trimethylsilyl ethers by treatment with 350 mL 
of pyridine:hexamethyldisilylazane:trimethylchlorosilane (3:2:1, v/v/v) at 60 °C for 30 min, dried down 
and re-dissolved in 100 mL of hexane .  
5. GC–MS analysis was performed utilising selected ion monitoring (SIM) to achieve maximum 
sensitivity 
222
.” 
To our knowledge, the Schmitz Group made the latest improvement of oxysterol separation with gas 
chromatography. They published two new methods: one based on GC-MS/MS, the other on gas 
chromatography coupled to time of flight mass spectrometry (GC-TOF) 
280,281
. The 8.5 min long GC-MS/MS 
method was used for the simultaneous analysis of 24(S)-OHC, 25-OHC, 27-OHC, 7-KC, lanosterol, lathosterol, 7-
dehydrocholesterol, desmosterol, stigmasterol, sitosterol and campesterol. For this, they hydrolysed the 
molecules with ethanolic potassium hydroxide solution, extracted them by liquid/liquid extraction with n-
hexane, derivatised them with N-methyl-N-trimethylsilyl-trifluoracetamide and applied positive chemical 
ionisation with ammonia, as reagent gas. Tandem MS allowed the use of specific multiple reaction monitoring 
(MRM) transitions, which allowed separating of co-eluting substances, like desmosterol and 7-
dehydrocholesterol, sitosterol and lanosterol, or lathosterol and zymosterol. The oxysterol experience gained 
through the GC-MS/MS method served as basis for a GC-TOF-MS method, in which the purpose was the proof 
of principle for the method and not the separation itself. The author’s aim was to combine the excellent peak 
resolution of GC with the soft ionisation of APCI ionisation sources and the high resolution obtained by TOF. 
Although the first attempt of coupling GC with APCI were made by Horning et al. in the 1970s and there are 
now commercially available sources from different manufacturers, GC–APCI–TOF-MS has not widely spread 
282,283
. After modification and optimisation of a commercial APCI interface, they applied the GC–APCI–TOF-MS 
method to the separation and detection of 7β-OHC, 27-OHC, 24(S)-OHC, 7-KC, lanosterol, lathosterol, 
sitosterol, and campesterol. The results were satisfying and the authors claimed it to be attractive for the 
identification of unknown and unexpected components but didn’t further comment on it 
281
.  
1.1.8.1.2 LIQUID CHROMATOGRAPHY COUPLED TO TANDEM MS (LC-MS/MS) 
Although GC-MS has the advantage of showing excellent chromatographic resolution, being easy to use and 
having relatively low cost for instrumentation run, it has limitations. Oxysterol analytics on GC-MS is mainly 
hindered by: (i) labor-intensive sample preparation, (ii) high injection volume, (iii) lack of sensitivity requiring 
relatively large plasma volumes, (iv) mass spectral scanning functions and (v) the loss of derivatising groups in 
the ion source making molecular weight determination difficult 
226,284,285
. High-performance liquid 
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chromatography–tandem mass spectrometry (HPLC–MS/MS) and ultra-high performance liquid 
chromatography–tandem mass spectrometry (UHPLC –MS/MS) even more, are powerful tools for the 
microanalysis of compounds in biological samples. Compared to GC-MS methods, they are more broadly 
applicable to various analytes especially thermo- sensitive ones, they are more versatile and flexible for 
stationary phase change and don’t suffer from baseline drift as much as GC column do. Sufficient selectivity is 
achieved by the combination of chromatographic separation and selected reaction monitoring 
286
. According to 
Ayciriex et al. LC-MS is nowadays the most frequently used technique for the identification and quantification 
of sterols and oxysterols in complex biological samples 
284
. However, also LC-MS/MS has its limitations for 
oxysterol analysis. One issue is that oxysterols are isomeric compounds resulting in very similar spectra and 
putting thereby a high demand on chromatographic performance. Identification of unknowns is almost 
impossible without authentic standards. The second issue is the poor ionisation capacity of oxysterols in both 
ESI and APCI ionisation sources, motivating many groups to oxysterols derivatisation prior LC-MS/MS analysis 
222
.  
1.1.8.2 OXYSTEROL ANALYSIS IMPROVEMENT  
 
Figure 16| Diagram of possible methodological improvements for oxysterols analysis. The abbreviations and acronyms are explained in 
the chapter. 
1.1.8.2.1 SENSITIVITY IMPROVEMENT FOR OXYSTEROL ANALYSIS. 
1.1.8.2.1.1 IONISATION 
Standard ionisation sources for LC-MS/MS analysis are ESI and APCI, which are often exchangeable in the same 
mass spectrometer. In ESI the “sample solution is sprayed across a high potential difference (a few kV) from a 
needle into an orifice in the interface. Heat and gas flows are used to desolve the ions existing in the sample 
solution” 
287
. Although the principle is quite simple there is still no consensus on the theory that explains the 
final production of gas-phase ions. ESI is a soft ionisation technique that is broadly applicable for polar 
compounds and a large range of molecular weights. Limitations of ESI are the generation of multiply charged 
species making the interpretation more complex than for other ionisation sources and the bad ionisation of 
uncharged, non-basic and low- polarity compounds like steroids. This is the reason why this compound class 
including oxysterols was preferentially analysed with the complementary method to ESI, namely APCI. APCI is 
also a soft ionisation method but in which “a corona discharge is used to ionise the analyte in the atmospheric 
pressure region. The gas-phase ionisation in APCI is more effective than ESI for analysing less-polar species” 
and was considered to be sensitive enough for direct analysis of sterols without derivatisation 
288–291
. APCI’s 
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inconvenience is the dehydration of protonated molecules hindering often the identification of the analyte’s 
molecular weight 
291,292
. Oxysterol detection limits obtained with HPLC-APCI–MS are reported to lie in the range 
of 0.1–0.8 ng (about 0.25–2.0 pmol) 
293,294
. In 2007 McDonald et al. showed efficient ionisation of neutral 
sterols by HPLC–ESI–MS/MS using the Applied Biosystems 4000 QTrap triple quadrupole system 
295
. The 
authors reported on-column detection limits of 5–20 fmol and 25–2000 fmol for dihydroxy- or epoxysterols, 
and monohydroxycholesterols, respectively 
295
. These values are not inferior to those obtained by APCI but still 
three orders of magnitude higher than for examples oxysterols derivatised with picolinoyl esters 
286,296
. 
However, it is difficult to make a general statement on ESI sensitivity since it is known to be strongly 
instrument-dependent 
286
.  
Independent of the ionisation method used, oxysterol ions are often adduct [M+NH4]
+
 ions that result in very 
few fragmentation product ions arising from carbon-carbon bond cleavages. Oxysterols form mainly a 369 m/z 
fragment due to the elimination of one or two neutral water molecules, or analogue ions depending on the 
number of hydroxyl groups and the basic steroid structure. The stability of the cyclic ring structure confers 
resistance towards ionisation and further fragmentation (MS/MS) at higher energies thus giving very little 
structural information of simple mono-and dihydroxycholesterols 
297
.  
Improved MS sensitivity, however, allowed several groups to go for underivatised oxysterol analysis avoiding 
the laborious sample preparation. The main chosen ionisation method is APCI. Besides McDonald et al. only 
Karuna et al. published an ESI-MS/MS oxysterol method of underivatised oxysterols. The group was able to 
separate 7β,25-OHC, 7β,27-OHC, 7α,25-OHC, 7α,24S-OHC, and 7α,27-OHC and quantified the low concentrated 
dihydroxycholesterols, 7α,25-OHC and 7α,27-OHC in human plasma while having a limit of detection (LOD) of 
0.5 nM 
220
. According to their experience, the ionisation efficiency for dihydroxycholesterols decreased in the 
following order: ESI > APCI > assisted-atmospheric pressure photoionisation, contradicting thereby an old 
ionisation dogma.  
1.1.8.2.1.2 DERIVATISATION 
To circumvent unspecific oxysterol fragmentation and bad ionisation, a set of different derivatisation methods 
were proposed (Figure 17 and Figure 18).  
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Figure 17| Oxysterol derivatisation reactions (Part 1) A. Derivatisation to trimethylsilyl ethers for GC-MS analysis B. Derivatisation to Girard hydrazones with Girard T (B.1) or Girard P reagent (B.2) C. Derivatisation to 
picolinyl esters . The abbreviations and acronyms are explained in the chapter. Figure adapted from Griffiths et al. (2013) 222. 
Chapter: Background on oxysterols 
 
32 
 
Figure 18| Oxysterol derivatisation reactions (Part 2) A. Derivatisation to N,N-dimethylglycine esters B. Derivatisation to 
dimethylaminobutyrate esters. Figure adapted from Griffiths et al. (2013) 222. 
1.1.8.2.1.2.1 DERIVATISATION TO GIRARD HYDRAZONES 
Shackelton et al. were the first to make use of the very well-known steroid derivatisation with Girard hydrazine 
reagents introducing in this way a quaternary nitrogen group in the molecules favouring positive ionisation 
298–
300
. Griffith et al. applied the cholesterol oxidase conversion of 3β-hydroxy-5-ene sterols to 3-oxo-4-ene sterols 
to obtain compounds susceptible for Girard P derivatisation 
271,272
. This approach was named as “Enzyme 
assisted derivatisation for sterol analysis” or also EADSA in literature. For plasma oxysterol analysis, the method 
consists in the following steps: ethanol protein precipitation accompanied by sonication, first solid phase 
extraction (SPE), enzymatic conversion of a fraction by the cholesterol oxidase, addition of Girard P reagent 
reagent to all fractions, second solid phase extraction and finally instrumental analysis. The 17 minutes 
separation was made on a Hypsersil Gold reversed phase column (1.9 µm particle size, 50 mm x 2.1 mm, 
Thermo Fisher) with mobile phases A and B being a mixture of methanol and acetonitrile both containing 0,1% 
formic acid. Oxysterols were detected by a high resolution APCI-linear trap quadrupole (LTQ)-Orbitrap hybrid 
mass spectrometer using up to five transitions over the course of the chromatographic run and MS/MS/MS 
also written as MS
3
 to even MS
4
 scans in some cases. Quantification was made using stable isotope dilution 
with three IS, one for side-chain oxysterols, one for B-ring oxysterols and the last one for 
dihydroxycholesterols. The drawbacks of this procedure are the enzyme activity with possible side-reactions, 
the prerequesit of a free hydroxyl group at position 3 of the sterol ring, the large excess of derivatisation 
reagent requiring a second solid phase extraction, syn and anti-forms per oxysterol with different retention 
times, and the laborious nature of the sample preparation protocol 
222,224,301
. In the meantime the “Enzyme 
assisted derivatisation for sterol analysis” was modified by different groups with reduced sample preparation 
times. The “Enzyme assisted derivatisation for sterol analysis” variants are still called “Enzyme assisted 
derivatisation for sterol analysis”, even if strictly spoken they aren’t any more. DeBarber et al. for example 
were interested to analyse three oxysterols in the context of CTX and could omit the enzyme conversion step 
since it was not necessary in their case. They decided also to bypass the cholesterol removal step, to reduce the 
amount of Girard P reagent and to cut the derivatisation time to 2h. A trap column in front of the analytical 
column removed the excess reagent instead of using a second solid phase extraction 
302
. Similar to DeBarber et 
al., Roberg-Larsen et al. omitted the cholesterol removal step and used prior to the analytical column, a trap 
column for removal of excess Girard T, instead of the Girard P reagent 
303
.  
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1.1.8.2.1.2.2 DERIVATISATION TO PICOLINYL ESTERS 
Honda et al. developed a method for derivatisation of hydroxyl groups of oxysterols by picolinyl esters. Only 5 
µL of serum were subjected to acid hydrolysis followed by n-hexane extraction. To the dried oxysterol extract a 
freshly prepared derivatisation mixture of 2-methy-6-nitrobenzoic anhydride, 4-dimethylaminopyridine, 
picolinic acid, pyridine and triethylamine was given and incubated for 1h at 80°C. Addition of n-hexane allowed 
the precipitation of excess derivatisation reagents. The precipitated derivatisation chemicals were then 
removed by centrifugation and the cleaned oxysterol picolinyl esters were dried, redissolved and injected into a 
LC-ESI-MS/MS system. This derivatisation protocol greatly improved the analytical sensitivity (LOD 5-25 amol 
on-column for oxysterol dipicolinates and epoxycholesterol picolinate) but oxysterol discrimination still relied 
on good LC separation 
303
.  
1.1.8.2.1.2.3 DERIVATISATION TO N,N-DIMETHYLGLYCINE ESTERS OR 
DIMETHYLAMINOBUTYRATE ESTERS 
Jiang et al. developed an oxysterol derivatisation protocol for the analysis of C-triol and 7-KC for the Niemann-
Pick type C (NP-C) diagnostics. 50 µL of plasma were subjected to protein precipitation by methanol, 
centrifuged, the protein precipitate was removed and the supernatants were dried down. To the dry oxysterol 
extract dimethylglycine, 4-dimethylaminopyridine, and subsequently 1-ethy-3-(3-dimethylaminopropyl) 
carbodiimide dissolved in chloroform were added. The mixture was heated for 1h at 45°C, quenched with 
methanol, dried down and redissolved prior to LC-APCI-MS/MS analysis. The MRM fragments of triol, 7-KC and 
their respective deuterated standards corresponded to the loss of dimethylglycine [M+H-103]
+
 and of the 
protonated dimethylglycine at m/z 104 
285,304,305
. Recently, a similar protocol for oxysterol derivatisation in the 
context of NP-C diagnosis was reported, with the main difference that dimethylaminobutyrate was used as 
derivatisation reagent instead of N,N-dimethylglycine 
228
. 
1.1.8.2.2 SELECTIVITY IMPROVEMENT FOR OXYSTEROL ANALYSIS 
1.1.8.2.2.1 BENEFICIAL USE OF RELEVANT INTERNAL STANDARDS  
Appropriate IS should be used for correct quantification with ideally each target analyte being quantified 
against its own isotope labelled counterpart 
222
. IS fulfil several roles at a time: first they compensate for loss 
during sample preparation, second they compensate for injection volume variation into the HPLC column, third 
they help to determine the variation in the retention time of each target analyte among different samples and 
runs, and finally they help for target analyte identification when peaks are small or not completely separated 
from interfering peaks 
286
. Specific deuterated sterols are considered to be the most ideal IS for HPLC-MS 
analysis and the structurally closest IS should be used as surrogate if a specific deuterated sterol is 
commercially not available 
225,295
. Alternatively, the surrogate can be a compound not naturally occurring in 
human serum, as for example coprostanol for cholesterol quantification, since coprostanol is only synthesised 
by intestinal bacteria and is thus not present in human serum 
306
. 
1.1.8.2.2.2 SAMPLE CLEAN-UP 
The biggest issue in oxysterol analysis, especially for non-MRM methods, is that samples usually contain 10
2
 to 
10
4
 times more cholesterol than oxysterols 
286
. Separation of cholesterol and oxysterols can be best achieved 
by SPE allowing a more selective separation of similar structures than for example liquid-liquid extraction. 
However, complete separation is difficult, especially for some less polar oxysterols. Often mainly nonpolar 
compounds such as phospholipids responsible for most matrix effects are removed instead of cholesterol 
307
. 
There is not one SPE cartridge that would be the best to use for cholesterol separation, although several groups 
compared different SPEs stationary phases and brands. Mendiara et al., suggest the use of Zirconia-coated 
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silica sorbent SPE cartridges from Sigma-Aldrich, while McDonald et al. used aminopropyl SPE columns from 
Biotage 
226,307
. Crick et al. first advised C18 reversed-phase cartridges (Sep-Pak tC18 200-mg cartridges from 
Waters) but their inter-batch variation convinced them to change for polymeric hydrophilic-lipophilic balanced 
reversed-phase cartridges (Waters Oasis HLB cartridges) 
308
.  
Depending on the research question, it might be interesting to unravel the oxysterol esterification degree. For 
this, the sample is subjected to alkaline hydrolysis and the esterification degree is calculated as the difference 
between total and free oxysterols. In plasma, 7α,25-OHC and 7α,27-OHC were found to have an endogenous 
esterification degree of 74 % and 82 %, respectively 
220
. Esterification is the mechanism of the cell to inactivate 
oxysterols. Hence, measuring the total oxysterol content is probably not relevant if the interest is in oxysterol’s 
biological activity.  
In summary, if one wants to analyse total oxysterols levels using a derivatisation step to optimize sensitivity 
and including a cholesterol and phospholipid removal step to minimize matrix effects, the workload per sample 
is quite high and the procedure difficult to automatise. Figure 19 summarises the typical work flow of plasma 
sample preparation for oxysterol analysis.  
 
Figure 19| Typical work flow of plasma sample preparation for oxysterol analysis with optional steps highlighted in blue. 
1.1.8.2.2.3 LC SEPARATION 
Since oxysterols tend to have isobaric mass and are positional isomers, their analysis relies on a good LC 
separation. Sterols can be separated on both normal and reverse stationary phases but the later is favoured 
since the reproducibility is higher and the polar mobile phase favours ionisation. Obtaining a good 
chromatographic oxysterol separation is challenging and co-elution of e.g. 24(S)-OHC and 25-OHC is often 
occurring 
295
. Even with increased choice of performance stationary phases, especially with the arrival of new 
selective UPLC and monolithic columns, separation of all oxysterols in a single run is still impossible. This 
separation problem should be considered when looking at quantitative data of oxysterol levels, which might be 
biased by one or several co-eluting oxysterol(s). For non-MRM methods, it should additionally be assured that 
cholesterol, still remaining after the poorly selective SPE step is not coeluting with one or several oxysterols 
309
. 
1.1.8.2.2.4 SELECTION BY MS/MS 
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Today the most selective detection system is the triple quadrupole mass spectrometer, which is also highly 
sensitive for sterol quantification. Using MS/MS transitions at specific collision energies eliminates interfering 
analytes. In combination with retention times and the handling of IS, the use of multiple SRM pairs for single 
sterols adds confidence to the compound identification. The higher the resolution of the mass spectrometer, 
the better the signal to noise (S/N) ratio and the less interfering peaks appear in the chromatogram. In order to 
have excellent selectivity, Griffith et al. worked with high-resolution MS (HRMS) by a hybrid quadrupole-TOF 
mass spectrometer or with high-resolution MS
n
 by a hybrid linear ion-trap/Fourier transform mass 
spectrometer 
292,301
. However, these mass spectrometers do not achieve the same sensitivity and dynamic 
range for quantification as the triple quadruple mass spectrometer does 
309
.  
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1.2 BACKGROUND ON NP-C  
1.2.1 INTRODUCTION TO NIEMANN-PICK DISEASES 
The first descriptions of one of the diseases known nowadays as Niemann-Pick disease (NPD), date back to 
1914, and were written by the German paediatrician A Niemann. He described a 1 ½ year old girl with 
hepatosplenomegalie and impaired brain and nervous system function. The pathologist L. Pick carried-out 
postmortem histochemical analysis on the spleen of Niemann’s patient. Based on the cholesterol cell load he 
proved that the patients’ disease was different to the lipidosis known at that time 
310,311
. Later in 1958, Crocker 
and Farber published a series of 18 NPD cases and were the first to classify the patients into different 
subgroups according to clinical and biochemical criteria 
312
. Nowadays NPD patients are divided into two 
diseases with one disease group classified in two categories: Niemann-Pick type C (NP-C), and Niemann-Pick 
type A (NP-A) and B (NP-B) 
313
. All NPD are rare lysosomal storage diseases with neurological implications 
presenting a large panel of disease unspecific symptoms. The disease course varies between patients but 
generally patients with milder disease forms may live to their adulthood, while severe disease forms are fatal in 
toddlerhood. NP-A and B prevalence is estimated to be 1 to 250 000 births and is due to mutations of the acid 
lysosomal sphingomyelin phosphodiesterase 1 (SMPD1) also known as acid sphingomyelinase (ASM) 
314
. This 
enzyme is involved in the last step of the lysosomal degradation pathway of glycosphingolipids and breaks 
down sphingomyeline to ceramide and phosphorylcholine. When dysfunctional, sphingomyelin accumulates in 
the lysosome. NP-A frequently-encountered symptoms are hepatosplenomegaly, neurological deterioration, 
respiratory infections and a cherry-red spot of the macula of the retina. NP-B is the milder form of NP-A, with 
later onset and less neurological implications. NP-A and B are diagnosed by ASM enzyme activity testing and 
are confirmed by molecular genetic testing of the ASM gene 
314
. Nowadays both diseases can only be treated 
symptomatically, but Genzyme (a Sanofi company) started this year a phase 2/3 study for an enzyme-
replacement therapy product 
315
.  
1.2.2 GENERAL CONSIDERATIONS ON NIEMANN-PICK TYPE-C 
In contrast, NP-C disease is caused by autosomal recessive inheritance of mutations in either the NPC1 or in 5 % 
of the cases in the NPC2 gene 
313,316
. The encoded proteins are responsible in a hand-in-hand manner to 
transport cholesterol out of the lysosome for further cellular processing 
317,318
. If dysfunctional, the intracellular 
lipid trafficking is impaired and cholesterol and glycosphingolipids accumulate in the lysosomes. The disease is 
estimated to occur in 1 per 120 000 births and has an extremely heterogeneous clinical presentation 
316
. The 
symptoms comprise systemic and neurological signs being neither age-, nor NP-C -specific and the disease 
progression occurs at different rates. Examples of symptoms are neonatal cholestasis often associated with 
spleno- or hepatosplenomegaly, impaired gait, dysarthria, dysphagia, dystonia, gelastic cataplexy, progressive 
cerebellar ataxia and progressive dementia 
313,316
. NP-C is nowadays treated with an iminosugar called 
Misglustat (N-butyldeoxynojirimycin, Zavesca®) from Actelion Pharmaceuticals, in addition to symptomatic 
treatment options. The drug was first designed for Gaucher Disease (GD) since it acts as competitive inhibitor 
of the glucosylceramide synthase, catalysing the first step in glycosphingolipid synthesis. Since 
glycosphingolipids are also accumulating in the lysosome of NP-C patients, the drug is used for NP-C since 2009 
in Europe and proved to stabilise and/or reduce the disease progression rate in NP-C 
313,316
. Hydroxypropyl-β 
cyclodextrin (HPβCD), another drug, is tested in a clinical trial since November 2012 on the initiative of a 
mother with NP-C affected twins. Direct HPβCD administration into the brain of NP-C presymptomatic and 
symptomatic cats slowed down disease progression significantly, being therefore a very new promising NP-C 
drug 
319–321
. The mechanism behind HPβCD efficiency in NP-C treatment is poorly understood but appears to be 
mediated through the activation of the transcription factor EB (TFEB), which is a master regulator of lysosomal 
biogenesis and autophagy 
322
. Laboratory diagnosis of NP-C follows an algorithm proposed by Vanier in 2010 
and was revised by Patterson et al. in 2012. The general concept is to first undertake useful preliminary tests 
such as the chitotriosidase assay, or enzymatic testing to exclude Gaucher disease and ASM deficiency, or 
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assessing the presence of foam cells in the bone marrow. The second step consists in sampling the gDNA and 
undertaking skin biopsies of the patient for fibroblast culture. Filipin staining of free cholesterol on the cultured 
fibroblasts should be done in parallel to the genetic testing on gDNA. Finally, the interpretation occurs on all 
combined results. However, these consecutive tests lack sensitivity and specificity and even mutation analysis 
is not always conclusive 
313,316
. In 2010, Porter et al. discovered two autoxidative oxysterols in the plasma of 
NP-C patients with diagnostic potential 
26,285
. 
1.2.3 RELATIONSHIP BETWEEN NP-C AND OXYSTEROLS 
C-triol, and 7-KC found to be specific in NP-C and interestingly correlate with the cholesterol accumulation in 
the cells of NP-C patients. However, the exact physiological mechanism explaining this correlation in NP-C is 
still unclear. Three different observations might be a starting point to answer the question of the oxysterol-
cholesterol relationship in NP-C disease. The first evidence is that the NPC1 transporter protein has higher 
binding affinity for oxysterols than cholesterol 
323
. Secondly, the oxysterol-binding protein-related protein 5 
(ORP5) is necessary for lysosomal trafficking of cholesterol 
324
. This last evidence suggests the requirement of 
oxysterols for cholesterol lysosomal export and the cellular oxysterol synthesis to compensate for the high 
cholesterol amount. Finally the third evidence and probably in relation to the second point, is the increased 
cellular oxidative stress due to the cholesterol lysosomal accumulation and due to other cellular dysfunctions 
observed in NP-C cells leading to ROS formation contributing in this way to non-enzymatic oxysterol formation 
325
. 
1.2.4 IN VIVO  FUNCTION OF THE NPC PROTEINS 
LDL delivers cholesteryl esters to the cell via receptor-mediated endocytosis. Due to endosomal acidification, 
LDL dissociates from its receptor, which recycles back to the plasma membrane for re-utilisation. The LDL is 
delivered to the late endosomes/lysosomes where the cholesteryl esters are hydrolysed by the lysosomal acid 
lipase (LAL) to form free cholesterol 
326
. The cholesterol is loaded on a small soluble cholesterol binding protein, 
called Niemann-Pick C2 protein (NPC2) and subsequently shuttled to Niemann-Pick C1 protein (NPC1) 
317,318
. 
NPC1 is a large glycoprotein with 13 transmembrane domains and one sterol sensing domain and is located in 
lysosomal membranes 
327
. By still badly-known mechanisms, cholesterol is transported to various organelles for 
further processing. The current knowledge indicates that NPC1 works in association with ORP5 for cholesterol 
ER targeting 
324,328,329
. ORP1L acts as cholesterol sensor for the NPC1-ORBP5 mediated cholesterol transport to 
the ER membrane. In addition ORP1L recruits proteins essential for placing lysosomes to the perinuclear region 
into proximity of the ER, enabling for effective cholesterol transfer 
330–333
. Interestingly, the cholesterol 
transport mechanism to the mitochondria seems to involve NPC2 and metastatic lymph node protein 64 
(MLN64) but not NPC1, which might explain the observed increase of mitochondrial cholesterol in NPC cells 
334,335
. In contrary to the NPC1 or NPC2 mediated cholesterol transport mechanisms, cholesterol moves to the 
Golgi implicating the trans-Golgi network (TGN)-specific soluble N-ethylmaleimide-sensitive factor attachment 
protein receptors (SNAREs), but not the NPC1 or NPC2 proteins. Mutations of either NPC1 or NPC2 as well as 
other proteins implicated in lysosomal cholesterol sorting, lead to lysosomal cholesterol accumulation and are 
responsible for the very similar phenotypes observed in other lysosomal storage disorders. Besides the harmful 
effect of NPC1 mutations in NP-C, it was recently shown that dysfunctional NPC1 completely stops Ebola virus 
cell entry. How Ebola virus use NPC1 to enter the cell is unclear but is currently under investigation since time-
dependent NPC1 auto-inactivation would be an interesting therapeutic options for future Ebola epidemics 
330,336,337
.   
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1.3 BACKGROUND ON IBD 
1.3.1 GENERAL CONSIDERATIONS ON IBD  
Inflammatory bowel diseases (IBD) are a group of chronic relapsing immune-mediated disorders of the 
gastrointestinal tract that are pathologically characterised by intestinal inflammation and epithelial injury 
338,339
. The pathophysiology of IBD will be described in the next section. IBD onset typically occurs in the second 
or third decade of life and affects an estimated 2,5–3 million people in Europe 
340,341
. Frequent symptoms 
during the active inflammatory state called flare ups are tiredness, weight loss, fever, night sweats, decreased 
appetite, nausea, vomiting, stomach pain, flush, and (bleeding) bowels. The disease activity is categorised from 
mild to severe 
342,343
. Diagnosis of IBD cannot be made straightforward with only one definitive diagnostic test 
selective for one particular disease. Instead, the diagnosis consists in the combined assessment of clinical 
history, and endoscopic, histological or radiological results, as well as laboratory results such as C-reactive 
protein, erythrocyte sedimentation rate, complete blood count, and fecal calcprotectin measurements 
342,344–
346
. Using these diagnostic procedures, it is often possible to make a firm diagnosis of IBD. Nevertheless, there 
are about 10 % of the patients in which the diagnosis isn’t certain and which are considered to have 
indeterminate colitis. The treatment options will depend on the patient’s clinical history, the physical findings, 
and the exact diagnosis. Common treatment strategies include 5-aminosalicylic acid, corticosteroids, 
immunosuppressive and immunoregulatory agents like azathioprine, anti-TNF therapy or the use of antibiotics 
and probiotics as well as adequate diet 
346
. Crohn’s disease (CD) and Ulcerative colitis (UC) are the two most 
important representatives of IBD, with shared characteristics 
347
. UC inflammation is exclusively localised to the 
colon and mainly starts from the rectum from where it progresses. UC macroscopic mucosa morphology shows 
perforation of the colon, erythema and friability of the mucosa, superficial ulceration and appearance of 
pseudopolyps 
347
. In CD lesions of the mucosa are discontinuous and might occur anywhere in the 
gastrointestinal tract but rectal involvement is rare. CD macroscopic mucosa morphology shows segmental 
transmural inflammatory lesions, linear ulceration, deep into the tissue going inflammation, and appearance of 
fistulae 
347
. IBD etiology remains unknown but appears to be multifactorial implicating a tight interplay 
between human intestinal microbiome and the mucosal immune system, with an important genetic 
predisposition. Additionally, the exposome influence appears to be very important, meaning all environmental 
factors to which a human has been exposed during lifetime such as dietary factors, air and water pollution, 
food additives, lifestyle factors, stress, hygienic conditions and drug treatment 
348
. 
1.3.2 IBD INITIATION AND PATHOPHYSIOLOGY 
The exact mechanism of IBD’s initiation is still under investigation and it remains unclear whether changes of 
the intestinal microbiota composition are the cause or the consequence of impaired mucosal immune function 
346,349,350
. Current evidence supports both hypotheses. Family aggregation of IBD was a first hint for genetic 
susceptibility, and currently 163 IBD risk loci have been identified by genome wide association studies (GWAS). 
The genetic susceptibility would be an argument for impaired mucosal immune function as starting point of 
IBD, but a recent publication in Nature Communication observed a shift of the microbiota composition in mice 
towards Escherichia coli (E. coli) overgrowth suggesting the microbiota shift as possible IBD trigger. The authors 
discovered that sialic acid availability on intestinal mucosa is, as a nutritive glycan, supporting E.coli 
overgrowth. Higher sialic acid levels on intestinal mucosa would be in turn due to the increased enzymatic 
sialidase activity of non- destructive bacteria species that proliferate when the mucosa is injured 
351
. This study 
was made by mean of dextran sulphate sodium (DSS)-induced colitis on 2,3 sialyltransferase (St3gal4) (ST) 
knockout mice as an approach of IBD model. Whatever IBD’s causes are, innate immune response is at the 
origin of the excessive activation of adaptive immunity. However, it is the latter and its associated cytokines 
that drive deregulation within the epithelial layer 
340
. In simple terms, sentinel cell populations, among others 
the antigen-presenting cells (APC) like dendritic cells (DC) are continuously monitoring the intestinal mucosa for 
luminal microbes 
340
. In normal situation, DC expresses pattern recognition receptors (PPRs) such as toll-like 
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receptors (TLRs) on their cell surface or nucleotide-binding oligomerisation domain (NOD)-like receptors (NLRs) 
in their cytoplasm 
352,353
. TLR4, recognises and is activated by lipopolysaccharides (LPS) from gram-negative 
bacteria like E. coli 
354
. The activation results in nuclear translocation and activation of the pro-inflammatory 
transcription factor Nuclear factor-κβ which in turn will produce pro-inflammatory cytokines and chemokines 
355,356
. On the contrary, the cytosolic NOD2 NLR is expressed in intestinal epithelial cells (IECs) and paneth cells, 
and senses bacterial muramyl dipeptide (MDP). NOD2 activation results, among others in the production of 
antimicrobial peptides like defensins and hence preserves the balance between the gut commensal 
communities and plays a protective role during intestinal damages 
357,358
. The right balance of the two PRR 
downstream effects contributes to homeostasis of the intestinal immune system. However, if the balance is 
impaired favouring TLR4 activation, APCs release pro-inflammatory cytokines such as IL-6, TNF-α, IL-12, and IL-
23 which activate T cells of the adaptive immune system 
339
. The activated T cells on their turn secrete pro-
inflammatory cytokines resulting in the inflammatory signalling cascade. TH1 cells are known to release IFN-γ, 
IL-6 and TNF-α, while TH2 cells are secreting IL-5, IL-6, IL-13 and TNF-α 
339
. Interestingly Crohn’s disease appears 
to be predominantly a TH1 and TH17-mediated process, while UC seems to be an atypical TH2 disorder 
359
. 
1.3.3 RELATIONSHIP BETWEEN IBD AND OXYSTEROLS  
Several evidences showing a relation between oxysterols and inflammatory disorders such as IBD have 
appeared throughout the last years. They all concerns different oxysterol receptors, which would suggest 
oxysterols implication in immunity not to be minor even if actually not much is known. The oxysterol receptors 
are the transmembrane receptor EBI2, the nuclear receptors LXRα and β and the RORγt.  
1.3.3.1 VIA THE TRANSMEMBRANE RECEPTOR EBI2 
As mentioned earlier, 7α,25-OHC was found to be the most potent EBI2 ligand on follicular naïve B cells and 
acts as a B cell chemoattractant in follicular microenvironments 
28,35
. Additionally this EBI2-7α,25-OHC system 
plays a role in the positioning of splenic cluster of differentiation (CD) CD4
+
 DC in the marginal zone of the 
bridging channels to prime T cells for an efficient antibody response 
360,361
. Recently, in addition to B cells and 
DC, macrophages were also demonstrated to migrate in an EBI2-depenent manner 
362
. EBI2 mRNA was 
furthermore found in T cells, natural killer cells (NK-cells), neutrophils, basophils and eosinophils 
28
. However, in 
these cells, no 7α,25-OHC promoted-motion could be shown, indicating different inflammatory response 
mechanisms of 7α,25-OHC. At the moment it appears that the chemotactic feature of EBI2 is due to the 
combined action of two EBI2 signalling pathways: the Gαi dependent signalling pathway and the β-arrestin 
recruitment pathway being G protein-independent. However, the Gαi dependent signalling pathway appears to 
have a more prominent action than the β-arrestin recruitment pathway 
363
. Other EBI2 downstream effects 
have been reported supporting the hypothesis that 7α,25-OHC triggers several inflammatory responses. 
Among the different downstream signalling pathways are calcium release, guanosine 5'-O-[gamma-
thio+triphosphate (GTPγS) binding, p38 mitogen-activated protein kinase activation and extracellular signal-
regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase activation 
28,35,128,129,363
. The occurrence of 
several downstream pathways for the EBI2-7α,25-OHC system indicates that it is an important immune 
regulator which needs to be tightly controlled. Besides 7α,25-OHC, 7α,27-OHC and 7β,25-OHC were also shown 
to bind to the EBI2 receptor but not as strong as 7α,25-OHC does.  
Three different observations implicate the EBI2 – dihydroxycholesterol system to have a role in the IBD human 
pathophysiology. The first and most important is the identification by Jostins et al. in 2012 that EBI2 is an IBD 
risk gene and that the T allele of the single nucleotide polymorphism (SNP) rs9557195 increases the risk for 
both, CD and UC with genome wide significance 
364
. Secondly, a single nucleotide polymorphisms (rs9585056) 
in the EBI2 gene was found to occur in inflammatory diseases such as type 1 diabetes 
365
. Finally increased EBI2 
receptor levels were shown in the ileum of CD patients with NOD2 mutations 
366
. Taken together these data 
strongly suggests not only an implication but although a protective role for the EBI2 receptor in IBD. EBI2 is at 
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the current state of knowledge activated by dihydroxycholesterols, and therefore these oxysterols are of high 
interest for the IBD research.  
1.3.3.2 VIA NUCLEAR RECEPTORS 
1.3.3.2.1 VIA LIVER X RECEPTORS 
The nuclear receptors LXRs are as already mentioned established regulators of lipid-inducible gene expression 
and are activated by a certain number of oxysterols, among them 24-OHC, 25-OHC and 27-OHC. However, the 
discovery of LXRs implication in immunology is just in its beginning and started in 2003 with two distinct 
studies. Both studies could show that the synthetic LXR agonist GW3965 inhibited the in vitro as well as the in 
vivo macrophage response to bacterial infections or to lipopolysaccharide (LPS) stimulation. The synthetic LXR 
agonist GW3965 inhibited macrophage expression of pro-inflammatory mediators, such as IL-1β, IL-6, 
metalloproteinase 9, nitric oxide synthase (iNOS), cyclooxygenase 2 (COX-2), monocyte chemoattractant 
protein-1 (MCP-1), MCP-3, macrophage inﬂammatory protein 1β (MIP-1β) and interferon inducible protein-10 
(IP-10) 
367,368
. Moreover, inflammation in murine models of contact dermatitis and atherosclerosis was reduced 
by synthetic LXR ligands 
367,369,370
. Only recently Jakobssen et al. showed an interconnection between LXR 
activation and inhibition of pro-inflammatory cytokines in IBD, with a more noticeable protective role for LXRβ 
than LXRα. They found that the expression of both LXRα and LXRβ were significantly suppressed in inflamed 
colons from IBD subjects compared to non-inflamed colons. The receptors were thus not able to exert their 
protective action in IBD patients. Based on their findings, the authors suggest LXRs to be an interesting 
pharmaceutical target to reduce the inflammatory state in IBD 
371
.  
1.3.3.2.2 VIA RAR-RELATED ORPHAN RECEPTOR GAMMA T 
A second nuclear receptor, RORγt was proven to be activated by oxysterols with the most potent being 7β,27-
OHC, which accelerated differentiation of pro-inﬂammatory T helper 17 (TH17) cells 
135
. TH17 cells are 
implicated in various chronic inflammatory diseases among others, CD and UC 
372–376
. At the moment, there are 
very contrasting findings on the role of TH17 cells in UC. There are suggestions for pathological as well as 
protective roles 
377–381
. This TH17 function discrepancy might be explained by the fact that the TH17 cells 
pathogenic capabilities depend on the environment of IL-17 production. If activated in presence of IL-23, TH17 
cells are more aggressive than TH17 cells activated with IL-6 and Transforming growth factor-β1 (TGF-β) 
382,383
. A 
minority of IL-6 and TGF-β-activated TH17 cells even expressed the anti-inflammatory IL-10, thus contributing to 
the discovered protective action of TH17 cells. 
384
.   
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2.1.1 ABSTRACT 
2.1.1.1 BACKGROUND 
Niemann-Pick type C (NP-C) is a rare progressive neurodegenerative lipid storage disorder with heterogeneous 
clinical presentation and challenging diagnostic procedures. Recently oxysterols have been reported to be 
specific biomarkers for NP-C but knowledge on the intra-individual variation and on reference intervals in 
children and adolescents are lacking. 
2.1.1.2 METHODS 
We established a LC-MS/MS assay to measure Cholestane-3β,5α,6β-triol (C-triol) and 7-ketocholesterol (7-KC) 
following Steglich esterification. To assess reference intervals and intra-individual variation we determined 
oxysterols in 148 children and adolescents from 0-18 years and repeat measurements in 19 of them. 
2.1.1.3 RESULTS 
The reported method is linear (r >0.99), sensitive (detection limit of 0.03 ng/mL [0.07 nM] for C-triol, and 0.54 
ng/mL [1.35 nM] for 7-KC) and precise, with an intra-day imprecision of 4.8 % and 4.1 %, and an inter-day 
imprecision of 7.0 % and 11.0 % for C-triol (28 ng/ml, 67 nM) and 7-KC (32 ng/ml, 80 nM), respectively. 
Recoveries for 7-KC and C-triol range between 93 % and 107 %. 
The upper reference limit obtained for C-triol is 40.4 ng/mL (95% CI: 26.4-61.7 ng/mL, 96.0 nM, 95% CI: 62.8-
146.7 nM) and 75.0 ng/mL for 7-KC (95% CI:55.5-102.5 ng/mL, 187.2 nM, 95% CI:138.53-255.8 nM), with no age 
or gender dependency. Both oxysterols have a broad intra-individual variation of 46 % ± 23 % for C-triol and 52 
% ± 29 % for 7-KC. Nevertheless, all Niemann-Pick patients showed increased C-triol levels including Niemann 
Pick type A and B patients. 
2.1.1.4 CONCLUSIONS 
The LC-MS/MS assay is a robust assay to quantify C-triol and 7-KC in plasma with well documented reference 
intervals in children and adolescents to screen for NP-C in the peadiatric population. In addition our results 
suggest that especially the C-triol is a biomarker for all three Niemann-Pick diseases.  
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2.1.2 INTRODUCTION 
Niemann-Pick type C (NP-C) disease is a neurodegenerative lipid storage disorder caused by dysfunction in one 
of the lysosomal proteins: NPC1 or NPC2 
1,2
. These proteins are responsible for displacing free cholesterol from 
the lysosome to other cellular compartments 
3–6
. Dysfunction resulting from mutations in either the NPC1 or 
the NPC2 gene leads to cholesterol accumulation in the lysosome, thereby damaging several organs. Typical 
symptoms include neonatal cholestasis 
7,8
 often associated with spleno- or hepatosplenomegaly, progressive 
cerebellar ataxia, speaking and swallowing difficulty, progressive dementia, and the affected children often die 
very young 
1
. The current diagnostic method is a set of consecutive tests including chitotriosidase assay, filipin 
staining of free cholesterol in fibroblasts, or genetic testing 
1
. Chitotriosidase assay 
9–12
 and Filipin staining 
13–16
 
lack sensitivity and specificity, and are only performed in a few medical centres 
17
. Mutation analysis is a useful 
diagnostic tool, however, it is time consuming and not always conclusive 
18–20
.  
New hope for a more straight forward diagnosis of NP-C arose from the discovery of higher amounts of 
Cholestane-3β,5α,6β-triol (C-triol) and 7-ketocholesterol (7-KC) in plasma of NP-C patients than in plasma from 
patients with other lysosomal storage diseases or from controls 
21,22
. These authors showed in addition that 
plasma concentrations of C-triol and 7-KC directly correlated with the disease state and that these oxysterols 
are specific biomarkers for NP-C 
21
. In particular, the oxysterols were not elevated in several other lysosomal 
storage diseases like infantile neuronal ceroid lipofuscinosis (INCL), GM-1 gangliosidosis (GM-1), GM-2 
gangliosidosis (GM-2), and Gaucher disease (GD). However, a later study indicated that Niemann-Pick type A 
(NP-A) and B patients (NP-B) may also show increased levels of oxysterols 
23
. NP-A and NP-B are 
sphingolipidoses with a similar clinical picture to NP-C but a distinct pathophysiology demanding specific 
treatment 
16,17,24
.  
It is not clear why these oxysterols are increased in NP-C. It was recently suggested that the dysfunction of 
several cellular organelles in NP-C patients would lead to oxidative stress which in turn would increase 
oxysterol levels 
25
. And it was shown that the NPC-1 protein is not only able to bind cholesterol but also some 
oxysterols 
26
, indicating a role in oxysterol metabolism.  
Although a GC-MS 
21
 and a LC-MS/MS 
22
 assay have been developed to measure C-triol and 7-KC in NP-C, there 
are no data on the intra-individual variability and on reference intervals in children and adolescents for these 
analytes. Here we describe a robust and accurate method to measure C-triol and 7-KC in plasma. Using this 
method we determined reference intervals and the intra-individual variability in a large group of children and 
adolescents, and we show evidence that especially the C-triol is elevated in all three Niemann-Pick diseases. 
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2.1.3 MATERIAL AND METHODS 
2.1.3.1 CHEMICALS 
4-(Dimethylamino)pyridine (DMAP), N,N-Dimethylglycine (DMG), 7-Ketocholesterol with > 90 % purity (7-KC), 
Cholestane-3β,5α,6β-triol (C-triol) with > 90 % purity (estimated by thin layer chromatography), n-Hexane, 
Ammonium hydroxide solution and Chloroform stabilised with amylenes with Sure/Seal™ system were 
obtained from Sigma-Aldrich Chemie GmbH, Buchs, Switzerland. 1-Ethyl-3-(3'dimethl-aminopropyl) 
carbodiimide (EDC) was obtained from VWR International GmbH Dietikon, Switzerland. 25,26,26,26,27,27,27-
[
2
H7]7-Ketocholesterol (d
7
-7-KC)  with > 98 % purity was purchased from Santa Cruz Biotechnology, Santa Cruz, 
CA., USA. 25,26,26,26,27,27,27-[
2
H7]cholestane-3β,5α,6β – triol (d
7
-C-triol) with > 99 % purity was bought from 
Avanti® Polar Lipids, Inc. Alabaster (Ala), USA. Methanol absolute was obtained from Chemie Brunschwig AG, 
Basel, Switzerland.  
2.1.3.2 PREPARATION OF INTERNAL STANDARD, CALIBRATORS AND QUALITY CONTROLS 
Deuterated C-triol and 7-KC were dissolved in methanol (MeOH) at a concentration of 40 ng/mL and stored at -
80°C until use. A stock solution of C-triol and 7-KC in MeOH was prepared at a concentration of 1000 ng/mL. 
The final concentrations of the calibration points for both oxysterols were 10, 30, 65, 100 and 300 ng/mL. 
2.1.3.3 SAMPLE COLLECTION 
Anonymised residual heparin samples 
27
 from children age 0 to 18 years were collected from routine analysis at 
the University Children’s Hospital Zurich. Plasma Samples were immediately frozen and stored at -80°C for a 
maximum of 4 months before analysis. Patient samples were obtained also in anonymised form from the 
metabolic units of the University Hospitals with indication of the genetically diagnosed disease only. All 
metabolic units have approval from their local ethics committees and written informed consent from the 
patients. 
2.1.3.4 SAMPLE PREPARATION 
Samples were prepared according to the protocol of Jiang et al. 
22
 with modifications. In brief, 50 µL of plasma 
were added to 250 µL of internal standard (IS) solution (40 ng/mL in MeOH) and centrifuged for 10 min at 
11’300 g. The supernatant was transferred into a new tube and then removed under a nitrogen stream till 
complete dryness of the probe. To assure reproducible derivatisation, 100 µL of DMAP/DMG (4 M: 1 M) and 
100 µL of EDC (1 M) solution were added to form dimethlylglycine esters from alcohols 
28,29
, the tube capped, 
vortexed and subjected to 1 min ultrasound before heating in a waterbath at 45°C for 1 h. Successful 
derivatisation was assessed by the shift of the solution colour from colourless to yellow. The reaction was 
quenched with 100 µL of MeOH. A liquid-liquid extraction with 2 mL of hexane and 1 mL of 0.1 N ammonium 
hydroxide was done twice. The samples were dried under a nitrogen stream and reconstituted with 200 µL of 
MeOH/Water (60:40).  
2.1.3.5 LC-MS/MS ANALYSIS 
The analysis was performed on an AB Sciex 4000 Q TRAP (AB Sciex, Zug, Switzerland) coupled with a Dionex 
Ultimate 3000 (Thermo Scientific, Olten, Switzerland), using a Gemini-NX
TM
 C18 column
 
(100 mm x 200 mm; 3 
µm particle size and 110 Å pore size from Phenomenex, Brechbühler AG, Schlieren, Switzerland). The following 
gradient was applied using solvent A (2 mM ammonium formate; pH 2.45) and B (2 mM ammonium formate in 
MeOH): Solvent B increased from 69 % to 75 % within 3 min, and subsequently increased to 99 % within 4.9 
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min. After 2 min at 99%, B decreased to 1 % within 1 min and stayed at 1 % for 5 min. B increased from 1 % to 
69 % within 30 sec and stayed at 69 % for 1.6 min. The flow rate was 250 µL/min and the injection volume 10 
µL.  
The source parameters of the AB Sciex 4000 Q TRAP were CAD: Medium, CUR: 15, GS1: 60; GS2: 70, IS: 4500, 
TEM: 500. Multiple reaction monitoring (MRM) in positive ion mode was used to identify the oxysterols with 
the precursor and selected product ions listed in Table 1. For quantification the first mentioned fragment ion of 
Table 1 was used and all ions were monitored with a dwell time of 50 msec.  
Table 1: MRM parameters and retention times for C-triol and 7-KC 
Positive ion mode [M+H]
+
with ESI 
Retention time 
(min) 
Precursor ion 
(m/z) 
Product ion 
(m/z) 
DP (V) EP (V) CE (V) CXP (V) 
Cholestane-3β,5α,6β-triol 4.76 ± 0.05 591.6 
488.6 130 10 28 10 
104.1 130 10 45 6 
D
7
- Cholestane-3β,5α,6β-triol 4.76 ± 0.05 598.6 
495.6 130 10 28 10 
104.1 130 10 45 6 
7-Ketocholesterol 7.91 ± 0.11 486.6 
383.5 110 10 26 10 
104.1 110 10 37 6 
D
7
-7-Ketocholesterol 7.91 ± 0.11 493.6 
390.5 110 10 26 10 
104.1 110 10 37 6 
2.1.3.6 LINEARITY, PRECISION AND RECOVERY 
The linearity was investigated by a 5 point calibration curve made in plasma. Intra-day (n=6) and inter-day 
imprecision (n=6) were assessed measuring a low quality control (LQC, human plasma), a medium quality 
control (MQC: plasma spiked with 30 ng/mL oxysterol) and a high quality control sample (HQC: plasma spiked 
with 100 ng/mL oxysterol). The absolute recovery of the oxysterols was calculated from the results of the 
spiked MQC and HQC samples. For calculation of the recoveries endogenous levels of oxysterols (LQC) were 
subtracted from the MQC and HQC samples. The mean of the recoveries was divided by the spiked amount and 
multiplied by 100. 
2.1.3.7 LIMIT OF DETECTION AND LIMIT OF QUANTIFICATION 
The limit of detection (LOD) and the limit of quantification (LOQ) were calculated as follow 
30
 : 
LOD= yLQC + 3.3 * sLQC 
LOQ= yLQC + 10 * sLQC 
With yLQC= y-intercept of the calibration equation 
SLQC= standard deviation of the peak area/IS area ratio of the inter-day LQC samples 
2.1.3.8 SAMPLE STABILITY 
To assess the stability of the C-triol and the 7-KC in plasma, MQC triplicates were stored at 22 °C (middle 
European temperature) and at 37°C (Southern temperature) and collected at different time points (day 1, day 
2, day 3, day 4 and day 5). After collection the samples were frozen at –80°C. The values determined for day 0 
were set to 100 %  
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2.1.3.9 DATA ANALYSIS 
Data analysis was made in Microsoft Excel 2010. Correction for endogenous oxysterol levels in the plasma pool 
used for calibration was made by ignoring the y-intercept of the linear function. To establish reference intervals 
and age dependency MedCalc® software was used. Logarithmic transformation was required for data 
normalisation prior to determination of outliers, reference intervals and the investigation of age and gender 
dependency. Outliers were calculated with the generalised extreme studentised deviate test 
31
. Two outliers for 
C-triol were detected (106.17 ng/mL [252.38 nM] and 286.42 ng/mL [680.87 nM]) and removed from the 
dataset. Reference intervals were estimated using the double sided non-parametric percentile method (2.5%-
97.5%). Since one side of the reference interval was lower than the measuring interval, only the upper limit of 
the reference intervals is communicated. Age dependency was initially visually evaluated (Figure 3) and then 
calculated using the correlation analysis of MedCalc® with the following age groups: 0-3 months (11 samples), 
3-6 months (9 samples), 6-12 months (no samples), 12 months-24 months (5 samples), 24-36 months (7 
samples), 36-48 months (12 samples), 4- 6 years (16 samples), 7-12 years (37 samples) and 13-18 years (51 
samples). Gender dependency was assessed graphically and using a two-sided t-test in Excel 2010. The intra-
individual variation (CVw) was calculated as the coefficient of variation for each non-NP-C control with repeat 
measurements. The average coefficient of variation and the standard deviation from all 19 controls with repeat 
measurements is communicated. For reference intervals values calculation only the average oxysterol 
concentration for each patient was included. For all statistical tests a p-value < 0.05 was considered significant. 
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2.1.4 RESULTS 
2.1.4.1 METHOD VALIDATION 
The quantification of C-triol and 7-KC in human plasma was performed by MRM in positive ion mode using 
specific transitions for each analyte (Table 1). The calibration was linear from 10 to 300 ng/mL (i.e. the observed 
oxysterol concentrations in patients and controls) with a correlation coefficient > 0.99 for both oxysterols. The 
assay has a limit of detection of 0.03 ng/mL [0.07 nM] and of 0.54 ng/mL [1.35 nM], while the limit of 
quantification is 0.08 ng/ml [0.19 nM] and 0.80 ng/ml [2.00 nM] for the C-triol and 7-KC, respectively (Table 2). 
Table 2: Linearity, limit of detection, limit of quantification, intra- and interday precision, and recoveries for C-triol and 7-KC  
 
Linear 
equation 
R
2
 
LOD 
(ng/mL) 
LOQ 
(ng/mL) 
Measuring 
interval 
 
Intra-day  
precision 
(n=6) 
Inter-day 
precision (n=6) 
      
QC 
(ng/mL) 
[nM] 
CV (%) Recovery (%) CV (%) Recovery (%) 
Cholestane-
3β,5α,6β-triol 
y=0.11x+0.02 0.99 0.03 0.08 10-300 
LQC 
(6) 
[14] 
7.8 - 12.4 - 
MQC 
(28) 
[67] 
4.8 93 7.0 97 
HQC 
(100) 
[238] 
2.8 100 1.8 102 
7-Keto-
cholesterol 
y=0.35x+0.22 0.99 0.54 0.80 10-300 
LQC 
(16) 
[40] 
14.9 - 24.9 - 
MQC 
(32) 
[80] 
4.1 107 11.0 103 
HQC 
(123) 
[308] 
2.6 123 9.1 111 
Using this method, the two oxysterols were quantified within 20 minutes with elution times of 4.8 ± 0.05 min 
for the C-triol (d
7
-C-triol and C-triol) and of 7.9 ± 0.11 min for 7-KC (d
7
-7-KC and 7-KC) (Figure 1). The specificity 
was ensured by recording two transitions for each analyte (Table 1).  
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Figure 1. A. MRM transitions chromatograms of Cholestane-3β,5α,6β-triol (retention time of 4.80 min) and 7-Ketocholesterol (retention 
time of 7,83 min) and their respective deuterated standards in plasma of non NP-C subjects. B. Structure of the derivatised Cholestane-
3β,5α,6β-triol molecule with its fragmentation sites following MRM. C. Structure of the derivatised 7- Ketocholesterol molecule with its 
fragmentation sites following MRM. 
The precision of the method was investigated by the intra-day and inter-day imprecision. The imprecision is 
generally low for both oxysterols with intra-day coefficients of variation (CV) ranging from 2.8-7.8 % for C-triol 
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and 2.6-14.9 % for 7-KC and with inter-day CVs of 1.8-12.4 % for C-triol and 9.1-24.9 % for 7-KC (Table 2). The 
larger imprecisions were only observed for concentration at the lower limit of quantification. 
The accuracy of the method was investigated by analysing recoveries of oxysterols in spiked plasma samples. 
The recoveries for both oxysterols varied between 93-107 %, excepted for 7-KC in the highest spiked 
concentration sample, where a recovery of 123 % was observed (Table 2). 
2.1.4.2 SAMPLE STABILITY 
Sample stability assays at 22°C and 37°C were performed to investigate whether plasma samples can be 
shipped at ambient temperature or will need shipment by overnight mail on dry ice. Figure 2A. shows that the 
C-triol concentration in human plasma is stable for four days at 22°C before decreasing by more than 15 %. In 
contrast, C-triol is not stable at 37°C with decreased levels detected already after one day. Similarly, 7-KC 
(Figure 2B) is stable in samples stored at 22°C but also decreased already after one day at 37°C. Hence, shipping 
plasma samples at ambient temperature is only suitable in a moderate climate ensuring delivery within four 
days.  
 
Figure 2. Stability of Cholestane-3β,5α,6β-triol (A) and 7-Ketocholesterol (B) in plasma following storage for 0 to 5 days at 22 °C and 37 
°C. The stability of the oxysterols is expressed as percentage of day 0. The error bars indicate the standard deviation of triplicates. 
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2.1.4.3 REFERENCE INTERVALS IN CHILDREN AND ADOLESCENTS 
The reference intervals for the oxysterols in children and adolescents were investigated by analysing plasma 
samples from 148 non NP-C children ranging from a few days of age to 18 years of age. We determined an 
upper reference limit of 40.4 ng/mL (95 % CI:26.4-61.7 ng/mL, 96.0 nM, 95 % CI:62.8-146.7 nM) for the C-triol 
and of 75.0 ng/mL (95 % CI:55.5-102.5 ng/mL, 187.2 nM, 95 % CI:138.53-255.8 nM) for 7-KC with no significant 
age or gender dependency (Figure 3). 
 
Figure 3. Cholestane-3β,5α,6β-triol (A) and 7-Ketocholesterol (B) concentrations by age and gender of non NP-C children and 
adolescents. White dots (○) represent boys, black dots (●) represent girls. Conversion factor for Cholestane-3β,5α,6β-triol: 1 ng/mL 
equals 2.38 nM, while for 7-Ketocholesterol 1 ng/mL equals 2.50 nM 
2.1.4.4 BIOLOGICAL VARIATION IN CHILDREN AND ADOLESCENTS 
The biological variation of oxysterols in 19 non NP-C children plasma was investigated by measuring different 
samples of the same volunteer. The number of samples per volunteer ranged between 2 and 5 and the samples 
were collected within maximally 2 months. A high biological variation was observed for both oxysterols in 
plasma from non NP-C children with an average CVw of 46 % ± 23 % standard deviation for C-triol and 52 % ± 29 
% standard deviation for 7-KC. 
2.1.4.5 OXYSTEROL CONCENTRATIONS IN CHILDREN AND ADOLESCENTS WITH 
NIEMANN-PICK DISEASES 
The diagnostic potential of the oxysterol measurement for NP-C, NP-B and NP-A was investigated, by 
measuring oxysterol levels in plasma of such patients (Figure 4). The C-triol concentration in plasma of NP-C 
patients ranged from 108.1-140.3 ng/mL [257.0-333.5 nM], while the concentrations for 7-KC ranged from 
113.2 -174.4 ng/mL [282.6-435.3 nM], values which are well above the upper reference limit for both 
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oxysterols. Similarly, NP-A and NP-B patients showed increased levels for both oxysterols with levels for NP-B 
ranging from 71.3-631.3 ng/mL [169.5-1500.7 nM] and 75.1-645.7 ng/mL [187.5-1611.7 nM] for C-triol and 7-
KC, respectively.  
 
Figure 4. Logarithmic box-and-whisker plot and raw data representation of Cholestane- 3β,5α,6β-triol (A) and 7-Ketocholesterol (B) 
concentrations in non NP-C children and children with Niemann Pick type C, B and A. Box 25th to 75th percentile, line: median, square: 
mean, box whiskers: 5th and 95th percentiles, cross: 1th and 99th percentiles, outer ticks: data ranges. Conversion factor for 
Cholestane-3β,5α,6β-triol: 1 ng/mL equals 2.38 nM, while for 7-Ketocholesterol 1 ng/mL equals 2.50 nM.  
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2.1.5 DISCUSSION 
Here we present a reproducible and robust LC-MS/MS method to measure the oxysterols C-triol and 7-KC in 
human plasma to screen for Niemann-Pick disease. The assay validation showed good recovery rates (93-123 
%) and good precision with CVs of < 15 % for both oxysterols at relevant concentrations. In addition, the 
method is linear over the entire measuring range, which covers oxysterol levels in plasma of non NP-C and NP-C 
children and adolescents. 
In comparison to previously published methods 
22,32
, the robustness of our method is secured by an improved 
sample preparation protocol, in which we ensure the reliability of the derivatisation reaction and decrease the 
matrix interference by extracting the derivatised oxysterol before analysis. The increase in the concentration of 
the derivatisation reagent assures a reproducible derivatisation of the sterically hindered C-triol molecule in 
presence of large amount of functional hydroxyl groups present in plasma. A lower concentration of the 
derivatisation reagent resulted in variable recoveries for the C-triol due to a presumably non-reproducible 
derivatisation in the different plasma samples.  
Using this method we report the upper reference limit in plasma from non-NP-C children and adolescents. For 
the calculation of the reference intervals we included oxysterol measurements from non-healthy children and 
adolescents because we have access to these samples and because such reference intervals better reflect the 
real diagnostic context in the hospital setting than a selection of healthy volunteers. As a consequence our 
upper limit of the reference intervals are slightly higher than previously published reference intervals using LC-
MS/MS (C-triol: 7.4-21.2 ng/mL [17.6-50.4 nM] and 7-KC: 11.4-44.4 ng/mL [28.5-110.8 nM] 
22
 and C-triol: 0.8-
8.1 ng/mL [1.9-19.3 nM] and 7-KC: 2.6-30.5 ng/mL [6.5-76.1 nM] 
33
). Although using such an approach may 
include one or two not diagnosed NP-C patients in the process of establishing reference intervals, outlier 
correction and the use of the 97.5 percentiles of the measurements to establish the upper reference limit 
would omit the influence of such potentially confounding samples. Indeed, all NP-C patients showed elevated 
oxysterol levels suggesting that the higher reference limits did not reduce the sensitivity of the oxysterol assay 
to identify NP-C patients. Such a clear separation by the oxysterols of NP-C from non-NP-C patients observed in 
this sample, however, may overestimate the diagnostic efficiency of the assay. Previous studies have indicated 
that there are some NP-C patients with C-triol and 7-KC levels in the reference intervals 
22
. 
In addition to the usefulness of the plasma oxysterols to diagnose NP-C disease, we show evidence that the 
oxysterol levels are also elevated in NP-A and NP-B patients. These findings are in agreement with a recently 
published study which already reported elevated 7-KC levels in NP-A/B patients 
23
, indicating that 7-KC is not a 
specific marker for NP-C but a biomarker for Niemann-Pick patients in general. Our study expands these 
findings showing that the C-triol plasma levels are also elevated in NP-A and NP-B patients and that the C-triol 
plasma levels are even more discriminatory to identify Niemann-Pick patients than the 7-KC levels. While some 
of the NP-B patients showed 7-KC levels under the upper reference limit, none of the Niemann-Pick patients 
had C-triol levels under the upper reference limit.  
Overnight shipment of plasma samples to the metabolic laboratory is often necessary and the stability of the 
analytes at ambient temperature will determine the pre-analytical precautions necessary for shipment. Our 
results indicate that samples can be shipped at room temperature by express mail or courier when there are 
mild temperatures because both oxysterols are stable at 22°C for four days. However, shipment in warmer 
regions should be done using cooling devices or frozen on dry ice. 
In summary, we present a robust LC-MS/MS method to measure two oxysterols in human plasma and we 
established upper reference limits in children and adolescents, which discriminate between controls and 
Niemann-Pick patients in general. In addition our results indicate that the C-triol is more discriminative than 
the 7-KC for the identification of Niemann-Pick patients. The presented method is rapid, non-invasive, 
quantitative, and specific, facilitating the diagnostic procedures in patients suspected for Niemann-Pick disease. 
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Particularly, it enables the investigation of children, adolescents and adults in large numbers with neurological 
disorders, hepatomegaly or splenomegaly for NP disease, improving the diagnostic procedures and facilitating 
genetic confirmation.  
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2.1.7 SUPPORTING INFORMATION 
 
Supporting Information Figure 1| Calibration curve examples 
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Supporting Information Figure 2| Graphical Abstract  
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2.2.1 ABSTRACT 
2.2.4.1 BACKGROUND 
Inflammatory bowel diseases (IBDs) are a group of chronic relapsing immune-mediated disorders of the 
gastrointestinal tract impairing significantly the patient’s quality of life with still badly understood 
pathophysiology. A set of oxysterol receptors have recently been implicated in IBD, namely the Epstein-Barr 
virus-induced G-protein coupled receptor 2 (EBI2), the Liver X receptors (LXRs) and the RAR-related orphan 
receptor gamma t (RORγt). We surmised that the oxysterols triggering these receptors may play a role in the 
pathophysiology of IBD and that there are differences in plasma levels between healthy controls and different 
IBD forms.  
2.2.4.2 METHODS 
We established a LC-MS/MS (ESI
+
) method to measure 24(S)-hydroxycholesterol (24(S)-OHC), 25-
hydroxycholesterol (25-OHC), 27-hydroxycholesterol (27-OHC), 7α,24(S)-dihydroxycholesterol (7α,24(S)-OHC), 
7α,25-dihydroxycholesterol (7α,25-OHC), 7β,25-dihydroxycholesterol (7β,25-OHC), 7α,27-dihydroxycholesterol 
(7α,27-OHC), and 7β,27-dihydroxycholesterol (7β,27-OHC) in human plasma. The method was subsequently 
applied to determine the oxysterol profile in plasma of healthy volunteers (n=22) and patients with Crohn’s 
disease (CD) (n=20) and Ulcerative colitis (UC) (n=23) during active and inactive disease stage.  
2.2.4.3 RESULTS 
The reported method is linear (r > 0.99), sensitive (detection limit ranging from 0,0018 nM to 0,24 nM for 
dihydroxycholesterols, and from 0,0077 nM to 1,09 nM for monohydroxycholesterols) and precise, with a 
median intra-day imprecision of 12 % and 8,8 % and a median inter-day imprecision of 4,5 % and 5,7 % for 
dihydroxycholesterols and monohydroxycholesterols, respectively. Recoveries for all oxysterols in the inter-day 
assay ranged between 82 % and 124 %. All oxysterols were separated in one chromatographic run using 
acetonitrile in the mobile phase. However, to increase oxysterol’s ionisation for MS/MS detection, in particular 
for matrixes containing low oxysterol concentrations, a second mobile phase using methanol instead of 
acetonitrile was applied. With these methods, 24(S)-OHC, 25-OHC, 27-OHC, 7α,25-OHC and 7α,27-OHC could 
be detected in human plasma of controls and IBD patients. The levels of 27-OHC and 25-OHC were lower in CD 
and UC patients compared to the control group, while the level of the other oxysterols did not differ.  
2.2.4.4 CONCLUSIONS 
With the LC-MS/MS assay reported here we were able to measure 24(S)-OHC, 25-OHC, 27-OHC, 7α,25-OHC and 
7α,27-OHC in plasma of healthy controls, CD and UC patients in active and in remission stage. The results 
indicate that IBD patients have lower 27-OHC and eventually 25-OHC levels in the active and the remission 
phases compared to controls, indicating a role for the oxysterol-LXR-axis in IBD. 
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2.2.2 INTRODUCTION 
Inflammatory bowel diseases (IBDs) are a group of chronic relapsing immune-mediated disorders of the 
gastrointestinal tract that are pathologically characterised by intestinal inflammation and epithelial injury 
1,2
. 
Clinical symptoms are various and include tiredness, weight loss, fever, night sweats, decreased appetite, 
nausea, vomiting, stomach pain, flush, and (bleeding) bowels, and they all strongly impair the patient’s quality 
of life 
3,4
. The disease onset typically occurs between 15 and 35 years, although IBD can occur in infants 
4–6
. The 
highest incidence rates and prevalences for IBD are found in industrialised countries and societies with western 
lifestyle like Europe and North America 
7
. In Europe about 2,5–3 million people are estimated to have IBD and 
despite many research efforts, the exact etiology is still unknown 
5,8,9
.  
IBD’s main diseases are Crohn’s Disease (CD) and Ulcerative colitis (UC), which share a similar clinical 
pathological phenotype. The difference between the two diseases lies in the localisation of the inflammation in 
the gastrointestinal tract, in immunological and histological patterns and in disease-specific complications 
10,11
.  
The particularity of IBDs is the relapsing character with remission periods of various length in which the 
inflamed mucosa of the gastrointestinal tract comes back to normal 
3,11
. Ideally, the aim of IBDs management is 
to keep the remission stage for as long as possible and to decrease the period and the severity of the disease 
activity during flare-ups 
3,12
.  
Oxysterols are oxidised derivatives of cholesterol being either of enzymatic or non-enzymatic origin with very 
few examples deriving from both origins 
13,14
. They mainly regulate cholesterol homeostasis, however, recently 
some enzymatically derived oysterols and their receptors have been implicated in inflammatory diseases 
13,15–
19
. 
24-hydroxycholesterol (24(S)-OHC), 25-hydroxycholesterol (25-OHC), and 27-hydroxycholesterol (27-OHC) are 
ligands for the liver X receptors (LXRs), LXRα and LXRβ, involved in fatty acid and cholesterol metabolism 
20–27
. 
Two studies recently indicated that the oxysterol/LXR axis may play a role in IBD. Polymorphisms in LXRs were 
shown to be associated with IBD in a Danish study and the mRNA expression for both LXRs are decreased in CD 
and UC patients compared to controls 
28,29
. 
7β,27-dihydroxycholesterol (7β,27-OHC) and 7α,27-dihydroxycholesterol (7α,27-OHC) bind to the RAR-related 
orphan receptor gamma t (RORγt), which drives the differentiation of CD4
+
naïve cells (CD referes here to 
cluster of differentiation) into pro-inflammatory T helper 17 cells (TH17 cells) 
30
. TH17 cells are implicated in CD 
and UC, although their exact role is not clear yet 
31–37
.  
Additionnaly, 7α,27-OHC together with the more potent 7α,25-dihydroxycholesterol (7α,25-OHC), ) and 7β,25-
dihydroxycholesterol (7β,25-OHC) were discovered to be Epstein-Barr virus-induced G-protein coupled 
receptor 2 (EBI2) ligands mainly involved in B cell motion in lymphoid tissues 
20,21,38,39
. Increased EBI2 
expression was detected in the ileum of CD patient with nucleotide-binding oligomerisation domain 2 (NOD2) 
mutations and a polymorphism in EBI2 showed an association with IBD in a genome-wide association study 
(GWAS) 
40–42
. 
These findings led us to surmise that enzymatically derived oxysterols binding to the EBI2, LXRs and RORγt 
receptors (Figure 1) may play a role in the pathophysiology of IBD and that there are differences in plasma levels 
between healthy controls and patients with CD and UC.  
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Figure 1| Oxysterols from enzymatic and non-enzymatic origins. Cholesterol is transformed to monohydroxycholesterols as for example 
24(S)-hydroxycholesterol (24(S)-OHC), 27-hydroxycholesterol (27-OHC) and 25-hydroxycholesterol (25-OHC) through the enzymatic 
action of cholesterol 24-hydroxylase (CYP46A1), sterol 27-hydroxylase (CYP27A1) or cholesterol 25-hydroxylase (CH25H), respectively. 
24-OHC is then converted to 7α,24(S)-dihydroxycholesterol (7α,24-OHC) by the action of the oxysterol 7α-hydroxylase 2 (CYP39A1), 
while 27-OHC and 25-OHC are both converted to their respective dihydroxycholesterols by the oxysterol 7α-hydroxylase (CYP7B1). 
Additionnaly to the enzymatic conversion, 25-OHC derives also from non-enzymatic origin through radical oxygen species (ROS). Other 
examples of non-enzymatic generated oxysterols are 7-ketocholesterol (7-KC) and cholestane-3β,5α,6β-triol (C-triol). The abbreviations 
and acronyms are explained in the chapter. Figure adapted from Cyster et al.(2014) 15. 
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2.2.3 MATERIAL AND METHODS 
2.2.4.1 CHEMICALS 
Oxysterols and their deuterated standards, 7α,24(S)-dihydroxycholesterol with > 99 % purity, 7α,25-
dihydroxycholesterol with > 99 % purity, 7β,25-dihydroxycholesterol with > 99 % purity, 7α,27-
dihydroxycholesterol with > 99 % purity, 7β,27-dihydroxycholesterol with > 99 % purity, 24(S)-
dihydroxycholesterol with > 99 % purity, 25-dihydroxycholesterol with > 99 % purity, and 27-
dihydroxycholesterol with > 99 % purity, 26,26,26,27,27,27-[2H6]7α,25-dihydroxycholesterol with > 99 % 
purity, 25,26,26,27,27,27-[2H6]7α,27-dihydroxycholesterol with > 99 % purity, 25,26,26,27,27,27-[2H6]7β,27-
dihydroxycholesterol with > 99 % purity, 25,26,26,26,27,27,27-[2H7]7α,24(R/S)-dihydroxycholesterol with > 99 
% purity, 26,26,26,27,27,27-[2H6] 25-dihydroxycholesterol with > 99 % purity, and 25,26,26,27,27,27-[2H6] 27-
dihydroxycholesterol with > 99 % purity were bought from Avanti® Polar Lipids, Inc. Alabaster (Ala), USA. 
Butylated hydroxytoluene (BHT) was purchased from Sigma-Aldrich Chemie GmbH, Buchs, Switzerland. 
Solvents used for LC mobile phases are: absolute methanol and acetonitrile (ACN), which were obtained from 
Chemie Brunschwig AG, Basel, Switzerland. Ultrapure water was obtained with the Elga-Purelab Genetic 
System from Labtech Service, Wohlen, Switzerland. Formic acid (FA) and ethanol (EtOH) were obtained from 
Sigma-Aldrich Chemie GmbH, Buchs, Switzerland. 
2.2.4.2 PREPARATION OF INTERNAL STANDARD AND CALIBRATOR SOLUTIONS 
Deuterated internal standards (IS) and BHT were dissolved in ethanol (EtOH) and mixed together to obtain a 
final concentration of 2 µM and 37,5 nM, respectively, and stored at -80°C until use. A stock solution of 24(S)-
OHC, 25-OHC, 27-OHC, 7α,24(S)-OHC, 7α,25-OHC, 7β,25-OHC, 7α,27-OHC,and 7β,27-OHC in EtOH was prepared 
at a concentration of 4,5 µM each. The final concentrations of the calibration points for the 
dihydroxycholesterols were 2,5, 6, 15, 40, 80, 120, and 175 nM, while for the monohydroxycholesterols they 
were 6, 15, 40, 80, 120, and 175 nM. 
2.2.4.3 SAMPLE COLLECTION AND PREPARATION 
For method validation, a plasma pool was made with anonymised left over plasma samples from routine 
analysis of the Division of Clinical Chemistry and Biochemistry from the University Children’s Hospital Zurich. As 
control samples immediately frozen anonymised Li-heparin plasma of healthy volunteers from the Swiss Red 
Cross was used, stored at -80°C for no longer than one week. Longitudinal samples in active and in remission 
stage from UC and CD patients were obtained from the the Swiss IBD Cohort Study. The samples have been 
stored at -80°C for no longer than 2 years. The Swiss IBD Cohort Study has approval from the local ethics 
committee and written informed consent was obtained from all patients.  
Samples were prepared similarly to the protocol of Karuna et al 
43
. In brief, 200 µL of plasma were subjected to 
protein precipitation after the addition of 20 µL of the 2 µM deuterated IS mix containing BHT by the addition 
of 230 µL cold EtOH, immediately mixed and stored at 4°C for 15 min. This step was repeated three times, 
adding 450 µL cold EtOH each time now. In total, 1,6 mL of cold EtOH were given to the 200 µL of plasma in a 
2mL Eppendorf tube, resulting in a 1:9 dilution. The mixture was mixed and centrifuged at 4°C for 20 min at 
16060 g. The supernatant was transferred into a new tube, vortexed and centrifuged a second time at 4°C for 
10 min at 16060 g. The supernatant of the second centrifugation step was transferred into a new tube and 
dried under nitrogen. Reconstitution was done with 75 µL EtOH containing 0,1% FA and then injected into the 
LC-MS/MS system.  
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2.2.4.4 LC-MS/MS ANALYSIS 
The LC-MS/MS analysis was performed on a Dionex UltiMate 3000 RS (Thermo Scientific, Olten, Switzerland), 
using an Acquity UHPLC BEH column (150 mm x 2,1 mm; 1,7 µm particle size and 130 Å pore size) from Waters, 
Brechbühler AG, Schlieren, Switzerland) and coupled with an AB Sciex 5500 TripleQuad (AB Sciex, Zug, 
Switzerland). 
The following gradient was applied using solvent A (H20: MeOH (95%: 5%); 0.1% FA; pH 3) and B1 (MeOH: ACN 
(62,5 %: 37,5 %; 0.1 % FA) or B2 (MeOH; 0,1 % FA). Solvent B (1 and 2) increased from 0,2 % to 73 % within 0,5 
min, and then to 81,2 % within 8 min. After an additional 8 min, solvent B further increased to 98 % in 3,5 min. 
Next, solvent B decreased to 0,2 % in 4 min and was kept constant for another 3 min. The flow rate was 400 
µL/min and injection was performed via a Performance Optimising Injection Sequence (POIS) with the weak 
solvent being water and the sample volume 10 µL.  
The source parameters of the AB Sciex 5500 TripleQuad were CAD: 6, CUR: 15, GS1: 40; GS2: 70, IS: 4500, TEM: 
550. Multiple reaction monitoring (MRM) in positive ion mode was used to identify the oxysterols using their 
precursor and selected product ions as listed in Table 1, although the transitions were not selective for one 
particular oxysterol. For quantification the transition indicated in Table 1 as “Quantifier” was used and all ions 
were monitored with a dwell time of 20 msec.  
Table 1| MRM settings for all oxysterols 
 Analyte in 
positive ion 
mode [M+H]
+ 
with ESI 
Type of transition 
Precursor 
ion (m/z)  
Product 
ion (m/z) 
DP (V) EP (V) CE (V) CXP (V) 
 7α,24(S)-OHC 
7α,25-OHC 
7β,25-OHC 
7α,27-OHC 
7β,27-OHC  
Qualifier 401.3 383.3 74 10 17 32 
 7α,24(S)-OHC 
7α,25-OHC 
7β,25-OHC 
7α,27-OHC 
7β,27-OHC 
Quantifier for 7α,24(S)-
OHC, 7α,25-OHC, 7β,25-
OHC, 7α,27-OHC, 7β,27-
OHC 
383.3 159.1 11 10 27 14 
 7α,24(S)-OHC 
7α,25-OHC 
7β,25-OHC 
7α,27-OHC 
7β,27-OHC 
Qualifier 383.3 145.1 11 10 31 14 
 d
6
 7α,25-OHC 
d
6
 7α,27-OHC 
d
6
 7β,27-OHC 
Quantifier for d
6
 7α,27-
OHC,  
407.3 389.3 110 10 13 32 
 d
6
 7α,25-OHC 
d
6
 7α,27-OHC 
d
6
 7β,27-OHC 
Qualifier 407.3 371.4 110 10 17 31 
 d
6
 7α,25-OHC 
d
6
 7α,27-OHC 
d
6
 7β,27-OHC 
Qualifier 407.3 159.2 110 10 34 14 
 d
7
 7α,24(S)-OHC Qualifier 408.3 215.1 80 10 33 18 
 d
7
 7α,24(S)-OHC Qualifier 408.3 390.3 110 10 13 32 
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 Analyte in 
positive ion 
mode [M+H]
+ 
with ESI 
Type of transition 
Precursor 
ion (m/z)  
Product 
ion (m/z) 
DP (V) EP (V) CE (V) CXP (V) 
 d
7
 7α,24(S)-OHC Qualifier 408.3 372.4 110 10 17 31 
 24(S)-OHC 
25-OHC 
27-OHC 
Quantifier for 27-OHC  385.2 161 100 10 25  
 24(S)-OHC 
25-OHC 
27-OHC 
Quantifier for 25-OHC 
and 24(S)-OHC 
385.2 147.1 100 10 31  
 24(S)-OHC 
25-OHC 
Qualifier 420.2 367.3 130 10 17  
 d
6
 25-OHC 
d
6
 27-OHC 
Qualifier 426.5 391.3 45 10 12  
 d
6
 25-OHC 
d
6
 27-OHC 
Quantifier for d
6
 27-OHC 391.3 159.1 120 10 35  
 d
6
 25-OHC 
d
6
 27-OHC 
Quantifier for d
6
 25-OHC  391.3 373.3 120 10 15  
2.2.4.5 LINEARITY, PRECISION AND RECOVERY 
The linearity was investigated by a 6 point calibration curve for the monohydroxycholesterols and by a 7 point 
calibration curve for the dihydroxycholesterols in EtOH. Intra-day (n=4) and inter-day imprecision (n=16) were 
assessed measuring plasma without any oxysterol addition and plasma spiked with 80 nM oxysterols. The 
absolute recovery of the oxysterols was calculated from the results of the 80 nM spiked plasma samples. For 
calculation of the recoveries endogenous levels of oxysterols from the non-oxysterol added plasma sample 
were subtracted from the spiked plasma samples. The obtained values were then divided by the spiked 
amount, averaged and multiplied by 100 to obtain a percentage value. 
2.2.4.6 LIMIT OF DETECTION AND LIMIT OF QUANTIFICATION 
The limit of detection (LOD) and the limit of quantification (LOQ) were calculated as follow 
44
: 
LOD= yLQC + 3.3 * sLQC 
LOQ= yLQC + 10 * sLQC 
With yLQC= y-intercept of the calibration equation 
SLQC= standard deviation of the peak area/IS area ratio of the inter-day non-oxysterol added samples 
2.2.4.7 DATA ANALYSIS 
Data analysis was made with Analyst 1.6.2 and then exported to Microsoft Excel 2010. Oxysterol quantification 
in IBD plasma samples were performed with a Signal to Noise ratio (S/N) ≥ 5. The average was taken, when two 
aliquots were available with the same disease activity from the same patient. Statistics were performed with 
MedCalc® Version 14.8.1 and Prism 6 for MacOSX. Sample size calculation was made with PS Power and 
Sample Size Calculations version 2.1.30. The comparison between the oxysterol concentrations between the 
two IBD diseases in active and in remission stage with the control group was made using the Kruskal–Wallis 
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test. Comparison between the oxysterols concentration of the two disease states within a disease were 
calculated with the Wilcoxon signed-rank test. For all statistical tests a p-value < 0,05 was considered significant 
at a level , while a p-value < 0,01 was considered to be highly significant.  
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2.2.4 RESULTS 
2.2.4.1 OXYSTEROL DETECTION AND SEPARATION  
10 µL injection of oxysterol standards in EtOH solution result in broad and overlapping peaks. However, if the 
oxysterol standard solution is simultaneously injected with a weak solvent (water) before and after the 
oxysterol standard solution, then the peak signals are thin and the analytes separated. This analyte band 
compression is called Performance Optimising Injection Sequence (POIS) by Phenomenex ® (Figure 2) 45. 
 
Figure 2| Extracted ion chromatogram (XIC) for oxysterol standards (A1) and deuterated standards (A2) obtained with 10µL regular 
injection of 120 nM oxysterols in EtOH (A) compared to the XIC for oxysterol standards (B1) and deuterated standards (B2) obtained 
with 10µL injection with the POIS procedure (B). The oxysterol standards of the chromatogram are 7β,25-OHC (1), 7β,27-OHC (2), 7α,25-
OHC (3), 7α,24(S)-OHC (4), 7α,27-OHC (5), 25-OHC (6), 24(S)-OHC (7), and 27-OHC (8). The deuterated standards of the chromatogram 
are d6 7α,25-OHC (9), d6 7α,27-OHC (10), d6 25-OHC (11), and d6 27-OHC (12). 
 
Atmospheric pressure chemical ionisation (APCI) is the traditional ionisation technique for underivatised 
oxysterols, however, recently Karuna et al. (2015) reported better oxysterol ionisation with Electrospray (ESI), 
contradicting so the old dogma 
43,46–48
. We tested the oxysterol detection using both ionisation sources and 
obtained significant better results using ESI, thereby supporting the statement of Karuna et al. (2015) 
(Supporting Information Figure 5) 
43
. 
Using POIS and ESI, all oxysterol standards can be separated in one unique run using mobile phase A (H20: 
MeOH (95 %: 5 %); 0.1 % FA; pH 3) and B1 (MeOH: ACN (62,5 % : 37,5 %); 0.1% FA) (Figure 3). 
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Figure 3| Extracted ion chromatogram of the di- and monohydroxycholesterols. The upper chromatogram (A) represent the di- and 
monohydroxycholesterol standards with (1) 7Β,25-OHC, (2) 7Β,27-OHC, (3) 7Α,25-OHC, (4) 7Α,24(S)-OHC, (5) 7Α,27-OHC, (6) 25-OHC, (7) 
24(S)-OHC and (8) 27-OHC. The lower chromatogram (B) represent the deuterated di- and monohydroxycholesterols internal standards 
with (9) d6 7Β,27-OHC, (10) d6 7Α,25-OHC, (11) d6 7Α,24(S)-OHC, (12) d6 7Α,27-OHC, d6 25-OHC (13), and (14) d6 27-OHC . 
However, with mobile phase B1, we observed decreased oxysterol signal intensity compared to mobile phase 
B2 (MeOH; 0,1% FA). These observations are in agreement with McDonald et al. (2007) who observed a modest 
to significant decrease in sterol intensity in ACN containing mobile phases 
49
. The inconvenience of using 
mobile phase B2 is that 24(S)-OHC and 25-OHC are co-eluting and cannot be differentiated by mass 
spectrometrical analysis. We therefore measured samples twice, first with mobile phase A and B1 and then 
with mobile phase A and B2. All oxysterols with the exception of 24(S)-OHC and 25-OHC were quantified using 
mobile phase A and B2 (Table 2). 
Table 2|Peak areas obtained with mobile phase B1 (containing ACN) and with mobile phase B2 (containing MeOH) for all oxysterol 
standards analysed in this project. Values displayed with * are the sum of 24(S)-OHC and 25-OHC 
Analyte Transitions Peak area obtained 
with mobile phase 
B1 (ACN 
containing) 
Peak area obtained 
with mobile phase 
B2 (MeOH 
containing) 
Peak Area obtained with 
mobile phase B2 / Peak 
Area obtained with 
mobile phase B1  
Final conclusion for 
mobile phase B2  
24(S)-OHC 385/147 43388 111190* 2,56 ↑ 
24(S)-OHC 385/161 73880 87082* 1,18 ↑ 
25-OHC 385/147 55907    
25-OHC 385/161 587    
27-OHC 385/147 64242 87500 1,36 ↑ 
27-OHC 385/161 106350 161730 1,52 ↑ 
7α,24(S)-OHC 383.3/159 103060 184130 1,79 ↑ 
7α,24(S)-OHC 383.3/145 88183 158950 1,80 ↑ 
7α,25-OHC 383.3/159 224750 314740 1,40 ↑ 
7α,25-OHC 383.3/145 130120 219410 1,69 ↑ 
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Analyte Transitions Peak area obtained 
with mobile phase 
B1 (ACN 
containing) 
Peak area obtained 
with mobile phase 
B2 (MeOH 
containing) 
Peak Area obtained with 
mobile phase B2 / Peak 
Area obtained with 
mobile phase B1  
Final conclusion for 
mobile phase B2  
7α,27-OHC 383.3/159 107980 173640 1,61 ↑ 
7α,27-OHC 383.3/145 73969 125940 1,70 ↑ 
7β,25-OHC 383.3/159 164290 257470 1,57 ↑ 
7β,25-OHC 383.3/145 95465 190800 2,00 ↑ 
7β,27-OHC 383.3/159 125130 260090 2,08 ↑ 
7β,27-OHC 383.3/145 80907 196990 2,43 ↑ 
d
6
 25-OHC 391/159 52606 52606 1,00 - 
d
6
 25-OHC 391/373 320610 363490 1,13 ↑ 
d
6
 27-OHC 391/159 31434 441054 14,03 ↑ 
d
6
 27-OHC 391/373 25892 25831 1,00 - 
d
6
 7α,24(S)-OHC 389/159 41061 62181 1,51 ↑ 
d
6
 7α,24(S)-OHC 407/383 320690 315960 0,99 ↓ 
d
6
 7α,25-OHC 389/159 136530 214920 1,57 ↑ 
d
6
 7α,25-OHC 407/383 166490 217640 1,31 ↑ 
d
6
 7α,27-OHC 389/159 50187 75387 1,50 ↑ 
d
6
 7α,27-OHC 407/383 314020 4077850 12,99 ↑ 
2.2.4.2 METHOD VALIDATION 
The quantification of 24(S)-OHC, 25-OHC, 27-OHC, 7α,24(S)-OHC, 7α,25-OHC, 7β,25-OHC, 7α,27-OHC, and 
7β,27-OHC in human plasma was performed by MRM in positive ion mode with the transitions displayed in 
Table 1. The calibration was linear from 6 to 175 nM for monohydroxycholesterols and from 2,5 to 175 nM for 
the dihydroxycholesterols with a correlation coefficient > 0.99 for all oxysterols. In this assay, the lowest LOD 
(0,0018 nM) and LOQ (0,0037 nM) was achieved for 7β,25-OHC , while 27-OHC generated the highest LOD (1,09 
nM) and LOQ (3,30 nM) (Table 3). Using the method with mobile phase A and B1, the target oxysterols are 
quantified within 19 minutes with elution times in the range of 4,71 min ± 0,02 min to 5,59 min ± 0,05 min for 
the dihydroxycholesterols and 8,61 min ± 0,07 min to 9,08 min ± 0,06 min for the monohydroxycholesterols 
(Table 3) and (Figure 3). The specificity was ensured by the chromatographic separation of all isomers of the 
mono- and dihydroxycholesterols and by recording of several transitions per oxysterol group (Table 1). The 
precision of the method was investigated by the intra-day and inter-day imprecision of plasma samples spiked 
with 80 nM. The median intra-day coefficient of variations (CV) are 12 % (with min 4,5 % and max 13 %) for the 
dihydroxycholesterols and 8,8 % (with min 1,1 % and max 10,6 %) for the monohydroxycholesterols, 
respectively. The median inter-day CVs are 4,5 % (with min 4 % and max 8,9 %) for the dihydroxycholesterols 
and 5,7 % (with min 3,7 % and max 4,9 %) for the monohydroxycholesterols, respectively (Table 3). The accuracy 
of the method was investigated by analysing recoveries of oxysterols in spiked plasma samples. The recoveries 
varied between 82 % and 124 % for all oxysterols when analysed on four different days (Table 3). 
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Analyte 
Retention 
time (median 
± SD) (min) 
R
2
 
LOD 
(nM) 
LOQ 
(nM) 
 Intra-day precision (n=4) Inter-day precision (n=16) 
 
     
Spiked 
with 
oxysterols 
(nM) 
Median (nM) ± SD CV (%) Recovery (%) Median (nM) ± SD CV (%) Recovery (%) 
7β,25-OHC 
4,71 ± 
0,02 
0,99 0,0018 0,0037 
- - -  - - -  - 
+ 80  97,17 ± 12,61 13 121 97,28 ± 4,35 4,8 124 
7β,27-OHC 
5,09 ± 
0,02 
0,99 0,031 0,039 
- - -  - - -  - 
+ 80  67,51 ± 3,21 4,8 95 80,60 ± 3,28 4,1 103 
7α,25-OHC 
5,20 ± 
0,06 
0,99 0,0036 0,0057 
- - -  - - -  - 
+ 80  74,46 ± 9,19 12 96 97,92 ± 4,79 4,9 121 
7α,24(S)-OHC 
5,46 ± 
0,04 
0,99 0,22 0,49 
- - -  - - -  - 
+ 80  94,16 ± 2,33 2,9 118 98,63 ± 3,95 4,0 120 
7α,27-OHC 
5,59 ± 
0,05 
0,99 0,24 0,68 
- - -  - - -  - 
+ 80  73,00 ± 3,31 4,5 91 90,93 ± 3,06 3,7 108 
25-OHC 
8,61 ± 
0,07 
0,99 0,0077 0,012 
- - -  - - -  - 
+ 80  71,02± 6,50 9,2 89 75,54 ± 5,48 7,3 96 
24(S)-OHC 
8,77 ± 
0,07 
0,99 0,0084 0,022 
- 6,54 ± 0,69 10,6  - 6,51 ± 0,37 5,7   
+ 80  79,83 ± 3,38 4,2 92 74,46 ± 3,28 4,4 82 
27-OHC 
9,08 ± 
0,06 
0,99 1,09 3,30 
- 66,25 ± 5,85 8,8  - 59,74 ± 5,30 8,9   
+ 80  145,37 ± 1,59 1,1 99 138,63 ± 5,58 4,0 99 
Median monohydroxycholesterols      8,8   5,7  
Median dihydroxycholesterols     12   4,5  
Table 3| Linearity, limit of detection in plasma, limit of quantification in plasma, intra- and interday precision, and recoveries for all oxysterols analysed in this project 
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2.2.4.3 OXYSTEROL PROFILE IN CROHN DISEASE AND ULCERATIVE COLITIS PATIENTS 
DURING ACTIVE AND INACTIVE DISEASE PHASE 
IBD plasma samples from the Swiss IBD Cohort Study registry and plasma samples of control subjects from the 
Swiss Red Cross were measured for their oxysterol profile. Generally, the oxysterol concentrations are low, in 
particular for the dihydroxycholesterols and not all oxysterols were detected (Figure 4). The detected oxysterols, 
although not in all samples, were 24(S)-OHC, 25-OHC, 27-OHC, 7α,27-OHC and 7α,25-OHC. The 
monohydroxycholesterols 27-OHC and 24(S)-OHC were detected in all control samples, while they were only 
present in 88 % and 70 % of UC and CD samples, respectively. In contrast, 25-OHC levels were only detectable 
in 36 % of control plasma samples (Supporting Information Table 4). 
The median concentration for 27-OHC in the control group is 79,42 nM, while in the IBD patient samples the 
27-OHC concentration is 44,60 nM in active CD patients and 23,36 nM in active UC patients (Figure 4). The 27-
OHC concentration in patients in remission is 35,09 nM and 24,76 nM for for CD and UC, respectively. These 
data show a significant difference of 27-OHC levels between the control group and the IBD patients (p-value = 
0,000001) but no significant difference between CD and UC patients. 
25-OHC was detected in 36 % of the control samples while no 25-OHC was detected in the CD and UC samples 
(p-value of 0,0031).  
In contrast, no difference was observed for the 24(S)-OHC levels, mainly due to the large spread of values in the 
different IBD groups. The median 24(S)-OHC was similar between controls (46,42 nM), CD patients (45,41 nM) 
and UC patients (30,86 nM) with active disease, and in patients in remission (in CD 42,93 nM and in UC 29,37, 
respectively) . 
The results are less clear for the dihydroxycholesterols where 7α,27-OHC and 7α,25-OHC were only detected in 
some controls and IBD samples (Supporting Information Table 4). The fact that only a few samples contained 
dihydroxycholesterols makes the interpretation very delicate. 7α,25-OHC for instance was rarely but mainly 
found in the condition of disease remission for both diseases with median concentrations of 7α,25-OHC 
containing sample of 1,78 nM and 0,70 nM for CD and UC, respectively. Patients in the remission stage with 
detectable 7α,25-OHC concentration always had measurable 7α,27-OHC, while the opposite was not 
necessarily true. However, 7α,27-OHC was inconsistently detected in all groups, meaning the control group, CD 
active, CD in remission, UC active and UC in remission. 
To exclude inter-individual differences for the association of the oysterols with disease activity, we compared 
the oxysterol levels between the active and remission stage of the same CD and UC patients. In doing so, we 
circumvented oxysterol dependence towards gender, age and ethnicity which was highlighted by Stiles et al. 
2014 
50
. However, no significant difference was observed between the active and the remission phases of UC or 
CD patients (Supporting Information Figure 6). 
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Figure 4| Box- and-whisker plot and raw data representation of 27-OHC (A), 25-OHC (B), 24(S)-OHC (C), 7α,27-OHC (D) and 7α,25-OHC (E) 
concentration in the control group and in CD and UC patients in active and in remission stage. Box 25th to 75th percentile, line: median, 
square: mean, box whiskers: 5th and 95th percentiles, asterisk: statistically significant difference.   
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2.2.5 DISCUSSION 
Here, we present a method for the analysis of mono- and dihydroxycholesterols in human plasma in the 
context of IBD research. The assay validation showed good recoveries (92 % to 125 %) and good precision with 
median CVs between 4 % and 12 %. In addition, the method is linear over the entire calibration range. 
Ideally for analytics, all target analytes are separated by one selective method to avoid confounding factors and 
misinterpretation. With the aim of separating all oxysterols in one run, we modified the mobile phase 
composition and gradient of Karuna et al. (2015) 
43
. Separation of all oxysterols was successfully achieved for 
the first time, but to do so we used ACN as a mobile phase (B1). Under such conditions the oxysterol signal 
intensity was decreased compared with mobile phases containing no ACN 
49
. The decreased oxysterol signal is 
not a problem per se, as long as the expected signals are high enough for detection. However, oxysterol 
concentrations in plasma are relatively low and we reached the detection limit for several of the oxysterols in 
the profile, asking for another mobile phase (B2) using methanol as a solvent. Using this second mobile phase, 
we were not able to separate 24(S)-OHC from 25-OHC, forcing us to apply the method twice, once with the 
mobile phase B2 in order to obtain maximal oxysterol signal intensity and a second time with mobile phase B1 
to separate and quantify 24(S)-OHC and 25-OHC 
43,51–54
. This analysis is a good example in which selectivity can 
compromise sensitivity and vice versa. It should be pointed out that the dihydroxycholesterols as well as the 
monohydroxycholesterols are isobaric compounds and consequently the precursor ions as well as the product 
ions are not selective for one specific analyte. The method’s selectivity is therefore principally based on the 
separation obtained by liquid chromatography.  
Low analyte concentrations, like oxysterol concentrations in plasma require improved sensitivity. The later is 
generally obtained with the addition of ionisation-friendly molecules to the target analytes through 
derivatisation which will lead to enhanced ionisation 
55–57
. However, derivatisation of the target analytes has 
several drawbacks, including the requirement of quantitative and reproducible reaction recoveries in the 
biological matrix, the requirement to obtain only one derivatisation product for each target analyte and the 
more laborious sample preparation often including a cleaning step to eliminate the derivatisation reagents. We 
tested the derivatisation with N,N-Dimethylglycine (data not shown) but we obtained in addition to single 
derivatised products, twice and three times derivatised products, making quantification difficult and unreliable. 
In addition, not all oxysterol-dimethylglycine esters could be separated from each other, even with long 
chromatographic runs. This is why we chose the analysis of underivatised di- and monohydroxycholesterols. 
Another possible option to improve sensitivity is the choice of the best ionisation source 
43,46–48
. AB Sciex 5500 
TripleQuad has two possible ionisation sources: APCI and ESI. We compared both ionisation sources and 
obtained the best results with the ESI sources similar to Karuna et al. (2015) 
43
. A third possible option to 
improve sensitivity is to analyse free and esterified oysterols instead of only measuring free oxysterols. 
Oxysterols are particular in that they are stored in the cell as oxysterol esters but they are only biologically 
active when they are free 
19,22,24,58
. We chose the analysis of free oxysterols to measure only oxysterols 
potentially acting on their corresponding receptors. However, considering the sensitivity issue, an alkaline 
hydrolysis step may release the oxysterols from the oxysterol esters, which are then detectable in LC-MS/MS 
and thus increases the amount of detected oxysterols.  
The pre-analytical steps of an analytical method are analyte-dependent and as important as the analysis itself, 
since they strongly influence the final results. It is therefore difficult to define a general pre-analytical protocol 
for samples potentially used for several analyses. Oxysterols are not stable more than two years in plasma and 
only very little stability data are available for oxysterols in plasma 
59
. Accordingly, samples for this study were 
selected from the Swiss IBD Cohort study to have been collected less than two years before analysis. 
Nevertheless, we observed a trend towards lower oxysterol concentrations in samples for which the time 
between the blood collection and the biobank storage (delta time) was longer (4 days as maximum). During the 
delta time, these samples were stored between 2 and 8 °C, which might have an impact on the oxysterol 
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concentrations. Pre-analytical differences may also explain the large spread of 24(S)-OHC levels in the samples 
from the Swiss IBD Cohort study, compared to the optimally collected samples from controls. 
With this method we were able to measure 24(S)-OHC, 25-OHC, 27-OHC, 7α,27-OHC and 7α,25-OHC in samples 
of CD and UC patients. The levels are relatively low especially for the dihydroxycholesterols but were found to 
be in the same order of magnitude as in the literature 
43,51–54
. 
The two monohydroxycholesterols, 27-OHC and 25-OHC, showed both lower levels in IBD patients than in 
controls, while 24(S)-OHC showed inconclusive results because of the very large concentration range in the IBD 
patients. 27-OHC is a LXR agonist and Jakobssen et al. (2014) observed lower LXRs mRNA levels in CD and UC 
patients and concluded that triggering LXRs may be protective in IBD 
28
. Our data of reduced 27-OHC level in 
IBD patients would support this notion, indicating that the LXRs as well as their agonist, 27-OHC, are reduced in 
IBD. However, it is not clear on whether the lowered level of LXRs will lead to reduced oxysterol production, or 
whether these are two independent events hampering the 27-OHC-LXRs axis. Interestingly, no difference could 
be found between 27-OHC concentrations in CD and UC patients, indicating a common disease mechanism in 
both IBD diseases due to inflammation depending on the 27-OHC-LXRs axis. This would also be supported by 
the data from Jakobssen et al. (2014), who also detected similar LXRs mRNA expression levels between CD and 
UC patients 
28
.  
We detected 25-OHC in 36 % of our control group samples while none of the IBD samples showed detectable 
levels. The median 25-OHC concentration of 5,39 nM of the 25-OHC containing control samples is in agreement 
with the values reported in literature 53,54. Considering these low levels of free 25-OHC in controls, we would 
anticipate that IBD samples would be under our detection limit, when we consider a similar reduction of 25-
OHC in IBD patients as observed for 27-OHC. In order to measure 25-OHC in IBD patients and to eventually 
make a distinction between controls and IBD patients, an alkaline hydrolysis could be helpful, since 25-OHC is 
known to be esterified up to 98,7 % 
43,50
. It is tempting to speculate that a reduced 25-OHC concentrations in 
IBD patients could be associated with a reduced anti-viral immune response in IBD patients 
15,20,21,60,61
. 
Since we obtained the most promising results for the LXRs agonists it would be interesting to add further LXRs 
agonists to the oxysterol panel that are for example not direct dihydroxycholesterol precursors. This would give 
first indications on whether the LXRs functions are hampered in general in IBD or not. Many LXRs agonists have 
been reported in in the literature including 7α-hydroxycholesterol (7α-OHC), 4β-hydroxycholesterol (4β-OHC), 
22(R)-hydroxycholesterol, 20(S)-hydroxycholesterol, 24(S),25-epoxycholesterol (24(S),25-EC), and cholestenoic 
acid, a metabolite of 27-OHC 
23,24,62,63
. These oxysterols have in vitro approximately the same binding affinity to 
LXRα and LXRβ and thus seem to select the receptor depending on the origin of the oxysterol and on the 
expression of the receptor. For instance, 24-OHC is only produced in the brain, which expresses also LXRβ 
forming the 24-OH- LXRβ axis 
64–67
. However, the more analytes are measured in a profile, the less sensitive the 
method will be. Therefore, a compromise needs to be found between the number of analytes to target and the 
sensitivity to reach.  
7α,25-OHC, and 7α,27-OHC were the only detected dihydroxycholesterols. However, the sensitivity of our 
method did not allow measuring the levels of the dihydroxycholesterols in most plasma samples, limiting the 
interpretation on their implication in IBD. The few 7α,25-OHC concentrations which were measurable, were 
slightly higher as the ones reported in the literature (median concentration of 7α,25-OHC containing sample: 
1,78 nM for CD in remission and 0,70 nM for UC in remission compared to 0,21 nM from Karuna et al. (2015), < 
0,48 nM for Griffiths et al. 2013, and 0,29 nM for Griffiths et al. 2013) 
43,53,54
. Interstingly, of the few 
measurable dihydroxycholesterol levels, 7α,25-OHC containing plasma samples always contained also 7α,27-
OHC, eventually indicating an activation of the oxysterol-EBI2-axis in IBD. To corroborate such an association 
we would need further improvement of the sensitivity of the method. An alkaline hydrolysis could be 
performed to measure the esterified oxysterols in addition to the free. Both dihydroxycholesterols were 
reported to be esterified by 73.8 % and 82.0 %, allowing the improvement of a factor of seven to eight for the 
detection limit 
43
.  
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The other three dihydroxycholesterols 7α,24(S)-OHC, 7β,27-OHC and 7β,25-OHC where not detected in our 
study. It is possible that they either do not exist in vivo (as 7β,25-OHC) or that they are not present in 
measurable amounts in the human body circulation (likely for 7α,24(S)-OHC and 7β,27-OHC) 
30,43,76,77
. We come 
to these statements since to our knowledge no cholesterol β-hydroxylase was shown to exist endogenously 
questioning the in vivo synthesis of both 7β-dihydroxycholesterols. Usually the 7β-dihydroxycholesterols have 
been included in oxysterol profile analyses to ensure the correct identification of 7α,25-OHC 
43
. However, 
Soroosh et al. were able to measure 3-12 nM 7β,27-OHC in mouse spleen suggesting that at least one of the 
two 7β-dihydroxycholesterols really exists in vivo 
30
. In contrast, 7α,24(S)-OHC was shown to occur in liver and 
the enzymes required for its synthesis are well characterised. However, this dihydroxycholesterol seems to be 
intracellularly localised because no 7α,24(S)-OHC concentrations have ever been reported in plasma 
76,77
. 
Hence human plasma concentrations of these three dihydroxycholesterols are below the current detection 
limit, which agrees well with the literature.  
In conclusion, we show that IBD patients have lower 27-OHC and eventuallay 25-OHC levels in the active and 
the remission phases compared to controls, indicating a role for the oxysterol-LXR-axis in IBD.  
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2.2.7 SUPPORTING INFORMATION 
 
 
 
 
 
 
Supporting Information Figure 5| Comparison between oxysterol ionisation with APCI and ESI ionisation sources using mobile phase B1 
(ACN containing) and mobile phase B2 (MeOH containing). 
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Supporting Information Table 4| Table summarising the results obtained for 24(S)-OHC, 27-OHC, 7α,27-OHC and 7α,25-OHC in CD and 
UC patients in active and in remission stage. For each condition the number of hits, the calculated median of that condition, the total 
number of samples of that condition, and the percentage of hits of that condition were given. Values with * indicates that the median 
was made out of all oxysterol containing samples instead of the total number of samples. 
Condition 27-OHC 25-OHC 24(S)-OHC 7a,27-OHC 7a,25-OHC 
Positive counts 60 8 52 14 5 
Total samples 65 65 65 65 65 
Positive counts % 92 % 12 % 80 % 22 % 8 % 
Median concentration in CD 
and UC (nM) 
29,65 0,00 40,76 0,00 0,00 
Standard deviation in CD and 
UC (nM) 
23,82 0,00 38,75 1,05 0,57 
Upper range in CD and UC 
(nM) 
95,93 0,00 155,78 3,70 3,06 
Lower range in CD and UC 
(nM) 
0,00 0,00 0,00 0,00 0,00 
Control hits 22 8 22 2 0 
Median Control (nM) 79,42 5,39* 46,42 5,70* 0 
Control ntotal= 22 22 22 22 22 
Control (%) 100 % 36 % 100 % 9 % 0 % 
CD active hits 10 0 7 3 1 
Median CD active (nM) 44,60 0 45,41 1,91* 2,08* 
CD active ntotal= 10 10 10 10 10 
CD active (%) 100 % 0 70 % 30 % 10 % 
CD remission hits 10 0 9 3 2 
Median CD remission (nM) 35,09 0 42,93 3,01* 0,00* 
CD remission ntotal= 10 10 10 10 10 
CD remission (%) 100 % 0 % 90 % 30 % 20 % 
UC active hits 8 0 5 2 0 
Median UC active (nM) 23,36 0 30,86 2,79* 1,78* 
UC active ntotal= 9 9 9 9 9 
UC active (%) 89 % 0 % 56 % 22 % 0 % 
UC remission hits 10 0 9 4 2 
Median UC remission (nM) 24,76 0 29,37 1,63* 0,70* 
UC remission ntotal= 14 14 14 14 14 
UC remission (%) 71 % 0 % 64 % 29 % 14 % 
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Supporting Information Figure 6| Line array representation for 27-OHC (A and E), 24(S)-OHC (B and F), 7α,27-OHC (C and G) and 7α,25-
OHC (D and H) in active and remission stage for each patient in CD (A-D) and UC (E-H).  
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3.1 GENERAL CONSIDERATIONS ON THE ANALYSIS OF OXYSTEROLS  
Traditional sample preparation methods for oxysterol analysis were optimised to take into account the possible 
in situ oxidation of cholesterol or of oxysterols themselves resulting in an array of different oxysterols. The fear 
was to obtain erroneous results not reflecting the in vivo oxysterol signature. Antioxidants -mainly BHT- were 
therefore added to the matrix directly after collection and the samples were immediately stored at -80°C. This 
approach of direct antioxidant addition is ideal but could be avoided with the use of a faster, simpler and 
gentler sample preparation for LC-MS/MS compared to the sample preparation for GC-MS as demonstrated by 
Helmschrodt et al. (2014) 
1
. In the particular case of 4β-OHC, an oxysterol of both enzymatic and non-
enzymatic origin, it was shown that the addition of BHT had no influence on the finally measured 
concentrations and that if oxidation occurred, it was negligible 
2
. Similarly, we showed that C-triol and 7-KC are 
stable in plasma at room temperature for four days, indicating that oxidation does not occur immediately 
3
. 
This point is crucial when working with matrices like plasma obtained from external clinicians or collaboration 
partners. It is very difficult or even impossible to obtain a reliable antioxidant addition to the sample from 
clinicians or external collaboration partners. We conclude that accurate pre-analytics for the analysis of C-triol 
and 7-KC is possible also without antioxidant addition like BHT to the plasma.  
Oxysterol research is strongly dependent on selective and sensitive analytical systems. Further development is 
still required to obtain more insides into the role of oxysterols in human physiological and pathophysiological 
functions. The oxysterol research still needs to find answers to the many open questions as for example the 
question of the oxysterol implication in inflammatory disorders such as IBD, besides our finding of lowered 27-
OHC and 25-OHC levels. From the chromatography point of view many improvements of conventional HPLC 
systems were achieved in the last 15 years with the most success for UHPLC. The appearance of commercial 
sub-2 mm columns used in UHPLC gave a new sparkle on liquid chromatography. UHPLC provides enhanced 
chromatographic resolution resulting in more narrow peaks with consequently less compounds co-eluting and 
the detection of approximately 20 % more compounds 
4,5
. Additionally, the more narrow peaks of UHPLC give a 
better signal to noise ratio than conventional HPLC, thus increasing the sensitivity and the reproducibility of the 
analysis 
6
. The higher velocity applied in UHPLC results in shorter analysis times increasing the sample 
throughput by a factor of 9 while maintaining similar efficiency to HPLC 
7
. Other advantages are the diversity of 
columns regarding stationary phases which are not only restricted to reverse phases and commercially 
available column lengths 
8
. Existing HPLC methods can be easily transferred to UHPLC methods without the 
need of extra qualified staff 
7
. The major but also the only drawback of this technology is the generated high 
background pressure requiring special and costly instrumentation 
8
. A conceivable near future chromatography 
advance with a potential for acceptance by the oxysterol community is the concept of ultra-performance 
convergence chromatography (UPC
2
). This technology has not yet been tested for oxysterols, but Waters 
demonstrated in an application note the efficient and short separation of several steroids with UPC 
2  9
. The 
concept of ultra-performance convergence chromatography (UPC
2
) was first mentioned by Giddings in 1964, 
but the first commercially available easy-to-handle system was introduced by Waters (ACQUITY UPC
2
 ™) only at 
the Pittcon conference in 2012. UPC
2
 is based on the control of density, diffusivity and viscosity of a 
supercritical fluid-based mobile phase, generally CO2. For increased selectivity, diverse stationary phases are 
available and any organic solvent can be added as a co-solvent, if deemed necessary 
10
. According to Gopaliya 
et al. this technology combines the advantages of LC and GC with increased analytes diffusion into the mobile 
phase giving a better peak separation, possible analysis of thermo-sensitive substances not resistant to high GC 
temperatures, and the low viscosity of supercritical fluids resulting in higher flow speed compared to HPLC 
11
. 
From the point of view of mass spectrometry, high resolution mass spectrometers (HRMS) are the most 
promising instruments with already some established oxysterol methods 
12–15
. High resolution mass 
spectrometers have the advantage of high mass resolving power and mass accuracy making the distinction 
possible between almost isotopic peaks 
16
. However, until a few years ago high resolution was only possible 
with Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometers which have a very limited scan 
speed 
17
. High scan speed was possible to achieve with time-of-flight (TOF) mass spectrometers but these 
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instruments do not reach the same resolving power and mass accuracy as FT-ICR does 
18–20
. Hybrid orbitrap 
instruments are the third type of recent analytical instruments attaining high resolution (QExactive from 
Thermo Fisher Scientific: 140 000 at 200 m/z). Their advantages are numerous, including high mass accuracy 
(QExactive < 5ppm), high scan speed (QExactive: 12 scans/sec), fast polarity switching and a large dynamic 
range (QExactive: three order of magnitude) 
21
. From a practical point of view the hybrid orbitrap instruments 
are benchtop instruments and don’t require expensive cooling apparatuses to maintain a superconducting 
magnet as it is the case for FT-ICR MS 
22
. From an experimental point of view, these types of instruments have 
the benefit to allow untargeted data collection for identification of unexpected compounds, retrospective 
review of the data and in case of untargeted experiments a simpler method development since they don’t 
require compound-specific sample preparation. However, high resolution mass spectrometers are expensive 
instruments and data analysis can be very complex. An important drawback for quantification is that the 
sensitivity does not reach these achieved by triple quadrupoles yet 
23
. We are convinced that the improvement 
of sensitivity is just a matter of time and will be soon equivalent to the triple quadrupoles allowing high 
specificity and sensitivity.  
An important issue that still deserves attention is the fact that oxysterol MS analysis is hampered in two ways 
by the chemical structure of the oxysterols. The first issue is the poor ionisation of oxysterols due to their 
apolar nature and their lack of ionisation-friendly chemical groups containing for example oxygen or nitrogen 
atoms 
23
. The general rule for ESI is: the more polar groups a compound possesses the better it can be ionised. 
In the case of monohydroxycholesterols the ionisation can only take place at the oxygen at the C-3 position of 
the sterol ring and at the oxygen present on the side chain. Dihydroxycholesterols for instance already ionise 
more readily than monohydroxycholesterols since they possess three possible ionisation sites. Positive ion 
formation in ESI can be slightly enhanced through the addition of traces of formic acid, usually at 0,1% v/v 
24
. 
The second issue of oxysterol MS analysis is the inefficient fragmentation due to the stability of the steroid 
backbone. During fragmentation the basic steroid structure is maintained with only the different substituents 
being separated, forming mainly one or two neutral water molecules. Even further fragmentations (MS
2
 and 
more) at higher energies give very little structural information 
25
. The unspecific oxysterol fragments don’t 
allow to distinguish between isobaric oxysterols, making the identification impossible without a good 
separation by liquid chromatography 
26
.  
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3.2 CONCLUDING REMARKS ON OXYSTEROLS AS BIOMARKER FOR NP-C DIAGNOSIS  
Rare diseases in Europe are defined by Orphanet as “diseases which affect a small number of people compared 
to the general population and specific issues are raised in relation to their rarity. In Europe, a disease is 
considered to be rare when it affects 1 person per 2000” 
27
. One rare disease example is NP-C with an 
estimated occurrence of 1 per 120.000 live births 
28
. NP-C disease onset, symptoms, and progression differ 
strongly among patients hindering thereby a straightforward diagnosis 
29
. The complex and often delayed 
diagnosis probably overlooks especially patients with milder forms which may become symptomatic in 
adulthood. Thus the real incidence of the disease is possibly higher than estimated. The lack of a fast, sensitive 
and specific diagnostic assay for NP-C was till recently an additional burden for NP-C diagnosis. It was therefore 
a big turmoil when Porter et al. discovered two biomarkers for NP-C 
30,31
. It is in this context that the University 
Children’s Hospital Zurich being one of the rare medical centers with NP-C diagnostic expertise, decided to 
implement a method for identification and quantification of the reported biomarkers. The aim was to diagnose 
NP-C in a screening-like manner in suspected cases. This method was successfully achieved as part of this thesis 
and since January 2015 the Division of Clinical Chemistry offers NP-C diagnosis on a fortnight basis. In the 
meantime, other laboratories in Europe offer a NP-C diagnostic assay based on oxysterol detection such as the 
laboratory of Münster (D), Manchester (UK), Padova (I), and Udine (I), thus covering different European 
countries for NP-C diagnosis in a very short time span. The NP-C diagnostic assay implementation by several 
groups has the advantage of inter-lab method comparison several times a year, guaranteeing accurate analytics 
for patient safety. However, with the necessary hindsight’s and the attention of many professional from 
different fields, several criticisms have emerged to which we would like respond.  
The first and major issue concerns the biomarker specificity. C-triol and 7-KC are products of oxidative stress 
and are not of enzymatic origin. The provenance of the oxidative stress in NP-C cells is currently unknown, but 
probably the excessive cholesterol accumulation in the lysosomes is responsible for cellular dysfunctions 
leading to oxidative stress. However, oxidative stress is not specific to NP-C and is known to be involved in 
several other diseases as for example Parkinson’s disease, Atherosclerosis, Diabetes or Asperger syndrome 
32–
35
. Indeed in the meantime, C-triol and 7-KC were found to be also elevated in other diseases such as, NP-A, NP-
B, lysosomal acid lipase deficiency or CTX, thus reducing their specificity for NP-C 
3,36
. In addition to false 
positive results, several groups reported false negative results during the 2014 Oxysterol Workshop in Münster. 
Based on these two issues, A. Dardis proposed at the same workshop to add the oxysterol assay as screening 
tool at the first position of the NP-C diagnostic algorithm but with no intention to make it a standalone method, 
and especially not replacing any former diagnostic methods. This illustrates the fact that every diagnostic 
method has some limitations regarding its sensitivity (ideally, 100 % detection of the true positive values) and 
its specificity (ideally, to have no false positive values). The most important aspect is to be aware of it. This 
oxysterol assay proposed here constitutes an important step ahead towards fast diagnosis of new patients, 
which is of inestimable value for the affected patients and families. Since we started with this assay in 
Switzerland, we were already able to diagnose 5 new cases, for a disease occurring only in 1 of 120.000 births.  
The second issue concerns the collection of reference values. Reference values are an important tool to 
distinguish healthy subjects from patients with a particular disease and can be derived by three different 
methods. The first method consists in calculating the mean ± standard deviation of the values obtained from a 
healthy population. However, this is only possible with a Gaussian distribution of the values, or a non-Gaussian 
distribution transformed to a Gaussian after logarithmic plotting 
37
. The second and most widespread method 
is the determination of the 2,5 - 97,5 percentile for a healthy population after eventually removing extreme 
outliers
37
. The last method being relatively uncommon is the application of the second method on a “not really 
healthy” population such as hospitalised infants in contrary to a healthy population 
37
. To do so has two 
advantages: first in the context of reference ranges for children it is extremely difficult to obtain sufficient 
healthy donors with an informed consent between 1 day and 18 years old. Second, the assay still needs to be 
sufficiently discriminative between the “not really healthy” population and patients because this is the regular 
clientele for laboratory analyses in the case of NP-C suspicion. In those cases the 2,5 - 97,5 percentile obtained 
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from a “not really healthy” population is much more robust for discrimination than the one obtained from 
healthy subjects 
37
.  
The third issue concerns sample preparation itself. Traditional oxysterol research methods contain an 
oxysterol-cholesterol separation step via SPE 
38,39
. This procedure is applied to avoid interference by cholesterol 
present in a concentration that is three orders of magnitude higher than the oxysterols. However, nowadays 
selective MRM scanning for the target analytes are applied, making the cholesterol separation step 
unnecessary. A second argument for the cholesterol separation step is the possible in situ oxidation of 
cholesterol during sample preparation. However, we showed that both oxysterols are stable in plasma for up to 
four days at room temperature indicating that if any oxidation occurs, it remains negligible.  
In addition to the three criticisms discussed above, it is worth noting that a novel derivatisation reagent for the 
oxysterol assay in the NP-C context has been described, while we were implementing the oxysterol assay 
40
. 
The sample preparation is very similar to the derivatisation with N,N-dimethylglycine but much faster. 
However, this derivatisation reagent is not commercially available and needs to be synthesised regularly since 
it is only stable for 1 week. Even if the sample preparation itself is faster than our method, we doubt that the 
proposed method would find acceptance in clinical laboratories since it requires regular preparation of the 
derivatisation reagent hampering stat-analysis of urgent samples.  
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3.3 CONCLUDING REMARKS ON THE ROLE OF OXYSTEROLS IN IBD AND THEIR 
ANALYSIS 
3.3.1 THE ROLE OF OXYSTEROLS IN IBD 
The analysis of mono-and dihydroxycholesterols as biomarkers of IBD is a novel approach which shows some 
promises. The most important finding in this context is that 27-OHC and eventually 25-OHC are reduced in IBD 
patients compared to healthy volunteers. Unfortunately the data obtained for 24(S)-OHC being the third LXRs 
agonist of this study, are inconclusive and cannot be used for interpretation. Since 27-OHC and 25-OHC are 
LXRs agonists, our findings could be an indication on impaired LXRs activity in IBD. However, it is still unclear 
which monohydroxycholesterol of these three activates the most strongly the LXRs in vivo in IBD. It was shown 
that in vitro the binding force to LXRs is in the following descending order: 24(S)-OHC > 25-OHC ≥ 27-OHC, 
indicating that 27-OHC is not the most important monohydroxycholesterol LXRs agonist 
41–43
. Consequently it 
would mean that the reduced 27-OHC concentrations in IBD would not have much effect on the LXRs activity. 
However, it is uncertain to which extend this in vitro findings are relevant in the in vivo situation. It is to denote 
that, in human plasma the monohydroxycholesterol concentrations are in the decreasing order: 27-OHC > 
24(S)-OHC > 25-OHC, placing 27-OHC as the first possible LXRs agonist. Furthermore Fu et al. demonstrate that 
the 27-OHC concentration was dose dependent of the cholesterol loading in human monocyte-derived 
macrophages and that 27-OHC activates LXRs actually in a dose-dependent matter 
44
. In addition, they showed 
that 27-OHC is an agonist of both LXRα and LXRβ 
44
. Taking all the data together it appears that the in vivo 
situation is unclear but that 27-OHC is still a possible important LXRs agonist in IBD.  
Setting up a panel of analytes for a method asks to define the number of analytes necessary to most likely 
answer the research question. We covered all EBI2 ligands, since we were particularly interested in their 
implication in IBD. In addition we included the RORγt ligand that is supposed to have opposite effects to the 
EBI2 ligands. Additionally we included the precursors of the dihydroxycholesterols - LXR ligands, for which we 
paradoxical obtained the most promising results. Since we obtained the most promising results for the LXRs 
agonists it would be interesting to add further LXRs agonists to the oxysterol panel that are for example not 
direct dihydroxycholesterol precursors. This would give first indications on whether the LXRs functions are 
hampered in general in IBD or not. Many LXRs agonists have been reported in in the literature including 7α-
OHC, 4β-OHC, 22(R)-hydroxycholesterol, 20(S)-hydroxycholesterol, 24(S),25-EC, and cholestenoic acid, a 
metabolite of 27-OHC 
41–43,45
. These agonists have in vitro approximately the same binding affinity to LXRα and 
LXRβ and thus seem to select the receptor depending on the origin of the oxysterol and on the expression of 
the receptor. For instance, 24-OHC is only produced in the brain, which expresses also LXRβ forming the 24-OH- 
LXRβ axis 
46–49
. However, the more analytes are measured in a profile, the less sensitive the method will be. 
Therefore, a compromise needs to be found between the number of analytes to target and the sensitivity to 
reach.  
Additionally to the possible expansion of the oxysterol panel for LXRs agonist, it would be interesting to deeper 
study the influence of the suppression of LXRs activity in IBD on downstream target gene expression. LXRs are 
master transcriptional regulators controlling sterol and fatty acid metabolism through up-regulating genes 
implicated in fatty-acid synthesis (SREBP-1c, and fatty acid synthase (FAS)), in cholesterol clearance (cholesterol 
7α-hydroxylase, and apoE), cholesterol cell efflux (ABCA1, ABCG1, ABCG5, and ABCG8), and acting on the 
metabolism of plasma lipoproteins (cholesteryl ester transfer protein, and lipoprotein lipase (LPL)) 
41,50–56
. In 
addition they negatively regulate cholesterol biosynthesis through regulation of the lanosterol 14α-
demethylase (CYP51A1) and squalene synthase 
57
. It could be helpful to unravel if LXRs agonist diminution in 
IBD influences one particular, several or all of these target genes. It would help to better understand the 
inflammatory pathways occurring in IBD as well as possible cell protective mechanism when LXRs activation is 
inappropriate. 
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The observation of reduced LXRs agonists in IBD redirected our interest for the implication of LXRs in 
inflammation, which appeared in the last years to be of protective nature. An important discovery going in the 
direction of LXRs protective role was the finding of the anti-inflammatory and anti-viral properties of 25-OHC 
already mentioned earlier 
58–63
. In brief, Type 1 IFNs release is an important host defence mechanism towards 
bacterial or viral TLRs ligands that increases CH25H expression and consequently 25-OHC synthesis 
64–66
. 25-
OHC activates LXRs which effects are mutually antagonistic to the action of SREBP2 being thereby suppressed 
and in turn decreases the expression of IL-1β and the inflammasome activity 
58,59,66
. In addition, reduced 
SREBP2 activity decreases the sterol biosynthesis and thus contributes to decrease virus cell entry and viral 
replication 
67
. Furthermore it was shown that the addition of synthetic LXR agonist to LPS stimulated 
macrophages, inhibited their expression of pro-inflammatory mediators 
68,69
. This discovery was taken as 
explanation for the reduced inflammation observed in murine models of contact dermatitis and atherosclerosis 
after administration of synthetic LXR ligands 
68,70,71
. Our results motivated us to further research in literature for 
eventually other discoveries not mentioned yet which would support the protective action of LXRs in immunity. 
Indeed, Joseph et al. discovered decreased macrophages resistance to apoptosis when challenged with Listeria 
monocytogenes in LXRs null macrophages 
72
. SPα is a soluble protein of the scavenger receptor cysteine-rich 
superfamily expressed by macrophages in lymphoid tissue with antiapoptotic functions 
72,73
. The authors could 
show that LXRs directly activate SPα and thereby limiting the apoptosis of macrophages during bacterial 
infection and consequently increases the antimicrobial activity of macrophages 
72
. Additionally a second 
discovery was descripted being in the same context as the first one. It reported that apoptotic cell engulfment 
activated LXRs in mice and that LXRs subsequently induced the expression of Mer, which is a tyrosine kinase 
crucial for phagocytosis 
74
. This pathway of Mer activation by LXRs was shown to occur in macrophages as well 
as in neutrophils and is important for appropriated apoptotic cell clearance and maintenance of the immune 
tolerance in mice 
74,75
. Taking both discoveries together, LXRs showed indeed to have a protective function 
during inflammation in increasing the macrophage resistance and increasing the phagocytic activity of immune 
cells. From this it appears that LXRs have direct immune functions but it is not elucidated to which extend the 
LXRs induced suppression of the cholesterol biosynthesis and the increased fatty acid metabolism mentioned 
earlier is involved in the protective LXRs immune functions. It is for instance known that isoprenoid being early-
stage intermediate of the cholesterol biosynthesis pathway are important for protein prenylation 
76
. Protein 
prenylation occurs among other on proteins involved in inflammatory responses such as the farnesylation on 
Ras (Rat sarcoma protein) or the geranylgeranlyation on Rac1 (Ras-related C3 botulinum toxin substrate 1) 
76,77
. 
All the data converge to an important contribution of LXRs in inflammation, although it is at the moment not 
known which of them is the most important in IBD. 
In order to obtain first hints on oxysterol signature in plasma of IBD patients we actually conducted a small 
“pre-study” with samples of 24 IBD patients of the Division of Gastroenterology and Hepatology of the 
University Hospital Zurich. In two of these samples we observed an additional peak which is not one of our 
analytes. The chromatographic behaviour of this compound is to elute between the IS of 7α,27-OHC and 7α,24-
OHC in the ACN gradient, while with the MeOH gradient this compound elutes between 7α,24-OHC and 7α,25-
OHC, having the same transitions as all other dihydroxycholesterols. We found out that both samples belonged 
to women with UC with strong disease activity and we were excited about the relevance of this additional peak 
in UC. However, in the Swiss IBD cohort study we detected only one sample with this additional peak and the 
sample belonged to a man with CD in remission stage. The inconsistence between the different samples with 
the additional peak indicates that it might be an interference with no relevance for the IBD research.  
3.3.2 ANALYSIS OF OXYSTEROLS IN THE SCOPE OF IBD 
Generally sample preparation of plasma is relatively simple and the availability of plasma is good compared to 
other biological tissues. This makes plasma the first-choice matrix for method development. We also followed 
this strategy, although plasma is most likely not the most oxysterol-rich tissue of the human body, since the 
oxysterol synthesising enzymes are located for instance in the liver, in lymphoid tissues, in the small intestine, 
in the brain, in the lung or in the kidney 
78,79
. In order to obtain a more comprehensive picture of the role of 
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oxysterols in IBD we would like to analyse oxysterols in other tissues, in particular in intestinal tissue left over 
from colectomy. In parallel to the oxysterol determination in humans, we would also like to analyse them in 
mice in particular in the lymph nodes where the EBI2 receptor is expressed, in the spleen and in the liver. 
Oxysterol extraction from mouse liver is already being implemented in our laboratory, while this manuscript 
was in preparation. 
As already highlighted throughout this manuscript, several techniques to improve the LC-MS/MS sensitivity for 
oxysterol analysis have been described. In addition to these general improvements, in the context of the 
oxysterol method for IBD research we encountered the specific problem of relatively high background level for 
the monohydroxycholesterol transitions even for oxysterol standards dissolved in EtOH. Testing different EtOH 
qualities for the standards did not improve this issue. Since our ACN and MeOH mobile phase solvents were of 
very high purity, we suppose that the water quality of the mobile phase was insufficient for this type of 
analysis. Karuna et al. (2015) used for their oxysterol method water of high purity, confirming the importance 
of the solvent’s purity degree for the method 
80
. However, buying extra pure water increases the running costs 
of the analysis.   
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3.4 CONCLUSION 
In this work, two LC-MS/MS methods were established for the analysis of oxysterols in human diseases. The 
first method was developed and implemented for the analysis of oxysterols of non-enzymatic origin in a clinical 
setting of NP-C. In addition, a second method was optimised for the analysis of enzymatically-derived 
oxysterols in the plasma of IBD patients, opening a new research domain. Even if these molecules have the 
reputation of being challenging to analyse, in both projects, a sensitive, selective and robust assay was 
essential for the detection, identification and quantification of the targeted oxysterols. In the first project, we 
tested the approach of oxysterol derivatisation, while in the second project we analysed underivatised 
oxysterols. In both projects dealing with two very distinct human diseases, oxysterols were evaluated for their 
use as biomarkers. For the NP-C diagnostic we conclude that they effectively fulfil the function of biomarker, 
although with no absolute disease specificity. On the contrary, the discovery of the oxysterol signature in IBD is 
in its beginning and it is too early to make a statement. However, the results are very promising for the 
monohydroxycholesterols to serve as novel biomarker for IBD.  
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